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Abstract 
Although bone has an intrinsic capacity for self repair, the healing of large bone 
defects that typically present in humans often involves complications which 
result in failure to heal, leading to delayed or non-union of the defect. Due to 
limitations of current therapeutic approaches of autografting and allografting, the 
use of tissue engineered scaffolds has emerged. Despite some success with 
this approach, these scaffolds often require a further stimulus to promote 
complete healing of large bone defects. microRNAs (miRNAs) have recently 
emerged as promising therapeutics to stimulate bone repair, owing to their 
ability to intercept entire gene cohorts. However, the development of a safe and 
efficient localised delivery system is required for successful clinical translation of 
miRNA therapeutics to bone tissue engineering (TE). The overall goal of the 
research presented in this thesis was to determine the potential of using in-
house synthesised nano-sized hydroxyapatite particles (nHA) to act as non-viral 
vectors for the delivery of a series of miRNAs to human (h)MSCs and to 
determine the combination leading to optimal osteogenesis and angiogenesis 
before ultimately producing miRNA-activated scaffolds capable of mediating 
enhanced osteogenesis by human MSCs. 
 
In the study presented in Chapter 2 of this thesis, nHA particles combined with 
reporter miRNAs demonstrated potential as highly efficient and minimally 
cytotoxic non-viral vectors for the delivery of miRNA enhancers and inhibitors 
(miR-mimics and antagomiRs) to human MSCs. Single administration of low 
miRNA doses rendered very pronounced silencing activities to a level 
comparable to viral and lipid-based vectors and ultimately, a 20 nM dose was 
brought forward for further study. In Chapter 3, efficient nHA-based delivery of 
antagomiR-133a, antagomiR-16 and a miR-210 mimic, three targets identified 
to have particular therapeutic potential, enhanced osteogenesis by human 
MSCs. AntagomiR-133a emerged as the optimal osteo-therapeutic, while both 
antagomiR-16 and the miR-210 mimic were deemed worthy of further 
investigation. 
 
4 
 
In Chapter 4, the coll-nHA scaffolds demonstrated significant potential for the 
efficient localised delivery of both miR-mimics and antagomiRs to human 
MSCs, representing the first non-viral, non-lipid, ‘off-the shelf’ 3D system 
developed in the field. Additionally, antagomiR-133a activated scaffolds 
upregulated Runx2 and orchestrated accelerated calcium deposition, thus 
showcasing the osteo-therapeutic potential of this innovative strategy for bone 
TE applications. In Chapter 5, while the miR-210 mimic showed a limited pro-
angiogenic therapeutic efficacy, the combinatorial delivery of the miR-210 mimic 
with antagomiR-16 demonstrated significant potential to simultaneously 
enhance the angiogenesis and osteogenesis capabilities of human MSCs. This 
dual formulation presents the first combinatorial miRNA approach harnessing 
these two processes and sits within seminal reports on the recently emergent 
field of combinatorial miRNA delivery. 
 
Collectively, this thesis has demonstrated that nHA particles are able to deliver 
miRNAs with superior efficiency than that reported for other non-viral systems. 
When applied in 3D, a miRNA-activated coll-nHA scaffold with significantly 
enhanced therapeutic potential was achieved. Together with the demonstration 
of successful combinatorial miRNA delivery to harness both angiogenesis and 
osteogenesis, this underlines the immense potential of extending this platform 
to different fields of TE beyond osteogenesis and bone repair. 
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Chapter 1. Introduction and Literature Review 
 
1.1.Tissue engineering and regenerative medicine: an overview 
 
The term "tissue engineering" (TE) originated in 1985 (1) and was first defined 
in a scientific paper by Langer and Vacanti in 1993 as an ‘interdisciplinary field 
that applies the principles of engineering and the life sciences toward the 
development of biological substitutes that restore, maintain, or improve tissue 
function or a whole organ’ (2). This definition encompasses the use of living 
cells and/or their extracellular products to regenerate tissues inside the patient’s 
body and for the purpose of drug discovery or diagnostics. Subsequently, the 
term “regenerative medicine” (RM) was coined to refer to a vast medical area 
with surgical connotation, within which TE was viewed as one amongst many 
strategies to treat tissues requiring repair due to dysfunction, disease, injury, 
age or congenital disorders (3, 4). Today, both TE and RM are used 
interchangeably (1) and in combination (TERM), and have emerged as a very 
significant field with a growing global market estimated to reach $89.7 billion by 
2016 (5).  
Traditional approaches to replace damaged tissue involve the use of allografting 
and autografting, which is widely regarded as the gold standard procedure. 
Respectively, these techniques consist of re-implanting cells or tissue harvested 
from patients themselves or from same-species donors, at the site of damage. 
Although both techniques display clinical success, they also present many 
constraints generally associated with the requirement for additional surgical 
procedures, limited donor tissue, donor-site morbidity and chronic pain (6). 
Moreover, allografting has the added risk of rejection by the patient’s immune 
system, graft-versus-host-disease, as well as risk of disease transmission from 
donor to patient (7). Furthermore, there is a widening gap between the amount 
of  tissue/organ donors available to meet the growing demands of an increased 
aging population (8). Another approach commonly used in some tissues 
including hip, knee and heart valve replacement is the use of prosthesis, which 
are artificial devices to substitute a missing or impaired part of the body. 
Inherent shortcomings to the use of prosthesis include the induction of scar 
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tissue formation, loosening and deterioration of the prosthesis limiting the half-
life of the implant, and mobility reduction in the case of joint replacement (9). 
Hence, the field of TE aims to provide alternative treatment prospects by 
typically introducing the use of three major components: biomaterials 
(scaffolds), cells and external stimuli. These three factors compose what has 
been coined as the ‘tissue engineering triad’ and can be applied individually or 
as part of multiple combinations (10) (Figure 1.1). In particular, scaffolds provide 
structural, morphological and biological cues to the cells to facilitate required 
tissue formation and external stimuli direct cells to produce tissue (2). The focus 
of this thesis will be on the use of bone biomimetic scaffolds incorporating 
microRNA delivery as an external stimulus to direct human mesenchymal stem 
cells to produce bone tissue and thus mediate bone repair. 
       
Figure 1.1 Overview of strategies applied in TE adapted from (10). a) Direct implantation of 
cell-free scaffold (grey). b) Cells are harvested, expanded and cultured in vitro using scaffolds, 
then constructs (green) are implanted at a defect site. c) Direct implantation of cell-free bio-
activated scaffold (orange) for localised delivery of bio-stimuli to promote tissue regeneration. d) 
Cells are harvested, expanded in culture, combined with biological cues and cultured in vitro 
using scaffolds, then constructs (blue) are implanted at a defect site. 
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1.2.Bone function, structure and composition  
 
Bone is a highly dynamic tissue, with remarkable remodelling and repair 
capabilities, which functionally provides biomechanical support to the whole 
body whilst permiting locomotion as well as formation of new blood cells and 
promotion of calcium homeostasis (11). Within bone, there are two distinct 
regions that differ in density and structural organisation (Figure 1.2). Firstly, a 
hard and highly dense outer layer is found, denominated compact or cortical 
bone, which accounts for 80 % of the total bone mass of an adult skeleton. 
Secondly, a spongy internal structure named trabecular or cancellous bone is 
found, which accounts for the remaining 20 % skeletal bone mass. In humans, 
trabecular bone  has nearly ten times the surface area of the compact bone and 
an ultimate compressive strength ranging from 5 to 15 MPa (12). It is through 
this interconnected porous network of trabecular bone that a network of 
vasculature is present. Within the interstices of this porous structure the 
medullary cavity is also found enclosing the bone marrow, which is responsible 
for the production of blood cells.              
 
Figure 1.2 Microstructure of bone adapted from (13) and (14). Cortical bone comprises the 
outer layer and is a highly dense structure of osteons and interconnected canaliculi. Trabecular 
bone is less dense and overall displays higher porosity in an interconnected network. Its pores 
allow perfusion by blood vessels and the intersticial space of trabecular bone contains the bone 
marrow.  
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Bone tissue comprises of organic and inorganic phases of an extracellular 
matrix (ECM) in conjunction with a cellular component. The organic phase of 
the ECM is composed of collagen type I fibres in a 95 % and the remainder 5 % 
encompasses proteoglycans as well as other non-collagenous proteins. With 
regards the inorganic or mineral phase, this accounts for almost 2/3 of the total 
bone tissue weight, and nano-sized crystals of hydroxyapatite (nHA) are the 
major characteristic component (70 %). A range of salts including calcium 
carbonate, fluoride, magnesium and sodium are combined with these crystals to 
complete de total inorganic phase of bone. The combination of both the organic 
and inorganic ECM phases results in a composite with high mechanical 
strength: the network of collagen fibres imparts elasticity and permits twisting 
and bending, whereas nHA is hard although brittle, and hence imparts a high 
compressive modulus to the tissue. Overall, this results in a stabilised 
framework which provides the mechanical strength and relative elasticity to this 
tissue, making bone able to resist impact loading (11). 
 
The cellular component of bone is estimated to be 2 % of the total bone mass; 
however, such a small mass is essential for bone metabolic function and 
homeostasis. There are four key cell types within bone: osteoprogenitor cells, 
osteoblasts, osteocytes and osteoclasts. Osteoprogenitor cells and 
preosteoblasts are immature cells committed towards differentiation into the 
osteogenic lineage, representing ~ 1 % of the bone marrow cell population (15). 
Osteoblasts and osteocytes are fully differentiated cells that populate the bone 
matrix. Osteoblasts are responsible for the deposition of new bone matrix 
involving the secretion of collagen type I and other non-collagenous proteins 
such as alkaline phosphatase, osteocalcin and osteopontin to form the so-called 
osteoids. nHA crystals are then deposited in alignment to the osteoid, forming a 
nucleation site that leads to tissue mineralisation and progression to mature 
bone (16). When osteoblasts become confined within the mineralised bone 
matrix they transform into osteocytes, which are mechanosensory cells with a 
pivotal role in the functional adaptation of bone and bone turnover (17). Finally, 
osteoclasts are multinucleated cells derived from monocyte and macrophage 
precursor cells located in the haematopoietic stem cell niche. They function as 
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resorptive cells by breaking down bone through a catabolic process called 
osteolysis (11, 18).  
 
1.3.Bone formation, remodelling & repair  
 
The cellular component of bone works globally to maintain a dynamic balance 
between the processes of bone formation and resorption, which is collectively 
referred to as bone remodelling (Figure 1.3) The equilibrium between bone 
formation and remodelling is critical to maintaining a healthy and functional 
tissue and is also a fundamental part of the bone repair process. 
 
Figure 1.3 The bone remodelling cycle, taken from (11). Schematic representation of the 
concerted function of every cellular component of the bone in the remodelling process, in order 
to maintain the mineral homeostasis and healthy bone turnover. 
 
Two main bone developmental processes can be distinguished: 
intramembranous ossification and endochondral ossification. The process of 
intramembranous ossification takes place in the formation of flat bones, such as 
skull bones, and involves the direct differentiation of mesenchymal stem cells 
(MSCs) into osteoblasts, which is defined as osteogenesis (19). On the other 
hand, endochondral ossification, the process responsible for long bone 
formation and elongation, implies an initial MSC condensation process to form a 
temporary cartilaginous template that is ultimately transformed into bone (20).  
 
1.3.1.Osteogenesis 
The process of osteoblast differentiation and bone formation is referred to as 
osteogenesis and the complex signalling mechanisms underlining this process 
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are summarised in Figure 1.4. Activation of osteogenesis is extracellularly 
triggered by several anabolic factors such as bone morphogenetic proteins 
(BMPs) and wingless-related integration site proteins (Wnts). Additionally, 
interplay with transforming growth factor beta (TGFβ), fibroblast growth factor 
(FGF) and insulin-like growth factor (IGF) signalling pathways also modulate the 
osteogenesis process (21). These extracellular signals are transduced to 
ultimately activate transcription factors of osteogenesis including runt-related 
transcription factor-2 (Runx2), the major driver that induces characteristic 
patterns of osteogenic gene expression. 
 
Figure 1.4 Molecular mechanisms of osteogenesis.  MSCs differentiate along the osteogenic 
lineage to become osteogenic progenitor cells (OPC) and then osteoblasts (OB) in progressive 
maturity stages. This process is initiated by extracellular ligands and transduced to the 
transcription factors by the intracellular signalling molecules. The transcription factors drive 
osteogenesis by orchestrating the gene expression of the cells. Red brake symbols (  ) 
indicate signalling pathways inhibitory for osteogenesis. Arrows designate activation of 
osteogenesis. 
MSC mediated osteogenesis can be divided in 3 distinct stages, each of them 
associated with particular gene expression profiles (Figure 1.5): (i) proliferation, 
(ii) ECM deposition and (iii) mineralisation (22). During the proliferative phase, 
genes such as activator protein-1, histone H4 and collagen type I are 
upregulated, which then decrease during the following stage of ECM 
production, for which alkaline phosphatase (ALP) is a pivotal marker. When 
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ALP expression declines osteocalcin and osteopontin simultaneously increase, 
which are late stage markers of mineralisation and maturation (23). 
 
Figure 1.5 Expression of bone formation markers over time, taken from (24). AP-1, H4 and 
COL I are measures of proliferation. Activator protein-1 (AP-1) represents c-fos and c-jun which 
are cell growth regulated genes. H4 histone is a cell cycle gene which reflects DNA synthesis. 
COL I is collagen type I. Alkaline phosphatase (AP) is expressed during matrix maturation. 
During the mineralisation phase, osteopontin (OP) and osteocalcin (OC) are expressed and 
calcium (Ca2+) is deposited. 
1.3.2.Bone repair and the role of angiogenesis  
Bone tissue has regenerative potential owing to the natural activation of a 
number of mechanisms immediately following tissue damage. The majority of 
bone fractures heal via a process involving callus formation (Figure 1.6;(11)). 
This process is initiated by the bleeding associated to the disruption of blood 
vessels resident in the bone. The augmented presence of blood components at 
the injure site begins an inflammatory reaction, in which a series of growth 
factors concentrate. These recruit osteoprogenitors and angioprogenitors to the 
damaged area. Consecutively, the second and third stages involve the 
formation and maturation of both an external soft callus and an internal hard 
callus to stabilise the fracture. Finally, during the late stage of bone repair an 
intensive remodelling activity takes place to revert both calli to the physiological 
size and structure of the pre-existing bone over a period of 6 to 8 weeks.  
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Figure 1.6 Diagram of the events in the course of repair of a bone fracture, adapted from 
(11). Initially a blood clot or fracture haematoma forms. The internal and external callus form to 
stabilise the edges of the defect and intensive remodelling takes place to complete the bone 
repair process. 
Another critical process within bone repair is the generation of a new 
microvascular network, mediated by angiogenesis and vasculogenesis. Both 
processes are guided by the morphogen vascular endothelial growth (VEGF) 
(11). Ultimately, the new vasculature surrounding the bone defect site allows 
the transport of oxygen, nutrients, growth factors and cells which are necessary 
and essential to support the osteogenic role of MSC as well as to promote bone 
formation and remodelling (11, 25).  
1.3.3.Bone defects and current clinical interventions  
Although bone has an intrinsic capacity for self repair, the healing of large bone 
defects that typically present in humans often involves complications, leading to 
delayed or non-union of the defects in roughly 10 % of all fractures which 
ultimately require surgical intervention (26). This renders bone as the second 
most transplanted tissue worldwide, next to blood, with approximately 2.2 
million conventional bone grafting procedures carried out globally every year 
(27) and a market value in excess of $2.5 billion only in the US (28). 
Specifically, surgical interventions commonly address the treatment of trauma-
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induced critical-size fractures or replace disease-related bone voids. The latter 
result from primary tumour resection, spinal fusion and dental surgery, as well 
as weakened and fractured bone associated to osteoarthritis. Failure rates as 
high as 30 % have been documented following the use of the current gold 
standard, that is, autologous bone grafting (26). Thus a substantial and unmet 
need for the development of tissue-engineered bone grafts still exists.  
In bone TE, focus is placed on the regenerative potential of several cell types to 
lay down bone tissue as well as in designing a biomaterial scaffold that upon 
implantation in the defect site is capable of both housing those cells and 
withstanding the mechanical loading typical of native bone tissue. The pre-
requisites to the development of TE scaffolds for bone repair and current types 
of materials relevant for this application are described in detail in following 
sections of this chapter. Although a number of commercially available tissue-
engineered bone grafts exist (29), incorporation of external stimuli within the 
scaffold is frequently needed to achieve optimal therapeutic potential required 
for successful repair of large bone defects (30). In that frame of mind, efforts 
have concentrated in the incorporation of several types of biomolecules which 
will also be reviewed in following sections of this chapter. 
1.4.Cells for bone Tissue Engineering 
 
By definition, bone TE encompasses the use of living cells and/or their 
extracellular products (2). Cell-based bone TE approaches involve the re-
implantation at the defect site of in vitro-cultured cells, which may be autologous 
or allogeneic. Regardless of their origin, cells used in TE can be expanded to 
provide sufficient numbers for tissue repair, or, on the other hand, they can be 
‘engineered’ or modified to enhance their regenerative capacity. This can be 
done by utilising a range of culture regimes and/or bio-stimuli in vitro. 
Furthermore, a plethora of immortalised cell lines and primary cells have been 
used in vitro to evaluate different aspects of bone TE biomaterials designed for 
prospective cell-free application. Overall, cell lines offer a suitable environment 
for in vitro testing, due to their accessible sourcing and long-term maintenance 
up to high passage numbers. However, primary cells are of greater use in TE 
research since they have good in vitro-in vivo correlation (31). The ST2 and 
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MC3T3-E1 cell lines are examples of clonal, non-transformed stromal and pre-
osteoblastic cells respectively. Both cell lines show the ability to produce 
calcified bone tissue in vitro (32, 33). In contrast, primary cells are directly 
expanded in culture following extraction from a donor, meaning that they are 
non-clonal and not immortalised. Of interest to bone repair, human umbilical 
vein endothelial cells (HUVECs) are a mature endothelial cell type regarded as 
an excellent tool to analyse angiogenic function in culture with different 
angiogenic cues (34). As angiogenesis is crucial for bone repair, the angiogenic 
potential of bone TE therapies is an important parameter to examine and this 
will be explored in Chapter 5 of this thesis. 
Stem cells are an attractive cell type for bone repair applications, given their 
vast regenerative potential. Many sources of adult stem cells can be found in 
the body (35), which are preferred to embryonic stem cells (ESCs) due to 
ethical concerns. Among the different types of adult stem cells, those derived 
from the mesenchyme (MSC) have been widely explored for several TE 
applications (4, 36), and their remarkable success in both pre-clinical and 
clinical trials over the last decade has highlighted their therapeutic value (37). 
Of note, over 490 clinical trials have been conducted or are underway involving 
MSCs (38). The term ‘mesenchymal stem cell’ was coined by Caplan et al. (39), 
who modified the initial-sharing terminology of  ‘marrow stromal cells’ which was 
in practice at the time to designate this cell type (36, 40). This is because their 
work demonstrated the multipotency of these cells. Particularly, these cells were 
shown to be able to both self-renew and give rise to all mesenchymal tissue 
types, including osteoblasts, chondrocytes, adipocytes and myocytes (Figure 
1.7; (39)). Currently, it is accepted that MSCs function to maintain organ 
integrity (35); hence MSC-like cells have been proposed to reside in virtually all 
tissues and organs in the body (36). MSCs can be found within the bone 
marrow (BM), umbilical cord (41), adipose tissue (42), peripheral blood (43), 
amniotic fluid (44), dental pulp (45) and placenta (46).  
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Figure 1.7 Diagram representing the differentiation of MSCs into various mesenchymal 
lineages, adapted from (47). 
MSCs are considered a promising cell source for TE strategies due to their 
aforementioned multipotency as well as because of their relative ease of 
harvest and immunosuppressive capacities (36, 47-49). The process of 
harvesting and isolating MSCs is aided by their plastic-adherence ability (40). In 
order to fully characterise MSCs, a number of markers need to be assessed 
(50, 51) in addition to their tri-lineage potential, namely the ability to differentiate 
into osteogenic, adipogenic and chondrogenic lineages (52). With regards the 
immunosupresive potential of MSCs, it has been shown that they control a low-
state of local immune surveillance of the damaged tissue, which benefits the 
process of tissue repair (47, 53-55). Additionally, pro-chondrogenic treatments 
are also of interest in approaches that recapitulate the process of endochondral 
bone formation (56). Addition of dexamethasone, β-glycerol phosphate and 
ascorbate-2-phosphate to the growth culture medium is considered a standard 
technique to drive MSCs towards the osteogenic pathway (57). In particular, 
BM-MSCs are the cell type of interest to this thesis, as they have shown 
enormous potential for bone regeneration when used in vivo in rats, mice, dogs 
and sheep (58), and have progressed to a Phase 2 clinical trial for the treatment 
of non-union fractures by direct administration in the defect site (38). 
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1.5.Biomaterials for bone TE 
Biomaterials research is a major field and influences the medical device, TE 
and drug delivery industries, with a global market value estimated at $200 billion 
dollars annually (59, 60). Overall, biocompatibility, bio-resorbability and ease of 
fabrication are key pre-requisites of biomaterials for use in TE applications (61). 
A biomaterial must be well tolerated upon implantation into the recipient, without 
generating rejection or an excessive immune reaction. The bio-resorbability of 
the material should allow native tissue to fully replace the defect site and 
prevents the need for subsequent surgical procedures. This implies that 
degradation of biomaterials must generate non-toxic and non-immunogenic by-
products in order to avoid undesired effects in the long term. Additionally, 
biomaterial fabrication should involve ease of sterilisation, stability and long 
term storage (62), highly important from the perspective of clinical applicability. 
 
For specific application as bone graft substitutes, biomaterial scaffolds must 
meet two additional key requirements: osteointegration and mechanical 
strength. Osteointegration refers to the ability of the construct to support cellular 
interaction, adhesion and proliferation, as well as ECM deposition. The 
mechanical strength relates to the ability of the construct to allow clinical 
handling as well as to withstand mechanical loading. Additionally, mechanical 
properties can stimulate the residing cells to enhance bone repair (63). 
Importantly, porosity and pore interconnectivity affect both the osteointegration 
and mechanical properties of the scaffold. Porosity can be defined as the 
percentage of void space within a scaffold (64) and is inversely proportional to 
mechanical strength or stiffness (65, 66). However, a highly porous, 
interconnected structure is beneficial for osteointegration and furthermore 
prevents core necrosis of the scaffold (67). Thus a compromise in the level of 
porosity must be reached to balance mechanical properties and 
osteointegration. In addition, the inclusion of nano-features in the internal 
structure of a scaffold may provide improved properties for cell interaction 
(Figure 1.8). Hence nanotechnology is increasingly influencing the design of TE 
scaffolds (68, 69). Taking into account all the aforementioned criteria, the 
development of the ideal off-the-shelf scaffold remains a challenge (69) and the 
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biomaterial composition of the scaffold also greatly influences the potential for 
success. Four distinct types of biomaterials are typically used in the field of 
bone TE: synthetic and natural polymers, ceramics and composites (70, 71).  
  
Figure 1.8 Cell-scaffold interaction varies depending on micron or nano-sized pores and 
features within the scaffold architecture, adapted from (68). Cells binding to scaffolds with 
microscale architectures flatten and spread as if cultured on flat surfaces, whereas larger 
surface area is available for contact on scaffolds that present their binding motifs on nano-scale 
pores and features, therefore improving cell attachment and cellular interactions.  
 
1.5.1.Synthetic polymers 
A range of synthetic polymers have shown promise in bone TE due to their 
versatility, which allows for tailoring and manipulation of their architectural and 
mechanical properties. These include polyethylene-glycol (PEG), 
polymethylmethacrylate (PMMA), polycaprolactone (PCL), and co-polymers of 
polyglycolide and polylactide (PLGA) (72, 73). The tailoring of their properties, 
in terms of strength, stiffness, porosity and degradation rates, is controlled by 
altering chain lengths and proportions of the components in case of mixtures. 
Although these materials hold Food and Drug Administration (FDA) approval for 
TE purposes, frequently their degradation generates acidic by-products which 
trigger inflammation responses (74-77) that exert an inhibitory effect on tissue 
formation (75). 
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1.5.2.Natural polymers 
Polymers of natural origin applied to TE typically involve components of natural 
ECM and hence present natural ligands that provide active sites for cell 
chemotaxis and adhesion, which make them bioactive. Commonly used natural 
polymers include collagen, elastin, gelatine, alginate, silk fibrin, chitosan, 
glycosaminoglycans and hyaluronic acid (70, 78-86). An alternative approach to 
the use of natural bulk polymers as scaffolds involves decellularisation of 
natural ECMs from tissue extracted from different sources. Overall, natural 
materials possess high biocompatibility and bioactivity, however their 
mechanical properties tend to be poor unless chemically or physically reinforced 
by a stiffer filler material or by applying cross-linking methods (87).  
Collagen is of particular interest for TE applications as it is the most abundant 
protein found in the ECM of all body tissues (88-90). More specifically, collagen 
type I is a key component of the ECM of skin, blood vessels, tendon, cartilage 
and bone (91, 92). Although collagen type I has demonstrated capabilities of 
conducting osteogenesis in vitro (93), it is also susceptible to rapid degradation 
rates. Thus, the development of a number of hybrid collagen-based constructs, 
which show superior physical properties in comparison to collagen alone, has 
been the focus of research for over a decade in the bone TE field. This includes 
intensive efforts in our Tissue Engineering Research Group (TERG) at RCSI 
that led to the development of a series of collagen-based constructs which 
display a highly porous architecture (7, 94-97). From these, a composite 
scaffold containing a ceramic of particular interest for bone repair, namely nano-
sized hydroxyapatite (nHA;(97)), is described in further detail below as it 
represents a key component of the work presented in this thesis.  
      
1.5.3.Ceramics 
Ceramics are inorganic crystalline structures made up from inorganic materials, 
with characteristically high melting points and high hardness. However, their 
brittleness and difficulties in reproducible fabrication limit their applicability in 
TE. Within this group of biomaterials the following types are used in bone TE: 
bioactive glasses, calcium carbonates and coral as well as calcium sulphates 
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and calcium phosphates. Bioactive glasses and calcium carbonates are able to 
enhance bone mineral deposition (98, 99), however they tend to very brittle 
(100). The more applicable ceramics for bone TE are calcium sulphates and 
more importantly calcium phosphates (CaPs), both of which are highly bioactive 
and, depending on the phase used, resorbable (99, 101). Specifically, CaPs are 
the most ubiquitous group of bioceramics in nature and they exhibit excellent 
bone-bonding properties. CaPs exist in different forms, including brushite, tri-
calcium phosphate and hydroxyapatite (HA; (102-108)), which differ mainly in 
the stoichiometric proportion of calcium to phosphate. HA is also found in the 
mineral component of teeth and bone (69, 109), and its detailed properties are 
described below, owing to the central role of nHA particles to the research 
presented in this thesis.  
1.5.3.1.Hydroxyapatite  
 
Hydroxyapatite (Ca10(PO4)6(OH)2) is a type of CaP that belongs to the class of 
minerals termed apatites. The main common feature of apatites is the 
disposition of the crystals in a hexagonal structure, first described in 1930  
(Figure 1.9; (110, 111)). Moreover, HA constitutes 70 % of the bone mineral 
phase in its crystalline structure (69, 109), and its bioactive properties are 
widely recognised. HA is clinically approved and is found commercially in a 
variety of forms including granules, pastes, cements and porous blocks, all of 
which are collectively used as bone fillers, in dental surgery or as coatings for 
the implantation of synthetic prosthesis (112). Furthermore, HA osteo-
conductive and osteo-inductive properties have previously been demonstrated 
in vitro and in vivo as reviewed by Habibovic et al. (113). Nano particulate HA 
(nHA) has proven to have enhanced osteointegration properties compared to 
micro and macro scale HA particles (114-119). This is because it displays high 
surface grain size and roughness, which leads to decreased brittleness and 
improved resorbability properties (120, 121). Additionally, the nano-features of 
HA also have a positive effect on cell proliferation and reduce cell apoptosis 
(122). Much ongoing research in the nHA area focuses on the development of 
improved methods for nHA particle synthesis and the subsequent incorporation 
of nHA into composite scaffolds involving synthetic and natural polymers.  
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Figure 1.9 Diagram of the three-dimensional (3D) structure of crystalline hydroxyapatite. 
Hydroxyapatite single unit crystals adopt hexagonal spatial organisation as typical of the apatite 
family of minerals. Calcium atoms are positioned within the screw axis (yellow) or at the 
vertexes of the hexagon (blue), while phosphorus atoms (magenta) are located in an 
intermediate position between the screw axis-calcium and the oxygen atoms, represented in 
green, distributed throughout the hexagon. 
1.5.3.2.Synthesis of HA and nHA 
 
Significant advances in HA and nHA synthesis have been based on wet 
chemical precipitation methods due to the simplicity and low cost of these 
techniques, which also allow for the modification of conditions which control HA 
stability. These conditions include the pH, solvent, temperature, pressure, 
nature of precursors and the complexing agents used for controlling the reaction 
kinetics (123). Two main routes of wet chemical synthesis of HA have been 
exploited using phosphoric acid as a key precursor. However, these reactions 
are limited by the formation of toxic by-products, which lead to the development 
of an alternative and more biocompatible technique by Kumta et al. (123), which 
was based on CaCl2, Na3PO4 and NaOH precursors (Equation 1.1). 
Equation 1.1 
10CaCl2 ∙ 2H2O +  6Na3PO4 ∙ 12H2O + 2NaOH →  Ca10(PO4)6(OH)2 +  20NaCl +  92H2O  
The reaction proposed by Kumta et al. was the focus of recent work in our 
laboratory which developed a novel synthesis technique for nHA particles 
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involving the use of low concentrations of a commercial solution of sodium 
polyacrylate, Darvan 821A®, as a dispersing agent (124). This synthesis 
technique prevents particle aggregation during the synthesis by wet 
precipitation (124, 125) and has been utilised in our laboratory for the 
development of composite collagen-nHA based scaffolds (97) and the use of 
nHA particles as non-viral vectors for plasmid deoxyribonucleic acid (pDNA) 
delivery for gene therapy in bone TE (126, 127). 
1.5.4.Composite scaffolds of polymers and ceramics 
The combination of ceramics with either synthetic or natural polymers 
represents a logical approach in the development of bone graft substitutes with 
enhanced therapeutic potential compared to scaffolds composed of either 
individual phase alone (128-132). The mechanical properties of scaffolds based 
on synthetic polymers can be enhanced when reinforced with nHA particles 
(133). The biological performance and in vivo bone healing potential of 
composite scaffolds have also been improved when incorporating nHA particles 
into collagen-PLGA and gelatine based scaffolds (76, 134, 135). Additionally, 
the potential of collagen-HA scaffolds for bone repair can be enhanced by 
varying the fabrication method and particle size of the HA phase (136, 137).  
A collagen (coll)-nHA composite scaffold has been developed in our laboratory, 
which meets all requirements for bone-grafting (Figure 1.10). It is fabricated 
using a lyophilisation process previously implemented in our laboratory (94, 
138, 139). This involves the growing of ice crystals within a collagen solution 
during the freezing process which subsequently sublimate during the drying 
phase, ultimately leaving the collagen fibres arranged in a continuous and 
highly porous network. The final freezing temperature determines the pore size 
of the resulting material which can range from 85 - 325 μm (94, 138, 139). In 
addition, physical and chemical crosslinking methods have been established, to 
structurally reinforce these scaffolds and reduce their degradation rates. These 
coll-nHA scaffolds have demonstrated significant osteogenic potential in vitro 
and in vivo (7, 97) and have since been successfully applied in our laboratory 
as bioactive depots for gene delivery. Collectively this previous research 
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illustrates the immense potential of the coll-nHA scaffolds to serve as depots for 
the localised delivery of microRNAs, which is the primary aim of this thesis.  
 
Figure 1.10 Coll-nHA scaffold synthesised in RCSI TERG, adapted from (125). a) 
Representative micro-computed topography image, scale bar 1 mm. b) Representative Energy 
Dispersive X-Ray map of a coll-nHA scaffold showing the widespread distribution of calcium 
(green), phosphate (blue) and sodium (red) overlying a corresponding scanning electron 
microscopy (SEM) image. 
 
1.6.Biomolecule delivery to enhance healing in bone TE 
The administration of biomolecules to progenitor cells is a frequent strategy to 
direct the cells towards enhanced matrix production and de novo tissue 
formation. From this perspective, several types of biomolecules may be 
incorporated as extra agents in bone TE strategies to enhance tissue healing. 
Intensive research efforts over the last 15 years have focussed on advancing 
the application of growth factors (140) and gene therapy (141), while the 
application of ribonucleic acid induced interference (RNAi) has started to 
emerge within the overall TE field over the last five years (142, 143). 
 
1.6.1.Growth factors 
Growth factors (GF) are large polypeptide molecules that play a pivotal role in 
the information transfer between cells and their microenvironment during 
morphogenesis and tissue repair (Figure 1.11). The multi-faceted effects of GFs 
can be divided in the following: (i) mitogenic; stimulating cell division, (ii) 
a b
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chemotactic; triggering cell migration, (iii) morphogenic; instructing cell 
differentiation, (iv) apoptotic; inducing cell death and (v) metabolic; modulating 
cell metabolism (144-146).  
 
Figure 1.11 Cross talk between cells mediated by growth factors (GFs) and ECM, taken 
from (147). GFs secreted by producer cells bind transmembrane receptors and the signal is 
transmitted into the cell through complex signal transduction machinery to elicit a specific 
biological response. The ECM can also influence this process by releasing GFs upon 
degradation or influencing cell migration towards gradients of GFs.  
The GF concentration and GF exposure duration are critical factors that dictate 
the eventual cell fate. In the case of morphogen GFs, concentration gradients 
are known to regulate embryonic development as well as tissue regeneration 
(148). Of particular interest, MSC osteogenesis can be modulated by altering 
the GF availability (149). The GFs most widely applied in bone TE as osteo-
inductive factors are BMPs (150) and VEGF (151-153), detailed in subsections 
below. Alternatively, the application of additional GFs involved in the bone 
repair process has also been approached. FGFs (154, 155), TGF-βs (156-158) 
and platelet-derived growth factors (PDGFs) (159, 160), as well as parathyroid 
hormone (PTH) (161, 162) and PTH related peptide (PTHrP) (163, 164) have 
reported stimulation of bone healing in vivo. More recently, the application of 
GFs in a combinatorial manner has emerged as an attractive avenue of 
research. Multiple combinations have proven beneficial compared to the effect 
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of the single GFs, including combinations of (i) BMPs with VEGF, FGF-2, 
PDGF, IGF-1, PTH, TGF-β3 and BMP binding protein (BBP), (ii) VEGF with 
FGF-2 or PDGF, (iii) FGF-2 with PDGF, IGF-1 or PTH, and (iv) PDGF with IGF-
1 or TGF- β1 (165).  
The major drawback associated with the application of GFs for bone repair is 
their sort half-life, which ranges from minutes to hours in vivo due to enzymatic 
degradation. Hence difficulties arise with achieving the local bioactive 
concentrations for the sustained time period needed to improve tissue repair. 
Frequently this results in the application of high doses with the associated 
increased cost, which may be prohibitive to widespread clinical use (166). 
Of relevance, an indirect route of administering the selected GFs surfaced more 
than a decade ago, which consists on the use of gene therapy to introduce GF-
encoding genetic material to progenitor cells, as discussed in further detail in 
the next section. 
1.6.1.1.Bone morphogenetic proteins (BMPs) 
The significance of BMPs to direct bone formation was first discovered in 1965 
(167). To date, over 30 BMPs have been discovered (144, 168), among which 
BMP-2, -4, and -7 are able to stimulate new bone formation in vivo in critical- 
sized defects (25). Importantly, BMP-2 and -7 delivery from collagen type I 
sponges has been approved by the FDA for restricted clinical use (169) and 
commercialised as Medtronic’s INFUSE® and Olympus Biotech’s OsigraftTM 
respectively (30). However, both products have reported numerous side effects 
and complications associated with the uncontrolled release of the BMPs from 
the collagen sponges (166). Such reports have emphasised the need for 
alternative strategies capable of controlling the localised release of GFs at the 
defect site. 
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1.6.1.2.Vascular endothelial growth factor (VEGF) 
VEGF, originally denominated vascular permeability factor, was first identified in 
1983 (170). Subsequently the importance of several VEGF family ligands and 
receptors in cardiovascular, haematopoietic and lymphatic development was 
shown (171, 172). Although the primary function of VEGF is the stimulation and 
migration of endothelial cells, it has also a demonstrated essential role in 
intramembranous and endochondral bone formation (173, 174). However, 
precise control over the levels of VEGF available to the cells is a pre-requisite 
that limits its clinical applicability (175), as supraphysiological VEGF levels lead 
to uncontrolled vessel formation, which is in high association with tumour 
growth (176). This makes local confinement of VEGF at the defect site of critical 
importance for VEGF-based bone repair strategies (146, 177). 
 
1.6.2.Nucleic-acid based therapy: Gene & RNA interference  
 
Nucleic-acid based therapy entails the introduction of genes or RNA 
interference (RNAi) to elicit a therapeutic effect on cell fate and metabolism and 
has been considered the medical treatment of the future (178). The number of 
nucleic-acid based therapy trials currently underway affirms the continued 
interest in the promise of its application (179). Originally, gene therapy emerged 
as a strategy to transform the target cells into producing factories of therapeutic 
protein. With this frame of mind, genes encoding a number of GFs and proteins 
have successfully been applied to bone repair including BMPs (71, 180), Runx2 
(181), IGFs and TGFs (182), PDGF (183-185), FGFs (186, 187) and VEGF 
(183, 184, 188). Currently, gene therapy has slowly progressed as a mature 
area of medicine (189) and the classical paradigm of genes as mere encrypted 
messages for protein production (190) has shifted to the interpretation of genes 
as ‘units of genetic information that code for proteins but also for RNA 
molecules with transcriptional, regulatory and/or other functional activities’ 
(Figure 1.12; (191, 192)). This implies that gene therapy can be used with 
objectives beyond inducing protein production. This is the case of harnessing 
RNAi therapy (193), where different RNAi molecules ultimately result in 
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inhibition of protein synthesis. The process of protein-silencing mediated by 
RNAi is presented later in further detail. 
 
Figure 1.12 Types of genetic information that may be encoded in a gene. A gene contains 
information that generates messenger (m)RNA or enzymatic RNAs. The final port of stable 
mRNA is the production of protein, with the cooperation of transfer (t)RNA and ribosomal 
(r)RNA and controlled by the RNA interference (RNAi) molecules. Long non-coding (lnc)RNAs 
and Piwi-protein associated (pi)RNAs are involved in additional enzymatic functions. 
A key accessory to nucleic-acid based therapy is pDNA, a stable nucleic acid 
structure naturally found in bacteria, which replicates independently of the core 
genome and thus serves as an endogenous route for the transfer of genetic 
information during the process of bacterial conjugation (194). pDNA can be 
engineered to incorporate a gene of interest and introduced to bacterial cells; 
bacteria then act as factories of pDNA copies and these copies are later 
extracted and purified to generate the pDNA that will be administered as a 
therapeutic. In classical gene therapy the gene of interest is protein-coding 
(195), but genes encoding short hairpin (sh)RNA or precursors of microRNA 
(miRNA) can also be incorporated into the plasmid in RNAi therapy.  
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Nucleic-acid delivery presents an opportunity to overcome the drawbacks 
associated with GF delivery, such as detrimental bolus effects (26, 196) as it 
offers the ability to engineer cellular protein production for a sustained time 
frame that mirrors the physiological response (Figure 1.13). While the sustained 
time frame of action is highly beneficial in TE applications, it is also crucial that 
the therapeutic effect comes to an end by the time that the tissue repair process 
is completed. In this context, the application of nucleic-acid based therapeutics 
to TE seeks to temporarily increase the ability of the target cells to produce 
tissue while avoiding to permanently modify their behaviour and regenerative 
potential, thus preventing undesired effects derived from permanent genome 
modification such as pathological tissue overgrowth. 
  
Figure 1.13 Nucleic acid delivery versus protein delivery, adapted from (195). With protein 
delivery, a large bolus release of the protein detrimental to healing is seen in the initial phases, 
which quickly subsides to levels that are inconsequential to tissue repair. In comparison, nucleic 
acid based therapy strategies do not cause an initial damaging bolus release of protein and the 
level remains constant to enhance the therapeutic effect over the relevant timeframe.  
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1.6.3.Gene expression control by RNAi 
RNAi plays a pivotal function as an intermediary controller of gene expression. 
When the expression of a protein-coding gene is activated, the transcription 
process takes place (192). Transcript messenger (m)RNA copies are generated 
from the template DNA strand, which locate to the cytosol. Here the translation 
process ultimately leads to synthesis of amino-acid chains which conform the 
coded protein (192). Prior to the translation process, mRNAs can encounter the 
mature RNAi molecules in the cytosol and undergo RNA-induced silencing 
(197-204).  
 
The RNA-induced silencing pathway (Figure 1.14) involves the processing of 
long double-stranded (ds)RNA, naturally or artificially found within the cell, into 
smaller RNAs such as shRNA, small interfering (si)RNA and miRNAs, that 
become incorporated into the RNA-induced silencing complex (RISC; (199, 
205-209)). shRNAs are single strands of RNA ~ 60 nt, that adopt a duplex 
conformation with perfect complementarity and the bent area generating a loop. 
Although they generally are further processed into siRNAs, recent evidence 
indicates that shRNAs may also present silencing activity (210-213). siRNAs 
are complementary perfect duplexes of 2 RNA strands ~22 nt generated from 
longer precursors, one of which elicits silencing activity. Both shRNAs and 
siRNAs bind to mRNA targets displaying perfect base-pair complementarity 
(205, 206). Finally, miRNAs may also be found prior to incorporation into the 
RISC as duplexes of 2 RNA strands ~22 nt generated from longer precursors, 
but these duplexes present imperfect base-pair interactions and their silencing 
activity is also associated with imperfect complementarity binding to the target 
mRNA (205, 206). With regards to the interaction with target mRNAs, a small 
sequence found within their untranslated region (UTR) is recognised by the 
RISC complexes based on perfect (or near perfect) complementarity. Although 
the 3’UTR region is regarded as the main area prone to interact with RISC, it 
has been shown that 5’ UTR regions are also capable of this interaction with 
miRNAs (214). Finally, the interaction of the target mRNA with RISC directs for 
mRNA cleavage or repression of its translation, resulting in a decrease in target 
and/or protein levels (215). 
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Figure 1.14 Pivotal role of RNAi in the control of gene expression, adapted from (216). 
Cellular entry and pre-processing of dsRNA into shRNA, siRNA and miRNA is followed by 
incorportation in the RISC. Target mRNAs interact with these complexes based on perfect or 
near-perfect sequence complementarity to the RNAi seed region. This interaction induces the 
mRNA degradation or translational repression among other more complex functions such as 
transcriptional repression, DNA degradation and alterations in heterochromatin. 
 
1.6.4.RNAi therapy and Stem Cell differentiation  
The application of RNAi therapy has potential to promote the differentiation of 
pluripotent, multipotent and progenitor cells, in addition to accelerating 
differentiation (217). In comparison with gene therapy, advantages of RNAi 
therapy facilitate some aspects of successful intracellular delivery, nowadays 
considered the limiting factor to realising the full potential of nucleic-acid based 
therapies. These include the smaller size of the molecules and their cytoplasmic 
activity, meaning that vectors can carry higher amounts of RNAi cargo than 
pDNA copies and do not need to enter the nucleus. Moreover, each type of 
RNAi cargo offers distinct therapeutic advantages: shRNAs and siRNAs display 
stringent complementarity on single messenger targets, eliciting a focalised 
regulatory effect, whereas miRNAs display a multi-targeting function towards 
several messenger targets, simultaneously controlling complex signalling 
pathways (218, 219). Thus, using miRNAs presents the advantage of increasing 
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the number of targets that can be manipulated simultaneously and intercept 
entire gene cohorts. In this way, a robust and widespread biological response, 
ideal to harness numerous tissue repair processes, is expected from the 
therapeutic delivery of miRNAs. Consequently, out of the different RNAi 
strategies, the application of miRNA therapeutics for TE purposes has begun to 
garner the most attention in recent years (220-224). Another interesting aspect 
of miRNAs, detailed in the following sections, is the possibility to inhibit or block 
their function, therefore providing a bidirectional regulation of gene and protein 
expression. 
 
1.6.4.1.siRNA-mediated stem cell differentiation 
Successful application of siRNA-mediated stem cell differentiation was first 
showcased by Hribal et al. with the administration of pan-Foxo siRNA to induce 
myogenic conversion (225). However, the field evolved slowly and siRNA-
mediated induction of osteogenesis was not reported until 2008, when chordin 
silencing demonstrated increased 4 fold ALP activity and 2 fold calcium 
deposition in hMSCs (226). Following this development, intensive research 
begun in the field, with reports of siRNA-mediated increases in in vitro 
osteogenesis by silencing BCL2C2 (142), LPA4 (227), MTA1 (228), mTOR 
(229), p21 (230), STAT3 (217) and Twist1 (231). All of these reports 
demonstrated an homogeneous ~ 4 fold increase in ALP activity in comparison 
with the control group while using MSCs of mouse and human origin. 
 
1.6.4.2.miRNA-mediated stem cell differentiation 
miRNAs have a pivotal role in regulating embryonic development (215), and it 
has been shown that they can induce similar levels of myogenic differentiation 
in ESCs as those seen with siRNA (232, 233). In particular, the miRNA-based 
induction of osteogenesis can be approached by either mimicking a panel of 
positive miRNAs, such as miR-29b (234), miR-148b and miR-489 (235), miR-
210 (236), miR-196a (237) and miR-2861 (238), or inhibiting a panel of negative 
miRNAs, including miR-30a-d (239), miR-31 (240), miR-100 (241), miR-133a 
and miR-135 (242), miR-141 (243) and miR-214 (244). Due to heterogeneity in 
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the methodology applied, widely variable outcomes in osteogenesis have been 
reported in these studies. These are further discussed in Chapter 3 of this 
thesis where three miRNAs were assessed as osteo-therapeutics, namely miR-
133a, miR-16 and miR-210. 
 
1.7.microRNA discovery, biogenesis & nomenclature 
miRNAs are an abundant and evolutionary conserved class of non-coding 
single-stranded RNA molecules averaging 22 nucleotides (nt) length in their 
mature form. Lin-4 RNA, discovered in 1993, is recognized as the foundation 
member of this class of RNAs in animals (245-247). A number of seminal 
studies in the field progressively unravelled the mechanism of action of miRNAs 
(248-252) and by 2001 over one hundred miRNAs had been identified among 
human, fly and 11 additional species (245-247). The field of miRNA research 
has since evolved at an accelerated pace, and there are over 2500 human 
miRNAs known to date (253), regulating up to 60% of the protein-coding 
genome (254). The importance of miRNA-directed gene regulation is coming 
into focus with increasing numbers of studies unravelling their biological effects. 
Some examples of miRNA function involve (i) the regulation of developmental 
stages of a cell, (ii) lineage commitment, (iii) differentiation, (iv) proliferation and 
(v) apoptosis, as well as (vi) inflammation, immune response events and related 
diseases including asthma and cystic fibrosis, (vii) tumour formation and (viii) 
the progression of viral infections (219, 220, 255-258).  
The biogenesis process of miRNAs can be divided in three main phases: 
transcription, maturation and RISC assembly (Figure 1.15). Initially miRNAs are 
transcribed either as intronic regions of protein-coding genes, separated from 
the exons during the splicing process, or directly as long primary transcripts 
from miRNA genes, termed pri-miRNAs, which can contain clusters of miRNA 
stem loops (259). Next, during the process of miR maturation a precursor 
miRNA (pre-miRNA) is generated in the nucleus by Drosha, which cleaves both 
strands of the pri-miRNA leaving a 60–70 nt stem loop intermediate (259, 260) 
with 5’ phosphate and ~2 nt 3’ overhang ends (261, 262). This pre-miRNA is 
actively transported to the cytoplasm by Ran-GTP and Exportin-5 (263, 264) to 
subsequently undergo processing by Dicer (202, 265)(24). Dicer cuts both 
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strands at the proximity of the stem loop, producing an imperfect duplex, termed 
miRNA:miRNA* (266). The half-life of this duplex is short and the two strands 
separate to yield the mature miRNA single strand and the opposing arm of the 
former duplex, that is designated miRNA*. The miRNA* fragment is more 
unstable and as such it is detected at much lower frequencies than the 
counterpart mature miRNA (267, 268). Finally, the mature single stranded 
miRNA is assembled into the RISC in a pathway that shares many 
characteristics with siRNAs, as earlier depicted in Figure 1.16. It has been 
proposed that the strand that presents the less tightly paired 5’ is directed for 
entry into the RISC (269, 270), and the formation of this complex has been 
coined as miRISC (271). Downstream from the formation of miRISC the 
interaction with the target mRNA takes place, which subsequently leads to 
mRNA cleavage or translational repression (215, 254).  
      
Figure 1.15 miRNA biogenesis taken from (272). A miRNA gene is transcribed generating the 
primary (pri)-miRNA. In the nucleus, Drosha cleaves the pri-miRNA to produce the precursor 
(pre)-miRNA. Exportin-5 transports the pre-miRNA into the cytoplasm, where it is cleaved by 
Dicer, releasing the miRNA:miRNA* duplex. The miRNA strand (red) is loaded into the RISC 
complex, whereas the miRNA* strand (green) is typically degraded.  
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From the discovery of the first miRNA, great lengths have been taken to 
establish a uniform nomenclature system to designate the different biogenic 
stages and variants, summarised in Table 1.1. This nomenclature system also 
maintains an orderly organisation of newly discovered miRNAs based on 
sequencing data and prevents overlapping in the denomination of new miRNAs 
(273). Specific nomenclature has also been established to designate the 
different types of base-pairing interaction that can take place between a miRNA 
and its target. In general, any miRNA is designated by using the prefix ‘miR’ 
followed by a number of 1 to 4 figures which is set based on order of discovery 
while taking into account sequence similarity or homology with previously 
known miRNAs. Moreover, based on evolutionary conserved sequences certain 
miRNA families have been established whose members present a high degree 
of homology, in particular in relation with their seed region on the 5’- end. 
Table 1.1 Nomenclature established for designating miRNAs and their types of 
interaction with the target mRNAs. 
Term Definition 
miR-XX miRNA coding gene 
mir-XX precursor hairpins (lower case) 
spp – miR-XX mature sequence miR-XX designated for a determined species 
miR-XX-1; miR-XX-2 mature identical sequences proceding from different genes  
(i.e. distinct pri-miRNA loci) 
miR-XXa/b closely related mature sequences differing in only 1 or 2 nucleotides 
miR-XX-5p/3p different mature miRNA sequences excised respectively from 5’- and 3’-arms of the 
same pre-miRNA  
(new nomenclature replacing miRNA and miRNA*) 
miRNA::mRNA Interaction of a miRNA and its target mRNA 
6mer-1A An exact match to positions 2-6 of the mature miRNA (the seed) followed by an 
adenine (‘A’) 
6mer An exact match to positions 2-7 of the mature miRNA (the seed) 
7mer-1A An exact match to positions 2-7 of the mature miRNA (the seed) followed by an 'A' 
7mer-m8 An exact match to positions 2-8 of the mature miRNA (the seed + position 8) 
8mer-1A An exact match to positions 2-8 of the mature miRNA (the seed + position 8) followed 
by an 'A' 
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1.7.1.Exogenous control of miRNA  
Synthetic molecules have been developed for either mimicking or inhibiting the 
function of endogenous miRNAs (299). On the one hand, miR-mimics act in the 
same manner as the endogenous miRNA, that is, binding to a target mRNA and 
subsequently causing suppression of protein synthesis by degrading the mRNA 
or inhibiting the translation into protein. Modifications for enzymatic stability and 
improved cellular uptake are limited for the “guide” strand to be suitable for 
incorporation into the RISC (303). On the other hand, miRNA inhibitors prevent 
the activity of miRNAs inside the cell, thus leading to an increase in mRNA and 
protein expression (274). Among the alternatives to pursue miRNA inhibition, 
antimiRs or antagomiRs can be chemically modified for improved binding 
affinity to the target miRNA strand and enhanced enzymatic stability (218). 
Some of these modifications include methylations to bridge the ribose in a 
locked postion, generating locked nucleic acids, and replacement of the 
phosphate backbone with methylations, thiolations or morpholino groups. In 
addition to the development of antagomiRs, “blockmiRs”, miRNA sponges and 
small chemical inhibitors have also been developed to abrogate miRNA-induced 
silencing (218), which offer high pharmacodynamic control but also present with 
drawbacks: blockmiRs limit the simultaneous multiple targeting of miRNAs, 
miRNA sponges are delivered as pDNA (275) and small chemicals present 
decreased specificity towards particular miRNA targets (276).  
1.7.2.miRNA therapeutics  
miRNA therapy accounts for a subset of miRNAs currently found in the pipeline 
as clinical candidates for the treatment of fibrosis (miR-21), inflammation (miR-
155), atherosclerosis (miR-33), heart failure (miR-208), cardiac repair (miR-15) 
and neoangiogenesis (miR-92a), as well as hepatitis C treatment (miR-122) and 
liver cancer treatment (miR-34) (223). A miR-122 inhibitor commercialised as 
Miravirsen - by Santaris Pharma -, has progressed to Phase IIa clinical trials, 
with successful results to date (277), and a miR-34 mimic (MRX-34 - by Mirna 
Therapeutics -) is currently in Phase I clinical trials, undergoing patient 
recruitment and with unreported results to date (278). The trends in miRNA 
patent filing capture the dramatic scientific progress in the field and forecast the 
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fast-paced advance towards commercial development in this field: the number 
of filed patents related to miRNA-based therapeutics surpassed 350 in the US 
by 2009 (223) and currently accounts for over 1500 patent applications (279). 
Nearly half of the filed patents were related to medicinal preparations, of which 
efforts in delivery vehicles and preparations represented 14 %, in close position 
with TE-related applications (Figure 1.16). These TE-related applications focus 
on bone, muscular, ocular and cardiovascular disorders as well as in wound 
healing, and accounted for 13 % of the total patent filing distribution. This 
underlines the high interest in developing advanced delivery systems for miRNA 
therapeutics and their incorporation in the field of TE (280, 281).  
Figure 1.16 miRNA-related patent distribution in the United States, taken from (303). a) 
The distribution of different technological fields as determined by International Patent 
Classification codes. b) Distribution of filed patents related to miRNA-based medicinal 
preparations divided by particular indications.  
1.8.Vectors for gene & RNAi delivery 
The delivery of naked nucleic acids, both in vitro and in vivo, has demonstrated 
limited success to-date (282). Due to the negatively charged phosphodiester 
backbone of these molecules and the susceptibility to nucleases their ability to 
enter into the cells is restrained, and once inside the cells they ultimately locate 
in endolysosomal compartments that degrade their content (283). Therefore, an 
important aspect of successful nucleic acid delivery involves the ability of the 
molecules to effectively escape this cellular digestion process, also known as 
endolysosomal escape (284). Hence the use of a delivery vector to carry the 
nucleic acids into the cells and aid the endolysosomal escape is necessary. 
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Different vector types are available that permit gene and RNAi transfer, which 
are broadly divided into two major categories, viral (285-289) and non-viral 
(290-292). By consensus in the field a number of pre-requisites have been 
established (293), summarised in Table 1.2, and the need to develop an ideal 
safe and effective vector that meets all these requirements has not been fulfilled 
to-date (284). Thus effective delivery remains as the greatest challenge to 
unleashing the vast potential of both gene and RNAi therapy.  
 
Table 1.2 Pre-requisites of nucleic acid delivery vectors. 
Fabrication Safety Stability Functionality 
Ease of fabrication Safe administration route 
Robustness/stability 
(chemical) 
Internalisation 
Inexpensive Non-pathogenic 
In physiologic fluids, 
including serum 
Endolysomal escape 
Facile purification Non-toxic 
For storage and 
administration 
Entry in non-dividing cells 
Targetability (to specific 
cells/tissue) 
Non-immunogenic 
Protection of cargo 
Nuclear transport 
(generally not RNAi) 
Packaging sufficient 
amount of cargo 
Efficient un/packaging 
  
1.8.1.Viral vectors 
A wide range of viral vectors may be used for nucleic acid delivery including 
retroviruses, adenoviruses and lentiviruses. By their very nature, viruses are 
excellent at gaining cellular and nuclear entry, which contributes to high levels 
of transfection of the target cells. Retroviruses are highly efficient at entering 
dividing cells, while lentiviruses and adenoviruses can enter both dividing and 
non-dividing cells (294). The first in vivo study using adenoviruses to deliver 
siRNA showed specific target silencing in brain and liver tissue (295). 
Interestingly, dose –dependent toxicity of adenoviral- miRNA delivery is reduced 
in comparison to the use of shRNA and siRNA (296). Additionally, enhanced 
osteogenesis has been shown following viral delivery of miR-424 and miR-31 
inhibitors (297, 298) as well as miR-346, miR-26a, miR-29b, miR-148b and 
miR-196a enhancers (299). In spite of the interest generated by the highly 
efficient nucleic acid transfer that viruses mediate, multiple issues, generally 
related to safety concerns, are associated with the use of these vectors. The 
key issue is the risk of insertional mutagenesis associated with retroviruses and 
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lentiviruses, which may affect host genes, such as was the case in initial 
fatalities within clinical trials (57). Other major drawbacks with viral vectors, 
include immunogenicity, inflammation, limited loading capacity of large size 
plasmids and large scale manufacturing issues (57). Finally the high and 
permanent transfer achieved with these vectors may result in pathological over-
expression of the introduced gene, as documented by cases of ectopic bone 
formation following viral delivery of BMP pDNA (300, 301). In summary, the use 
of viral vectors is very efficient but entails a compromise with regards to their 
safety (302). For this reason, non-viral vectors have become increasingly more 
attractive as safe and valid alternatives (303). 
 
1.8.2.Non-viral vectors 
The advantages of non-viral gene transfer methodologies widely relate to 
increased safety, as they exhibit low immunogenicity and low toxicity. Another 
beneficial factor is that they incur a low production cost and simplified large 
scale production in comparison with viral vectors (304). Although non-viral 
methodologies are sometimes regarded as a minority pursuit in nucleic acid 
transfer, they permit high cargo loads and a temporary release of the RNAi 
cargo or the synthesised protein (280, 305). In TE applications a temporary 
release of the cargo is beneficial to promote tissue regeneration, as this 
reduces the risk of undesired bolus effects at the initial stages while avoiding 
permanent activation of the tissue repair process once the tissue has been 
regenerated. Hence, the temporary effects characteristic of non-viral vectors 
poses a significant advantage for TE applications over the permanent effects 
observed with viral-based delivery (4, 304). Another important consideration in 
applying non-viral delivery vectors is that their transfection efficiencies vary 
depending on the cell type targeted (284, 293, 304), and primary stem cells 
have been deemed more difficult to transfect than immortalised cell lines (306). 
Considering the beneficial prospect of applying MSCs for bone repair over other 
cell types (4, 36, 58), developing non-viral vectors to deliver nucleic acids to 
MSCs remains a major unmet need in TE. 
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Within the different non-viral approaches for nucleic acid delivery, physical and 
chemical techniques can be distinguished. Physical techniques are based on 
temporary disruption of the cell membrane, and involve electroporation, 
hydrodynamic pressure, magnetofection, microinjection and ultrasound 
microbubbles (282). Current developments in chemical non-viral technologies 
include the use of synthetic nanoscale complexes, mainly categorised in (i) 
cationic lipid-based vectors and (ii) synthetic cationic polymers. Numerous 
cationic polymers have been synthesized for DNA and/or siRNA delivery in 
different research fields (307, 308). However, the use of polymer-mediated 
miRNA delivery is rarely reported in the field of TE (309) and in turn, the use of 
cationic lipid-based vectors is widely popular, as summarised in Table 1.3.  
Table 1.3 Representative lipid-based miRNA delivery systems for TE, taken from (298).  
Vector 
miRNA 
delivered 
Approach 
(effect on miRNA) 
Cell type 
Potential 
application 
 
HiPerFect 
miR-146b-5p 
miR-23b 
miR-99a 
Enhancement neural stem cells Neurogenesis 
DharmaFECT® miR-198 Enhancement Keratinocytes Wound healing 
SiPORT™ NeoFX™ 
miR-1 
miR-499 
Enhancement 
Cardiomyocyte 
Progenitor cells 
Cardio-
myogenesis 
miR-21 
miR-335-5p 
MiR-17 
Enhancement 
MSCs 
Primary calvarial 
osteoblasts 
Osteogenesis 
Lipofectamine® RNAi-
MAX 
MiR-720 Enhancement hDPCs Osteogenesis 
MiR-682 Inhibition 
Myogenic 
progenitor cells 
Myogenesis 
Lipofectamine® 2000 
MiR-375 Inhibition 3T3-L1 adipocytes Adipogenesis 
MiR-1 Inhibition ESCs Osteogenesis  
Lipid vectors are frequently formulated as liposomes, many of which have 
progressed to commercial formulations, including FuGene®, HiPerFect, 
DharmaFECT®, SiPORTTM NeoFx TM, DOTAP® and Lipofectamine® 2000 (303, 
310). Advantages of liposomes include versatility, ease of large scale 
production and an unlimited cargo loading capacity (311), however they 
generate toxicity and immunogenicity, which represents a significant concern 
when translating to clinical applications (311-313). Polyethyleneimine (PEI) is a 
frequently used  alternative synthetic cationic polymer popular due to its 
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relatively high nucleic acid transfer efficiency (174, 314), however its application 
has also been associated with high cytotoxicity and significant cell damage 
(315). Thus, research efforts have recently turned to the exploration of natural 
non-viral vectors such as chitosan and CaPs. Chitosan is a biodegradable, 
biocompatible and non-toxic polymer proceeding from crustacean shells which 
has recently shown potential for pDNA mediated bone regeneration (316). 
Furthermore, a number of groups have assessed chitosan particles as RNAi 
and miRNA delivery vectors. The major drawback of this vector is perhaps its 
variable transfection efficiency, which is highly dependent on the cell type (312).  
1.8.3.Calcium phosphate (CaP) and hydroxyapatite (HA) as non-viral nucleic 
acid delivery vectors 
The use of CaP nanoparticles as non-viral vectors for nucleic acid delivery was 
first documented by Graham and van der Erb in 1973 (317) and they are 
renowned for their remarkable biocompatibility, low toxicity and good 
biodegradability as well as being relatively easy to fabricate and use (126). 
Additionally CaPs are associated with a non-immunogenic response and non-
toxic degradation products (318, 319), and have also been explored as delivery 
vectors for a range of drug cargos, including therapeutics such as insulin and 
cisplatin as well as contrast agents for imaging-based diagnostics, such as 
lanthanide ions (Figure 1.17; (320)). An interesting feature of CaPs is their pH-
dependent solubility in association with their physico-chemical nature. CaPs are 
chemically inert and structurally maintained by electrostatic interactions (321). 
This triggers their dissolution in the presence of an acidic pH found in 
intracellular compartments (322), which in turn prevents extracellular liberation 
of their cargo. Another interesting feature is their ability for immediate 
complexation with nucleic acids, due to the affinity towards their phosphate 
backbone chain, which is also an effective and easy approach to limit the size 
growth of CaP crystals (318, 322, 323). These beneficial properties have 
resulted in the development of commercial CaP transfection kits and in the field 
of siRNA delivery, CaP-based particles have demonstrated significant luciferase 
and green fluorescent protein (GFP) reporter silencing efficiencies (324-327). 
62 
 
        
Figure 1.17 Schematic of CaP NPs for drug delivery applications, taken from (318). a) 
single shell CaP for nucleic acid transfection. b) single shell entrapping or dopping the CaP core 
with fluorophore agents for imaging-based diagnostics. c) multi-shell functionalisation for nucleic 
acid transfection. d) Surface functionalisation by polymer coating approach, beneficial for drugs 
or biomolecules that are poorly adsorbed on CaP. 
Hydroxyapatite (HA), besides being the mayor CaP phase found in bone also 
has the ability to complex with nucleic acids and serve as a safe transfection 
reagent (319). The advantageous dual function of these nHA particles as bone 
mineral biomimetics and vectors for nucleic acid delivery has led to intensive 
research of nHA-based pDNA delivery in our laboratory. As a result of that 
work, nHA particles were optimised to achieve greater transfection efficiency 
than a commercial CaP transfection kit in hMSCs (126); which further translated 
in enhanced osteogenesis when delivering pDNA encoding BMP-2 (126). These 
particles thus served as the basis for microRNA delivery in the research 
presented in this thesis.  
 
1.9.Scaffolds for localised delivery of biomolecules in bone TE 
The primary role of three-dimensional (3D) scaffolds in TE is to act as templates 
for cell attachment and tissue repair; however increasingly they are being used 
to locally deliver biomolecules in order to enhance their therapeutic potential 
while limiting the exposure of off-target tissues to these biomolecules, thus 
reducing safety concerns (147, 281, 290). To work effectively, scaffolds must be 
able to retain the  biomolecule while providing sufficient exposure to infiltrating 
cells (328). Reciprocally, the incorporation of biomolecules must not negatively 
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affect the mechanical and structural features of the construct or deter cell 
retention and attachment to the scaffold (329). Another important consideration 
in scaffold design is to control the spatiotemporal sustained release of 
biomolecules in order to achieve a pharmacokinetic profile able to promote 
tissue repair (330-332). To meet these basic requirements different strategies 
have been explored using a wide range of scaffold types and biomolecule 
cargos. 
1.9.1.Growth factor delivery from scaffolds and controlled release strategies 
Currently, in bone repair, two products based on directly incorporating GFs onto 
collagen sponges have progressed to a commercial stage, which are the 
INFUSE® Bone Graft Kit, delivering BMP-2, and OsigraftTM, delivering BMP-7. 
Although both have been granted FDA approval, a number of problems 
surfaced following their market launch, resulting from the uncontrolled GF 
release profile (146). Significant research is thus ongoing on strategies to 
improve control over the pharmacokinetic delivery profile using methods to 
sufficiently retain the GF such as attachment or physical inclusion methods 
(333, 334). Attachment methods physico-chemically immobilise GFs onto the 
scaffold surface (30), while physical inclusion methods involve the previous 
incorporation of the GFs in microparticulate polymer systems that protect the 
GF from degradation (335). For example, methods to control the release of GFs 
include loading of VEGF encapsulated within chitosan onto PLGA scaffolds 
(336) and incorporation of VEGF encapsulated in alginate and BMP-2 in PLGA 
microparticles into collagen-based scaffolds (337, 338).   
1.9.2.Gene & RNAi-activated scaffolds 
A critical consideration when applying gene & RNAi therapy relates to the need 
for efficiently sustained therapeutic effect in a localised manner (339). While the 
delivery vectors described in Section 1.8 may improve the process of cellular 
uptake of nucleic acids, their rapid clearance from the target site in vivo often 
results in excessively short therapeutic timeframes (340). Thus, combination of 
these vectors with 3D scaffolds may provide extended timeframes of localised 
delivery (61, 195, 341). The scaffold acts as a depot for the nucleic acid 
complexes with their respective vectors, and then infiltrating cells establish 
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contact with the nucleic acids deposited along the structure of the scaffolds and 
internalise them to become transfected. The idea of scaffold-based gene 
delivery emerged in the late 1990s, coining the term ‘gene-activated matrix’ 
(GAM) (195). In this seminal work collagen-based scaffolds delivering β-
galactosidase pDNA significantly promoted new bone formation (195, 342). 
Scaffold-based nucleic acid delivery approaches can be classified as in vivo –
‘cell-free’- or ex vivo -‘cell-mediated’-. In vivo transfection consists of the direct 
application of the nucleic acid containing scaffold to the defect site (343, 344), 
and this approach has recently attracted interest for gene therapy. On the other 
hand, ex vivo transfection exposes the cells to the nucleic acid treatment prior 
to loading onto the scaffold. Although it requires in vitro culture before 
implantation in the defect site, being more laborious and cumbersome from a 
clinical application perspective (345), the small number of studies on scaffold-
mediated RNAi therapy published to date have typically focused on this 
approach (58, 340).  
 
Some examples of scaffold-mediated pDNA delivery for bone repair include the 
delivery of VEGF naked pDNA from collagen-CaP scaffolds (290) and the CaP-
based delivery of BMP-2 pDNA from collagen scaffolds (85, 291). Of particular 
interest for this thesis, the use of coll-nHA scaffolds as GAMs for the 
incorporation of BMP-2 pDNA, VEGF pDNA and EphrinB4 pDNA has 
demonstrated successful osteogenesis and bone repair in recent work from our 
laboratory (126, 127, 346). The research presented in this thesis builds on this 
work and uses coll-nHA scaffolds for miRNA delivery. With regard to scaffold-
mediated miRNA delivery, a small number of studies to-date have 
demonstrated the application of cell-mediated (58, 297, 299, 347, 348) and ‘cell-
free’ or in vivo strategies (349, 350). Among the cell-mediated strategies, 
baculovirus and lentivirus transduction of stem cells with pre-miR-148b and 
miR-31 inhibitors significantly improved bone healing in vivo (297, 299). 
Alternatively, ‘cell-free’ approaches have used direct entrapment or surface 
immobilisation technologies. Direct entrapment appeared particularly suited for 
in situ-forming materials such as PEG-based hydrogels or electrospun 
nanofibres delivering naked miRNAs (349, 350). However, bolus release effects 
were observed with these approaches and additional incorporation of non-viral 
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vectors was proposed to improve pharmacokinetics of cargo delivery (309). In 
line with this, immobilisation approaches involve the prior step of miRNA 
complexation with polymers. An example by Wu et al. immobilised miRNA- 
Lipofectamine® 2000 complexes onto a microporous titanium oxide surface 
(351). As a central rationale for this thesis, it is speculated that ‘cell-free’ 3D 
platforms for miRNA delivery incorporating nHA within the in-house developed 
coll-nHA scaffold holds essential advantages from the biomaterial standpoint.  
1.9.3.Combinatorial delivery of biomolecules from bone tissue-engineered 
scaffolds 
Combinatorial delivery of biomolecules from bone tissue-engineered scaffolds 
represents a promising approach to recapitulate the natural tissue repair 
process (165, 352). This was initially approached using delivery of GFs (183, 
353, 354) including delivery of GFs capable of promoting both angiogenesis and 
osteogenesis (165, 353, 355). The combinatorial approach has progressed 
more recently to the delivery of multiple genes (127, 288, 356). Within the ex 
vivo transfection approaches documented, delivery of VEGF plus BMP-2 pDNA 
to MSCs either by baculovirus or adenovirus transduction successfully improved 
bone formation (355, 357). Examples of ‘cell-free’ in vivo transfection 
approaches include adenoviral-based BMP-7 plus PDGF and VEGF plus BMP-
2 pDNA delivery from collagen-chitosan scaffolds (289, 358). In the area of non-
viral in vivo transfection, CaP cement scaffolds incorporating nanomicelles with 
activin receptor-like kinase 6 plus Runx2 pDNA (292) as well as recent work 
from our laboratory on coll-nHA VEGF plus BMP-2 GAMs (127) represent 
significant contributions to the field. In particular this in-house work underlined 
the importance of vector choice, with nHA-based delivery surpassing the 
outcome of PEI-based delivery. However, minimal research has been 
conducted on combinatorial approaches to scaffold-mediated RNAi and miRNA 
delivery with only one study on combined miRNA delivery from 3D scaffolds 
reported to date (58). In this study, Mariner et al. adopted an ex vivo approach 
where hMSCs nucleofected with miR-148b mimic plus antagomiR-489 were 
then incorporated on PEG-based hydrogel scaffolds (58). No published study 
delivering miRNA combinations has focused on simultaneous angiogenesis and 
osteogenesis yet. With this in mind, the research presented in Chapter 5 of this 
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thesis focused on combinatorial miRNA delivery to simultaneously promote an 
angiogenic and osteogenic response in MSCs. 
1.10.Project aims and objectives 
The overall goal of the research presented in this thesis was to determine the 
potential of using nano-sized hydroxyapatite particles (nHA) to act as non-viral 
vectors for the delivery of a series of miRNAs to human (h)MSCs and to 
determine the miRNA therapeutic combination leading to optimal osteogenesis 
and angiogenesis before ultimately producing miRNA-activated scaffolds 
capable of mediating enhanced osteogenesis by hMSCs.   
The specific aims of this PhD project were thus to: 
− Investigate the potential of in-house synthesised nHA particles as non-
viral vectors for miRNA delivery using synthetic reporter miRNAs and 
determine the delivery profile and the optimal miRNA concentration for 
this system (Chapter 2) 
− Assess the pro-osteogenic therapeutic efficacy of nHA-based delivery of 
(i) antagomiR-133a, (ii) antagomiR-16 and (iii) miR-210 mimic and 
establish the optimal candidate for incorporation in a miRNA-activated 
scaffold (Chapter 3) 
− Assess the potential of coll-nHA scaffolds as miRNA delivery platforms to 
manipulate hMSC gene expression by incorporating reporter miRNAs 
(Chapter 4) 
− Apply the miRNA-activated coll-nHA scaffold system to therapeutically 
enhance osteogenesis by incorporating the optimal therapeutic candidate 
earlier established, namely antagomiR-133a (Chapter 4) 
− Investigate the pro-angiogenic therapeutic efficacy of nHA-based delivery 
of the miR-210 mimic to enhance the pro-angiogenic capabilities of 
hMSCs through the direct targeting of the EphrinA3 gene (Chapter 5) 
− Assess the potential of combinatorial delivery of the miR-210 mimic with 
antagomiR-133a or antagomiR-16 to simultaneously enhance the 
angiogenesis and osteogenesis capabilities of hMSCs (Chapter 5) 
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Chapter 2. Investigation of nanohydroxyapatite particles as 
non-viral vectors for microRNA delivery to human 
mesenchymal stem cells  
 
Research presented in this chapter has been included in the following peer-
reviewed publication:  
Castaño, IM et al., A Novel Collagen-Nanohydroxyapatite microRNA-activated 
Scaffold for Tissue Engineering Applications Capable of Efficient Delivery of 
both miR-mimics and antagomiRs to Human Mesenchymal Stem Cells. J 
Control Release 2015; 200: 42-51. 
 
2.1.Introduction 
 
A variety of biomolecules including proteins, GFs and pDNA have been 
explored in recent years to potentiate the body’s own healing ability to repair 
tissue voids as part of advanced TE strategies. Recently, overexpression or 
inhibition of miRNAs is gaining attention in TE approaches, since delivering 
miR-mimics or antagomiRs respectively may enable the required modulation of 
protein expression to improve tissue regeneration. However, effective delivery 
of miRNAs remains the greatest challenge to unleashing their vast potential. 
Transient delivery of miR-mimics and antagomiRs into cells has been 
approached by using viral or non-viral vectors formerly applied to pDNA 
delivery. Although pDNA and miRNAs share several physicochemical 
properties, due to their negatively charged phosphodiester backbone, 
susceptibility to nucleases and poor intracellular cytosolic delivery, the chain 
size is critically smaller in miRNAs resulting in low charge density, in addition to 
having a short and rigid structure (326, 339). Taken together, this points to a 
necessity of tailoring efficient vectors for the successful delivery of miRNAs, 
which may not necessarily translate from successful DNA delivery (359). 
Significant research efforts have focussed on using viruses belonging to the 
adenovirus and lentivirus families which are highly efficient at delivering miRNA-
related molecules including both miR-mimics and antagomiRs; however their 
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clinical applicability is limited by the threat of adverse immune responses in 
patients and the risk of insertional mutagenesis following viral integration (57). 
Current developments in non-viral miRNA delivery technologies  include 
nucleofection as well as the use of nanoscale complexes with Lipofectamine® 
2000 (310), PEG (307) or PEI (308). Although these compounds exhibit efficient 
delivery yields, evidence of significant cell damage derived from their use 
remains a considerable drawback in terms of clinical application. Thus, research 
efforts are focussed on developing an ideal non-viral vector which would ensure 
maximum efficacy of delivery but without significant cytotoxicity concerns (315).  
CaPs are a promising alternative non-viral vector as although their efficacy of 
delivery is typically lower than that of the aforementioned lipids and synthetic 
polymers, advantages include low toxicity, biodegradability and ease of use 
(126). CaP complexes with nucleic acids form precipitates at the cell surface 
and undergo endocytosis partially dependent on clathrin and dynamin (283, 
360, 361). In spite of the advantageous high biocompatibility of CaPs, the 
growth in size of different phases of CaP crystals is associated with limited 
reproducibility in terms of efficiency of delivery, meaning a drawback for the 
application of these systems (318, 323). To overcome this limitation, different 
strategies have been undertaken with limited success so far (326), including 
customisation with synthetic or lipidic polymers. Some examples of modified 
CaP particles for siRNA delivery reported in the literature include incorporation 
of PEG added either directly in the particle synthesis process (324) or combined 
with calcium chelators or the nucleic acid cargo (325). Alongside this approach, 
CaP particle coating with conjugates of chitosan and 3,4-
dihydroxyphenylalanine (dopa) as well as hyaluronic acid and dopa have also 
been investigated in the literature (326, 327).  
 
In this study, we focused on the application nHA particles as novel non-viral 
miRNA delivery vectors. HA is a crystalline ceramic found predominantly in the 
bone extracellular matrix and thus is of particular interest for bone repair 
applications; a Darvan®-aided wet precipitation synthesis technique was 
previously developed in our group to overcome reproducibility limitations 
associated with HA crystal growth and therefore improve the applicability of this 
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material for bone repair (124). This methodology generates non-aggregating 
nanosize particles in a simple, low-cost manner by combining CaCl2, Na3PO4 
and NaOH solutions with low concentrations of Darvan® as a dispersant. 
Moreover, these nHA particles have been used to safely achieve higher 
transfection efficiency for pDNA delivery to hMSCs compared to a commercial 
CaP transfection kit (126). Therefore, the research presented in this chapter 
aimed to demonstrate for the first time that the combination of nHA particles 
with miRNAs can be tailored to result in an efficient non-viral system for miRNA 
delivery to BM-derived hMSCs, a cell type commonly utilized for TE strategies 
due to their multilineage differentiation capacity and accessible sourcing (362). 
 
2.2.Hypothesis & aims of the study 
 
The underlying hypothesis of this study was that these in house-synthesised 
nHA particles could act as non-viral vectors for miRNA delivery to hMSCs. 
Thus, the overall aim of this study was to determine the miRNA delivery profile 
for nHA particles, by utilising scrambled (scr) miR-mimic and antagomiR 
sequences, which act as controls and encompass sequences with non-existent 
targets in mammalian cells. A secondary aim was to determine the 
concentration of miRNAs most suitable for progression of the research 
presented in the following chapters of this thesis. The specific aims of this 
chapter involved:  
• Determination of size and surface charge (zeta potential) of nHA 
particles loaded with miRNAs, (termed nanomiRs hereafter) 
• Assessment of nanomiR morphology using transmission electron 
microscopy 
• Analysis of hMSC cytotoxicity following nanomiR treatment  
• Analysis of uptake efficiency using fluorescently tagged scrambled 
miRNAs 
• Assessment of silencing capability of nanomiR-mimic delivery using a 
commercially available functionality reporter miR-mimic which targets 
GAPDH, expressed by hMSCs at a basal level 
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• Assessment of silencing capability of nanoantagomiR delivery with a 
commercially available functionality reporter antagomiR which targets 
miR-16, expressed by hMSCs at a basal level  
 
2.3.Materials & Methods 
 
2.3.1.nanohydroxyapatite (nHA) - miRNA (nanomiR) system  
nHA particles were synthesised following a protocol established in our 
laboratory (124). Briefly, a solution of 12 mM phosphate, containing 0.017 % 
Darvan® 821A (RT Vandervilt, Norwalk, CT), was added to an equal volume of 
a 20 mM calcium chloride (Fisher Scientific, Ireland) solution and filtered 
through a 0.2 μm filter. The nanomiR transfection mix consisted of 150 µl of the 
nHA solution added to a miRIDIAN mimic or antagomiR (Dharmacon, 
ThermoScientific, Germany) solution prepared at final concentrations of either 
10 or 20 nM and combined with 0.25 M CaCl2, as adapted from the in-house 
method for pDNA delivery (126).  
 
2.3.2.NanomiR physicochemical characterisation 
In order to characterise the physicochemical properties of complexes formed by 
a delivery vector and the agent delivered, in this case miRNAs, size and surface 
charge were studied. Hydrodynamic size and surface charge was determined 
using dynamic light scattering (DLS; ZetaSizer 3000 HS, Malvern instruments, 
UK). DLS measures the time dependent fluctuations in the scattering intensity 
to determine the size of the particles in the form of the hydrodynamic diameter 
(DH), for which the particle sample must be contained in an aqueous solution to 
resemble the size adopted in the presence of physiological fluids. The surface 
charge of the particles determines their stability in dispersion. The zeta 
potential, which is the electrical potential at the hydrodynamic plane of shear of 
the particles, is the indicative parameter of surface charge of particles in 
suspension. Freshly prepared blank nHA particles or nanomiR samples were 
diluted 10 times in low UV absorbance ultra-pure water (Sigma Aldrich, Ireland). 
The solution was then transferred to a fine quality glass cuvette designed for 
71 
 
zeta potential and size analysis (Particular Sciences 74 Ltd., Ireland). The 
particle size and zeta potential of three samples was analysed. Measurements 
were performed at 25°C with the 100 mW laser set at an angle of 90° to the 
sample. The sample was allowed to equilibrate prior to five readings being 
taken. The mean particle size, the standard deviation and the polydispersity of 
the sample were determined using the systems data analysis functions based 
on cumulants analysis.  
To analyse particle morphology, transmission electron microscopy (TEM) was 
used. In TEM, nanoscale high resolution images are obtained from the 
interaction of the electron beam with the sample. Before examination, 1 droplet 
of freshly prepared nHA or nanomiR samples were deposited onto rapid setting 
epoxy resin coated aluminium grids and allowed to precipitate while air drying. 
Imaging was carried out at 200 kV using a Jeol 2100 TEM (Jeol, UK).  
2.3.3.Cell culture 
Human mesenchymal stem cells (hMSCs) were derived from iliac crest bone 
marrow aspirates obtained from healthy human volunteers with informed 
consent at the Regenerative Medicine Institute, the National University of 
Ireland, Galway. All procedures were performed with ethical consent from the 
Clinical Research Ethical Committee at University College Hospital, Galway. 
hMSCs were isolated using standard protocols and stringent analysis of cell 
phenotype (363).  
 
Cells were expanded in culture by direct plating (364), using hMSC growth 
medium consisting of low-glucose DMEM (Sigma-Aldrich, Ireland) 
supplemented with 10 % foetal bovine serum (FBS) plus 1 % penicillin/ 
streptomycin (Sigma-Aldrich, Ireland), and maintained at 37°C, 5 % CO2 and 90 
% humidity. Subsequently, cells were passaged using 0.25 % trypsin/EDTA at 
5-7 day intervals and expanded until sufficient cell numbers were obtained at 
passage 5 for experimentation. Cells were then plated at a density of 5 x 104 
cells per well in 6 well plates 24 hours before adding the control, nanomiR-
mimic or nanoantagomiR treatments at final concentrations indicated in Section 
2.3.1. 
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2.3.4.Cell viability after nanomiR treatment 
Cell viability was studied to monitor potential cytotoxic effects derived from the 
nanomiR treatment of hMSCs, for which nHA particles were loaded with 
scrambled (scr) miR mimic/antagomiR, which act as controls and encompass 
cel-miR-67 sequences with non-existent targets in mammalian cells. The 
Quant-iT PicoGreen dsDNA kit (BioSciences, Ireland) was utilised according to 
the manufacturer’s protocol to study cell number at days 3 and 7 post-
treatment. Briefly, 100 μl of the PicoGreen reagent solution was added to 
samples containing the 0.2 M carbonate 1 % TritonX (Fisher, Ireland) cell lysate 
buffer and fluorescence was read at 538 nm using a VarioSkan Flash plate 
reader (ThermoScientific, Germany) and SkanIt RE for VarioSkan software. 
Complimentary cell redox metabolic activity was assessed with the colorimetric-
based MTS assay CellTiter 96® AQueous One Solution (Promega, Ireland) 
following manufacturer’s instructions. Briefly, 20 μl of the Celltiter 96® reagent 
per 100 µl of culture medium was added to each well and incubated for 3 h at 
37°C, before absorbance was measured at 490 nm using the aforementioned 
VarioSkan Flash plate reader. The following equation was applied to calculate 
cell viability (%): 
 
Equation 2.1 
cell viability % = abs[treatment group] / abs[untreated cells control] x 100 
 
2.3.5.Microscopy evaluation to assess nanomiR uptake efficiency in hMSCs  
Dy547-miRIDIAN scr miRNA molecules (Dharmacon) incorporate a red 
fluorescent tag and so serve as tools for monitoring the uptake process by 
fluorescence emission at 547 nm. nHA particles were loaded with 10 and 20 nM 
doses of Dy547-tagged scr miR-mimic/antagomiR miRIDIAN molecules and 
added to hMSC monolayer culture in order to study the uptake of nanomiR 
complexes in the cells. Live cells were examined for nanomiR fluorescence at 3 
and 7 days after treatment. To do so, fluorescence and phase contrast 
microscopy was performed using a Sony-Lennox Optika 4083.CL5 microscope 
digital system coupled to Optika Vision Pro software (Lennox, Ireland). 
73 
 
 
To achieve more detailed observation of the internalised nanomiRs, staining 
with Alexa488 Phalloidin (Invitrogen, UK) and counterstaining with diamidino-2- 
phenylindole (DAPI) was performed at 3 and 7 days after treatment. Cells were 
cultured on microscopy coverslips pre-coated with 0.001 % poly-L-lysine, fixed 
in 4 % para-formaldehyde (PFA), permeabilised with 0.1 % Triton-X100, 
blocked in 1 % bovine serum albumin (BSA) in phosphate buffered saline 
(PBS), stained and mounted onto glass coverslips using Ibidi® mounting 
medium (Ibidi GmbH, Ireland). Digital imaging was performed using the 
Olympus IX51-AnalySIS imaging system (Olympus Scientific Solutions 
Americas, UK). 
2.3.6.Flow cytometry quantification of nanomiR uptake efficiency in hMSCs 
Flow cytometry analysis was carried out to quantify the percentage of cells 
internalising the Dy547-labelled nanomiR complexes at 24 h, 3 days and 7 days 
after treatment. For flow cytometry sample preparation, cells were detached 
from cell culture wells using 0.25 % trypsin/EDTA, following which they were 
fixed in 5 % formalin for 15 minutes and centrifuged at 500 xg for 5 minutes. 
Samples were then resuspended in 200μl of PBS and analysed for red 
fluorescence emission using a BD FACS Canto II and BD FACS Diva software 
(BD Biosciences, UK). Percentage of uptake efficiency was calculated as the 
percentage population displaying high fluorescence intensity (over median), 
after substracting nHA alone treatment values from those of the Dy547-tagged 
nanomiRs.  
 
2.3.7.Functionality assessment of nanomiR treated hMSCs using quantitative 
Real Time Polymerase Chain Reaction (qRT-PCR) 
miRNA bioactivity after nHA-mediated delivery to hMSCs was verified by 
measuring the silencing functionality of reporter miRNA molecules by qRT-PCR. 
For this purpose, prior to addition to the monolayer culture, nHA particles were 
loaded with either the miRIDIAN positive controls (Dharmacon, 
ThermoScientific, Germany), which are designed to silence targets expressed 
at a basal level in healthy cells, or with their scrambled counterparts as 
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reference controls. The miR-mimic utilised is designed to target the mRNA of 
the housekeeping glyceraldehyde phosphate dehydrogenase (GAPDH), 
involved in the normal glucose metabolism of cells, and the selected antagomiR 
targets the tumour suppressor miR-16, basally expressed in non-tumorigenic 
cells (365).  
Total RNA extraction including miRNA: 
Total RNA extraction was performed adding 500 µl QIAzol lysis buffer (Qiagen, 
UK) directly onto the cell culture plates, then cell lysates were extracted using 
cell scrapers (Sarstedt, Ireland) and transferred into microcentrifuge tubes. This 
was followed by an ultracentrifugation step at 4°C and 8000 g for 15 min in the 
presence of 100 µl chloroform. The resulting aqueous phase was processed 
using the miRNeasy Mini purification kit (Qiagen, UK) according to 
manufacturer’s instructions. RNA quality and concentration was determined 
using a Nanodrop 2000 (Thermo Scientific, UK) spectrophotometer.  
Messenger (m)RNA Reverse Transcription and Polymerase Chain Reaction: 
The Quantitect Reverse Transcription kit (Qiagen, UK) was used to perform 
mRNA reverse transcription (RT) reactions (20 µl) on 200 ng of total RNA. Real-
time PCR reactions (15 µl) were carried out on an Eppendorf Realplex4 
EpgradientS Mastercycler (Eppendorf, Germany) using the Quantitect SYBR 
Green PCR master mix (Roche, Ireland). The following validated pre-designed 
human Quantitect Primer Assays (Qiagen, UK) were applied for the 
measurement of GAPDH and 18S levels: Hs_GAPDH_1_SG and 
HS_RRN18S_1_SG. Consequently, the relative expression of GAPDH mRNA 
was calculated normalising to the level of the housekeeping 18S ribosomal 
RNA, and using the 2(-ΔΔCt) method.  
MiRNA Reverse Transcription and Polymerase Chain Reaction: 
To assess miR-16 levels, the hsa-miR-16 Taqman® MicroRNA assay, the 
probe-specific Taqman® Micro RNA kit and Taqman® Universal PCR Master 
Mix were used (all from BioSciences, Ireland). Stem-loop miRNA RT reactions 
(15 µl) were carried out on 100 ng of total RNA using an Eppendorf Personal 
Mastercycler (Eppendorf, UK) and miR-PCR assays (10 µl) were performed 
using the aforementioned PCR system. Consequently, the relative expression 
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of miR-16 was calculated normalising to the level of the housekeeping 18S 
ribosomal RNA, and using the 2(-ΔΔCt) method.  
2.3.8.Statistical analysis 
Experiments were performed in triplicate, unless otherwise specified within 
figure captions, and are representative of a minimum of three independent 
repetitions using two cell donors. Data analysis was performed using the 
SigmaPlot 11.0 software package. Results were presented as the mean + 
standard deviation and subjected to a two-way analysis of variance (ANOVA) 
plus a Tukey post-hoc test. p<0.05 and p<0.001 were considered significant 
differences. 
 
2.4.Results 
 
2.4.1.NanomiR complexes adopt multiparticulate formations and posses a 
negative surface charge  
nHA particles utilised in this work were combined with a relatively low dose of 
20 nM miRNA which was selected after reviewing the miRNA dosing range 
reported in the literature (220). DLS characterisation of the nanomiR complexes 
demonstrated an average hydrodynamic size of the particles within the 300 - 
400 nm range (Figure 2.1a) with no statistical differences between groups: 
blank nHA particles were 301.5 nm, miR-mimic loaded nHA particles were 
329.5 (± 24.7) nm, and antagomiR loaded nHA particles were 398.33 (± 79.6) 
nm. Zeta potential remained within the range of - 5 mV to - 10 mV with no 
statistical differences between groups, and was highest in the nanomiR-mimic 
group (-9.9 ± 5.3 mV, Figure 2.1b). Although not statistically significant, the 
observed changes indicated the existence of an electrostatic interaction 
between miRNAs and nHA particles. To further observe this interaction, TEM 
analysis was carried out. The topographic images of the precipitate complexes 
obtained in this study showed the formation of multiparticulate structures in 
varying shapes for both scr nanomiR-mimic and nanoantagomiR complexes 
(Figure 2.2b-c), in comparison to the rod-shaped conformation that the nHA 
particles adopted in the absence of miRNAs (Figure 2.2a). 
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Figure 2.1 Physical characterisation of nanomiR complexes. nHA particles were loaded 
with a final concentration of 20 nM of scrambled (scr) miR-mimic or antagomiR. a) Size 
determination presented as particle diameter (nm) showed nanomiR complexes in the range of 
300 to 400 nm. b) Surface charge analysis presented as zeta potential (mV) demonstrated a 
nanomiR surface charge of -7 to -10 mV. Mean + standard deviation, n = 3, no statistical 
significance.  
 
Figure 2.2 TEM analysis of nanomiR complexes. a) Blank nHA particles adopted rod-shape 
conformations while b) scr nanomiR-mimic and c) scr nanoantagomiR were arranged in bead-
branched multiparticulate formations. Scale bar = 200 nm. 
 
2.4.2.Cell viability was maintained after nanomiR treatment  
The cell viability study demonstrated that there was no nanomiR treatment-
derived cytotoxic effects at the doses tested (Figure 2.3). Cell number remained 
unaffected at day 3 after treatment although a reduction in cell metabolic activity 
was observed in the scr nanomiR-mimic 20 nM group. Nevertheless, the cells 
were capable of normal metabolic activity and even significantly increased 
proliferation at the later timepoint. Considering that after a longer period in 
culture no detrimental effects were observed, it is proposed that nanomiR 
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complexes at the studied concentrations did not result in a cytotoxic effect on 
hMSCs. 
 
Figure 2.3 Cytotoxicity of scr nanomiR-mimic & nanoantagomiR in hMSCs. a) dsDNA 
quantification indicated that viable cell number was maintained (scr nanoantagomiR) or 
significantly increased (scr nanomiR-mimic) compared with control groups at day 7 post-
treatment, demonstrating no treatment associated cytotoxic effects. Mean + standard deviation, 
n = 3, ** = p<0.001. b) Cell viability assessment by MTS assay. Mean + standard deviation, n = 
3, ## = p<0.001 vs. cell at day 3, * = p<0.05 vs. cell at day 7.  
2.4.3.NanomiR uptake in hMSC monolayer was highly efficient  
In order for the nanomiR system to be effective, the first requirement is that the 
complexes are taken up by the cells. From the fluorescence microscopy 
images, the presence of Dy547 nanomiR deposits were noted, and phase 
contrast images captured for the respective fields were collated in merged 
images to serve as references for intra- or extracellular location of the 
complexes, since Dy547 nanomiR is inherently fluorescent (Figure 2.4b). 
Additionally, the phase contrast images showed no morphological changes 
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between groups at all timepoints and cells proliferated normally over the culture 
period, indicating no adverse effects with any treatment.  
Further assessment of Dy547 nanomiR internalisation using complementary 
labelling of the actin cytoskeleton with phalloidin (green) and nuclei with DAPI 
(blue) confirmed the ability of nHA particles to deliver miRNAs intracellularly 
(Figure 2.5). Cell nuclei and actin cytoskeleton labelling allowed the detection of 
Dy547 nanomiRs in points of the cell cytoplasm as well as in the proximity of, or 
superimposed to, the nucleus. Qualitatively, it was noted that Dy547 nanomiR-
mimic displayed co-localisation with cell nuclei at day 3 and a more cytoplasmic 
distribution at the later timepoint of day 7, while in the Dy547 nanoantagomiR 
treatment group, internalisation was more evident in the proximity of the cell 
nuclei at both timepoints.  
Flow cytometry was used to quantify uptake efficiency at three timepoints: day 
1, 3 and 7 (Figure 2.6). Uptake kinetics proved different for both types of 
molecules: Dy547 nanomiR-mimic at the 20 nM dose showed a cyclical uptake 
firstly peaking at day 1, then decreasing at day 3 and yielding maximum 
internalisation efficiency (17.4± 5.6 %) at day 7, while no uptake of 10 nM 
Dy547 nanomiR-mimic could be detected at the timepoints assessed. 
Furthermore, an initially sustained uptake profile with a 10 % reduction at the 
last timepoint was determined for both the 10 and 20 nM dose of Dy547 
nanoantagomiRs. Specifically, 33.5 ± 1.5 % and 39.6 ± 4.7 % uptake efficiency 
values were quantified respectively for the 10 and 20 nM Dy547 
nanoantagomiR doses by day 3, with significantly higher percentages over the 
complete time course in comparison to Dy547 nanomiR-mimics.  
In summary, this study showed that the fluorescently labelled nanomiR 
complexes (indicated by the arrows) were internalised in hMSCs localising 
mostly in the proximity of the nucleus as well as depositing outside the cells, 
and achieved different uptake efficiencies reaching maximum levels close to 20 
% for the 20 nM nanomiR-mimic at day 7 and 40 % for the 20 nM 
nanoantagomiR at day 3 post-treatment.
ND 
 
b b 
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Figure 2.4 Live cell imaging of hMSCs after treatment with red fluorescently labelled (Dy547) scr nanomiR-mimic & nanoantagomiR. a) Schematic of 
the procedure to assess uptake efficiency. b) Composite depicting representative epifluorescence, phase contrast and merged images of hMSCs treated with 
10 & 20 nM doses at two of the timepoints studied. NanomiR deposits can be observed both internally and extracellularly, while hMSCs displayed a normal 
fibroblastic-like morphology and increase in cell confluence indicated normal proliferative cell capacity over time. Scale bar = 200 µm, n = 3.  
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Figure 2.5 Assessment of nanomiR internalisation in hMSC. Composite images depicting 
representative fluorescence images of Dy547 nanomiRs (red) plus cell nuclei labelled with DAPI 
(blue) and merged images with cell cytoskeleton staining using Alexa488-Phalloidin (green). 
Arrows refer to nanomiR localisation, observed intracellularly in points of the cell cytoplasm and 
more predominantly in the area around the nucleus, but also localised extracellularly. Scale bar 
= 200 µm, n = 3. 
  
Figure 2.6 Quantification of nanomiR uptake efficiency in hMSCs. NanomiR-mimic and 
nanoantagomiR achieved different uptake efficiencies and kinetics at the doses and timepoints 
tested. Mean + standard deviation, n = 3. ** = p<0.001, ɸ = non-significant compared to day 7 
nanoantagomiR 10 nM, ǂ = p<0.05 compared to day 7 nanoantagomiR 20 nM. ND= not 
detectable. 
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2.4.4.Reporter nanomiRs caused highly functional interference after nHA-based 
delivery  
qRT-PCR analysis performed on samples 1, 3 and 7 days post-treatment with 
the 10 and 20 nM doses of the miRIDIAN positive controls of transfection, which 
are research tools designed to silence targets expressed at a basal level in 
healthy cells, demonstrated a high interfering activity of the reporter nanomiRs 
towards their respective targets.  
The reporter nanomiR-mimic silenced GAPDH expression significantly to an 
average of 0.07 ± 0.02 fold of the relative expression level with both doses of 10 
and 20 nM, indicating over 90 % functionality of the nHA-delivered miR-mimic 
once cellular internalisation occurred (Figure 2.7). Similarly, miR-16 expression 
decreased significantly upon treatment with the 10 and 20nM doses of reporter 
nanoantagomiR, to an average of 0.01 ± 0.01 fold of the relative expression 
level. This effect was maintained over 7 days for the lower dose, indicating ~99 
% functionality of the nHA-delivered antagomiR after internalisation, although at 
the latter timepoint of 7 days a reduction to 30 % interfering functionality (0.7 ± 
0.65 fold change) was detected for the 20 nM dose; this matched the trend of 
temporal reduction in uptake which was quantified previously (Figure 2.8).  
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Figure 2.7 Functionality of reporter nanomiR-mimic. a) Schematic of the treatment carried 
out for nanomiR-mimic functionality tests. b) qRT-PCR analysis showed that treatment with 
reporter nanomiR-mimic significantly decreased GAPDH expression. Scr nanomiR-mimic was 
introduced as a reference control. Relative expression was normalised to 18S and calculated 
using the 2(-ΔΔCt) method. Mean + standard deviation, n = 4, * = p<0.05. 
 
Figure 2.8 Functionality of reporter nanoantagomiR. a) Schematic of the treatment carried 
out for nanoantagomiR functionality tests. b) qRT-PCR analysis showed that treatment with 
reporter nanoantagomiR-16 significantly decreased miR-16 levels. Scr nanoantagomiR was 
introduced as a reference control. Relative expression was normalised to 18S and calculated 
using the 2(-ΔΔCt) method. Mean + standard deviation, n = 4, * = p<0.05. 
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2.5.Discussion 
 
Recently in the field of TE, a small number of explorations into incorporating 
RNAi therapeutics, such as siRNAs and miRNAs, in non-viral delivery systems 
have been performed. Notably, commercial vectors with recognised limitations 
have been applied for these few studies and miRNA delivery systems using 
nHA particles have not been reported previously in the literature. The aim of this 
study was to assess the potential of using in house-synthesised nHA particles 
to act as non-viral vectors for miRNA delivery to hMSCs, a particularly difficult 
cell type to transfect effectively. The data presented here showed that nHA 
particles combined with miR-mimics and antagomiRs, forming complexes we 
term nanomiRs, resulted in high cellular uptake in monolayer hMSCs with 
limited cytotoxicity at a 20 nM dose. Furthermore, single administration of 
reporter nanomiRs translated into high silencing functionality, to a level 
comparable to viral and lipid-based carriers for this cell type (219). Taken 
together, the results indicated that nHA particles are potentially efficient non-
viral vectors for miRNA delivery, thus demonstrating the potential of using these 
natural-based nanoparticles to unleash the vast potential of miRNAs for 
therapeutic applications in TE and regenerative medicine.   
 
It was determined that nanomiRs formed negatively charged complexes in the 
300 - 400 nm range, which was consistent with the nHA-pDNA complexes 
which previously demonstrated successful transfection of hMSCs (124, 126). 
Several implications, including safety, release kinetics and cellular 
internalisation, have been described as dependant on particle size and surface 
charge properties (318). Classically, it is estimated that cellular internalisation 
requires positively charged particles of less than 200 nm (366). However, 
evidence of successful internalisation of miRNA-PEI or miRNA-chitosan 
complexes greater than 500 nm in size (256), as well as of negatively charged 
siRNA lipoplexes (367) has been noted, which support the potential of 
nanomiRs for effective miRNA delivery. Of note from the current study, small 
size variations were found between blank nHA particles and nanomiRs, with 
distinctive trends in size and charge variation found between miR-mimics and 
antagomiRs. The nHA dose previously optimised for pDNA delivery was 
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combined with the low miRNA doses of 10 and 20 nM in a cost effective low 
miRNA to nHA ratio; however, this ratio can conceal physicochemical 
differences between blank and miRNA loaded nHA particles. Taken together, 
both trends in size and charge variation found between miR-mimics and 
antagomiRs may be explained by the higher molecular weight of the latter, 
which results from the lipidic modifications in the phosphate groups of the 
backbone chain (83). In summary, the structural analysis demonstrated the 
ability of nHA particles to complex with both miR-mimics and antagomiRs, 
forming nanomiRs, meaning a successful translation of the ability of the nHA 
particles to form complexes with DNA to miRNA. Ultimately, bearing in mind the 
overall aim of this project, which was centred on the successful incorporation of 
nanomiRs within a 3D scaffold depot to target infiltrating cells, the 
physicochemical features of nanomiRs were deemed fit-for-purpose. 
 
As a rule of thumb, safety of miRNA delivery methods is influenced by the dose 
of miRNA used, together with the amount and nature of the vector applied. In 
this study, no evidence of permanent nHA- or miRNA-derived cytotoxicity was 
found by observation of cell morphology over the culture period or by the 
quantitative data analysis. It is known that high miRNA doses may affect cell 
viability or metabolism, and dose reduction is desired to prevent side effects 
such as deregulation of the RNAi pathway and more specifically RISC 
overloading; when RISC is overloaded with exogenous miRNA, endogenous 
miRNA compete with them to carry out their RNAi functions, resulting in off-
target effects (224). For example, doses ranging from 25 to 100 nM miRNA 
have been tested in studies assessing the role of various miRNAs in bone 
repair (237, 242, 243, 284, 368, 369). Interestingly, in this work, even lower 
doses of miR-mimics and antagomiRs were delivered to hMSCs, posing an 
advantage of the system in this regard. With regards the role of the vector in 
relation to safety and cytotoxicity, CaP-based delivery of nucleic acid is 
renowned for its excellent biocompatibility and enhanced cell proliferation (370). 
Although other researchers have reported a reduction in metabolic activity at 
early timepoints of culture (322, 371), this is in opposition to the elevated 
cytotoxic effects over the time course of cell culture of vectors like 
Lipofectamine® 2000 and RNAiMax® (280, 367, 372), which indicate 
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irreversible cell viability impairment. The transient reduction in metabolic activity 
associated with the use of CaPs at early timepoints correlated with high 
internalisation of calcium ions occurring immediately after treatment until the 
initial medium change (322, 371). This is consistent with the effect observed in 
this study, for which the time of initial medium change was three days after 
treatment: although a 14 % reduction in cell metabolic activity was observed at 
day 3 in the scr nanomiR-mimic 20 nM group, cell number remained unaffected 
across all groups. Since the cells were capable of normal metabolic activity and 
even significantly increased proliferation at the later timepoint, it is suggested 
that the transient metabolic decrease reflects a process of re-equilibration to in 
vitro culture and calcium internalisation that is surpassed after continued culture 
without permanent negative effects on cell viability, which is contrary to the 
issues with Lipofectamine® 2000 and RNAiMax®. Taken together, these results 
demonstrated that nanomiR treatment at the studied concentrations did not 
have a permanent detrimental effect on hMSC viability. 
 
Analysis of intracellular localisation of nanomiRs demonstrated that complexes 
were found inside the cells in all treatment groups and at all timepoints with the 
presence of nanomiR complexes in proximity to the nucleus also noted. Despite 
the fact that the mature synthetic miRNA molecules introduced in the cells 
would be expected to bind to the RISC complex in the cytoplasm, localisation in 
areas in proximity to the nucleus was overall more prominent than cytoplasmic 
distribution. Interestingly, the amount of Dy547 nanoantagomiR complexes 
observed was notably higher than that of the Dy547 nanomiR-mimic treatment. 
Peri-nuclear localisation analysed qualitatively was more prominent across 
timepoints for the nanoantagomiRs, in contrast with that evidenced only at the 
early timepoint of 3 days for the nanomiR-mimic, revealing differences between 
the two types of molecules for the cellular internalisation process.  
The different uptake kinetics for miR-mimics and antagomiRs were again 
evidenced by flow cytometry quantification, and consistent with the differences 
in size and charge between the two types of complexes, the bigger and more 
lipophilic nanoantagomiR complexes were internalised in a more rapid manner. 
This kinetic behaviour may be beneficial from the perspective of manipulation of 
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cellular miRNA levels with a temporal control in a combined system with a miR-
mimic and an antagomiR targeted at processes occurring at different stages. 
Although a sensitivity limitation of flow cytometry to assay miRNA uptake from 
nanomiR-treated hMSCs might be implied from the presented data for the 10 
nM dose, it is important to note that such a limitation may be influenced by the 
excess ratio of nHA particles at the lower miRNA dose in comparison with the 
20 nM dose. Even though flow cytometry is a well-established technique for the 
purpose of uptake quantification of nucleic acid delivery, it is proposed that the 
detection limit for small RNA molecules tagged with fluorescent dyes may differ 
from that of transgene fluorescence emission assessed for pDNA delivery. 
Furthermore, the mismatch between this quantitative parameter and effective 
interference functionality has recently been noted for the case of miRNAs as 
opposed to siRNAs, and thus complementary assessment of silencing capacity 
by PCR is deemed crucial (219). In the current study however, the uptake 
efficiencies determined for nanomiR-mimic (20 nM) and nanoantagomiRs (10 
and 20 nM) were higher than the 12 % previously reported for nHA-mediated 
delivery of pDNA (126), a system which successfully led to a subsequent 
improvement in tissue repair in vivo (127). This indicates that nanomiR delivery 
may have enhanced potential for the prospective application of therapeutic 
miRNAs. In summary, the combination of qualitative and quantitative 
assessment together confirmed the ability of the nHA particles to deliver both 
nanomiR-mimics and nanoantagomiRs to hMSCs, which from a therapeutic 
perspective, points to a wide spectrum of application possibilities for the 
tailoring of both types of RNAi. 
Consequently, nanomiR treatment of hMSCs demonstrated greater than 90 % 
silencing functionality with a single dose, and this effect was generally 
maintained along all timepoints, as opposed to the different kinetics seen in the 
flow cytometry quantification of nanomiR uptake. Nevertheless, the 20 nM dose 
of the nanoantagomiR showed a reduction in silencing activity at day 7, 
therefore matching the reduction in uptake efficiency quantified by flow 
cytometry at this timepoint. Importantly, nanomiR-mimic at the 10 nM dose 
caused silencing levels similar to those of the 20 nM dose, despite the fact that 
uptake was undetected by flow cytometry experiments. Subsequently based on 
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these results, and considering the choice of doses in the available literature 
together with the risk of under-dosing resulting in negligible effects, the single 
20 nM dose was selected as the lead candidate for progression of the research 
presented in the following chapters of this thesis. 
Critically, the level of silencing functionality achieved with nanomiRs was 
comparable with the level described for viral and lipid-based vectors for delivery 
of siRNAs and shRNAs in different cell lines, but much higher than these type of 
systems for miRNA delivery to stem cells (219). A more relevant comparison of 
the silencing efficiency of nanomiRs presented in this chapter is perhaps versus 
CaP-based siRNA delivery systems reported to-date, (even though these have 
mainly been developed targeting different tumour-model cell lines, generally 
regarded as easier to transfect than stem cells). Luciferase siRNA complexes 
with CaP particles coated with Polyanion-modified PEG (at 100 nM doses) 
achieved 60 % efficiency in silencing luciferase expression in Huh-7 transfected 
cells, but this efficiency dropped to approx. 8 % when a 20 nM dose was 
administered (324). Lipid-CaP particles (LCP) were shown to exhibit a 
maximum of 70 % silencing of the H460 cell line with a dose that corresponded 
to approximately 16.6 µM at merely 24h post treatment (323). Although the 
effect of delivering lower siRNA doses in vitro using this system were not 
presented, a 50 % silencing effect was determined in their in vivo xenograft 
mouse model using the same cell line 24h after systemic intravenous (iv) 
administration of the siRNA-LCP complexes. Following this, the same research 
group developed an improved formulation involving an asymmetric lipid bilayer 
coating of CaP that yielded 90 % luciferase silencing functionality after 24 h in 
vitro when combined with 100 nM siRNA. However, once again, a 20 nM dose 
was associated with just 10 % silencing (373). Interestingly, the chelated PEG 
CaP complexes introduced by Giger et al. (325) were capable of significantly 
reducing Bcl-2 expression using and doses of 10 and 30 nM siRNA, which is 
closer to the results found in this chapter. Their work demonstrated 60 - 80 % 
silencing functionality for the respective doses after 48 h of treatment using PC-
3 & J744.2 cell lines, which corresponded to 75 % silencing in protein levels 
assessed after 72 h. Lee et al. (326, 327) also produced dopa-conjugated CaP 
siRNA complexes that rendered silencing efficiency levels of approximately 50 
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% using a luciferase or GFP silencing approach respectively for HTC-29 LUC or 
MDA-MB-435-GFP cell lines, a result that was replicated with their in vivo 
xenograft model using the same cell line (326). In summary, the nanomiR 
delivery system developed within this chapter was able to outperform the 
silencing efficiency of the few CaP-based siRNA delivery systems reported to 
date, encouraging further experimentation to implement the nHA-based miRNA 
delivery system in a number of therapeutic applications not merely limited to the 
TE field. 
 
2.6.Conclusion 
 
The research presented in this chapter has demonstrated the potential of in 
house-synthesised nHA particles to act as non-viral vectors for miR-mimic and 
antagomiR delivery to hMSCs and to subsequently manipulate post-
transcriptional gene regulation in a highly efficient and minimally cytotoxic 
manner, with single administration of low miRNA doses rendering very 
pronounced silencing activities. Specifically, nHA particles were able to complex 
with both miR-mimics and antagomiRs resulting in ~18 - 40 % uptake efficiency 
in hMSCs with different temporal patterns and silencing functionality to a level 
comparable to viral and lipid-based vectors. Furthermore, this study utilised low 
miRNA doses as compared with the literature and we determined that a 20 nM 
dose was optimal to continue the proposed work of the project. Ultimately, the 
results demonstrated the enormous potential of the nHA particles to act as 
miRNA delivery vectors. Following development of this system, we next 
investigated its application to (i) deliver pro-osteogenic miRNAs to hMSCs and 
(ii) incorporate the system into a collagen-nHA scaffold, as well as to (iii) deliver 
pro-angiogenic miRNAs to hMSCs, all of which is presented in the following 
chapters.  
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Chapter 3. Nanohydroxyapatite-based delivery of osteogenesis-
related miRNAs to enhance hMSC osteogenic differentiation  
 
Research presented in this chapter has been included in the following peer-
reviewed publication:  
Castaño, IM et al., Next generation bone grafting: Non-Viral Inhibition of MiR-
133a Using Collagen-Nanohydroxyapatite microRNA-activated Scaffolds 
Rapidly Enhances Osteogenesis by Human Mesenchymal Stem Cells. 
Manuscript submitted. 
 
      
3.1.Introduction 
nHA particles are chemically similar to the inorganic component of bones and 
hold osteogenic potential beneficial for bone repair applications (109, 318, 374). 
Having characterised the efficient nHA-based delivery of reporter miRNAs in 
Chapter 2, this study applied the same system to bone repair. In order to do so 
the focus was placed on the incorporation of therapeutic miRNAs to enhance 
and/or accelerate hMSC osteogenesis. As outlined in Chapter 1, MSCs have 
significant potential for bone repair applications. Osteodifferentiation is 
regulated by complex fine-tuned mechanisms involving the activation of master 
transcription factors of osteogenesis including Runx2 (21). In addition to the 
protein-based control of osteogenesis, recent research efforts have unravelled 
the role of several miRNAs in regulating osteodifferentiation either positively or 
negatively (Figure 3.1; (220, 221, 234-240, 242, 244, 368, 375-378)). Strategies 
for manipulating miRNA levels have recently been proposed for the treatment of 
bone defects and bone-related diseases such as osteoporosis and osteoarthritis 
(220, 221). Recent research efforts carried out by several groups have 
collectively identified a selection of miRNAs as potential osteo-therapeutics; 
however, many of these miRNAs have direct targets that only play a secondary 
role in the osteogenesis pathway (379). In this study, three candidate miRNAs 
were selected for incorporation into the nanomiR system to investigate their 
resulting effect on hMSC osteodifferentiation in monolayer culture. 
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Figure 3.1 Panel of miRNAs influencing osteogenic differentiation and their reported 
targets (experimentally validated).  Inner circle: red ovals accompanied by red brake symbols 
(  ) indicate proteins with inhibitory roles in osteogenesis, green ovals accompanied by 
green arrows (         ) indicate proteins which display an activator role in osteogenesis. Outer 
circle: miRNAs represented in blue are positive regulators of osteogenesis and miRNAs 
depicted in red are negative regulators of the process.  
 
Firstly downregulation of miR-133a was pursued as it has been identified as a 
negative regulator of the master transcription factor of osteogenesis, Runx2 
(242). Hence, the direct relationship between miR-133a levels and Runx2 
expression provides a possibility to target a central activator of osteogenesis. It 
was hypothesised that exogenous inhibition of miR-133a levels in hMSCs with 
antagomiR treatment would increase Runx2 levels in these cells and enhance 
their osteogenic potential (Figure 3.2a).   
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Figure 3.2 Schematic of molecular processes leading to enhanced osteogenesis following the manipulation of each of the miRNAs selected for this 
study. a) antagomiR-133a treatment, b) antagomiR-16 treatment, c) miR-210 mimic treatment. Black arrows indicate exogenous delivery, green arrows 
indicate activation or enhancement, brake symbols ( , red) represent inhibition, x symbols (black) depict decreased activity, discontinuous brake shapes 
symbolise abrogated silencing signal. 
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The second candidate for this work was miR-16. Many anti-tumoral approaches 
have sought to increase miR-16 to induce cancer cell apoptosis (380), while 
decreasing miR-16 has the therapeutic potential to promote cell survival. 
Currently, there is no defined role for miR-16 in osteogenesis but Eguchi et al. 
pointed at a potential marker role for miR-16 in maintaining stemness and 
deterring osteocyte maturation in human and murine MSC osteogenesis (239). 
Previously, Selbach et al. carried out proteome-wide analysis of manipulation of 
miR-16, alongside four other miRNAs belonging to highly conserved miRNA 
families, in HeLa cells (381). In that study, evidence of direct interaction 
between miR-16 and Smad5, an intermediate activator of BMP signalling in 
osteogenesis, was reported through proteomic analyses. More recently, all 
members of the miR-15 family, including miR-16 and miR-195, which 
encompasses a near-identical sequence to miR-16, were associated to multiple 
target genes involved in BMP signalling in mouse bone cells using quantitative 
PCR (382). Therefore, it can be proposed that treatment with antagomiR-16 
may enhance SMAD5 levels and thus trigger MSC commitment towards the 
osteoblastic or osteocytic lineage (Figure 3.2b).  
 
Lastly, miR-210 was selected due to its positive secondary role in osteogenesis, 
which has been described to occur by targeting activin receptor 1b (AcvR1b) in 
a study performed in BMP-4 induced differentiation of mouse BM-derived 
stromal ST2 cells (236). Little is known about the direct AcvR1b-mediated 
inhibition of osteogenesis; AcvR1b is involved in activin signalling as part of the 
TGFβ pathway, ultimately leading to Runx2 inhibition. Moreover, Mizuno et al. 
confirmed the inhibitory role of AcvR1b in osteogenesis by demonstrating the 
osteogenic phenotype following chemical inhibition of AcvR1b (236). 
Considering this, exogenous treatment with mature miR-210 mimics might be 
applied to further reduce AcvR1b and subsequently enhance hMSC 
osteogenesis (Figure 3.2c). Additionally miR-210 may indirectly benefit 
osteogenesis through the promotion of angiogenesis. miR-210 has been 
implicated as a positive regulator of angiogenesis (383), and increased 
angiogenesis has the potential to enhance osteogenesis, as reviewed in 
Chapter 1, thus this bi-modal function of miR-210 may lead to a robust 
beneficial effect on bone formation. 
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3.2.Hypothesis & aims of the study 
 
The underlying hypothesis of this study was that efficient delivery of these three 
individual miRNAs might lead to enhanced hMSC osteogenesis. The overall aim 
of this study was thus to assess the pro-osteogenic therapeutic efficacy of nHA-
based delivery of the following miRNAs: (i) nanoantagomiR-133a, (ii) 
nanoantagomiR-16 and (iii) nanomiR-210 mimic with a view to establishing the 
optimal osteo-therapeutic candidate for delivery in a 3D scaffold-based system 
in Chapter 4.  
The following specific tasks were carried out in order to analyse the pro-
osteogenic therapeutic efficacy of each of the nanomiR treatments selected:  
• Identification of additional predicted and validated targets of interest that 
support the role of each miRNA in osteogenesis using bioinformatic tools 
• Determination of efficient nHA-based miRNA delivery by confirmation of 
specific miRNA intracellular level manipulation  
• Analysis of functional nHA-based miRNA delivery by confirmation of (i) 
increased mRNA levels of direct targets following nanoantagomiRs 
treatment or (ii) decreased mRNA levels of direct targets following nanomiR-
mimic treatment 
• Assessment of the efficacy of the miRNA treatment in influencing hMSC 
osteogenesis by osteogenic gene marker analysis, ALP bioactivity assays 
and mineral deposition examination  
 
3.3.Materials & Methods 
 
3.3.1.Bioinformatic analysis  
Bioinformatic analysis provides detailed information about the features of 
putative and experimentally validated interactions of a given miRNA entry, 
which may further relate to a suggested function for such miRNA. To gather 
further knowledge regarding the function in osteogenesis of the three miRNAs 
studied in this chapter, online tools were explored in terms of (i) identification of 
putative messenger RNA targets implicated in osteogenesis and (ii) 
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identification of validated targets for which the miRNA interaction was assessed 
in the context of a cellular function different to osteogenesis. A subsequent 
analysis was carried out to assess (iii) homology in the interaction of miRNAs 
and their relevant direct targets across human, rat and mouse species, as well 
as (iv) the types of miRNA::mRNA target interaction taking place and (v) 
occupancy of nearby seed region by other neighbour miRNAs. All of these 
features were explored by searching the following peer-consulted databases 
available online: Targetscan (382), microRNA.org (384), miRTarBase (385).  
3.3.2.Cell culture and treatment with nanomiR system 
hMSCs were cultured in complete DMEM medium as described in Section 2.3.3 
until sufficient cell numbers were obtained at passage number 4 for 
experimentation. 24 hours in advance of the nanomiR treatment, cells were 
plated at a density of 3 x 104 cells per well in 6 well plates. At the time of 
administering the control (blank nHA particles) or nanomiR treatments, 
nanomiR complexes were prepared with the antagomiR-133a, antagomiR-16 
and miR-210 mimics as well as with scrambled (scr) antagomiR and scr miR-
mimic (all from Dharmacon) at a final dose of 20 nM following the procedure 
detailed in Section 2.3.1. Immediately after the addition of the treatments, 
hMSCs were cultured in complete osteogenic medium, which consisted of 
standard growth medium supplemented with 50 µg/ml ascorbic acid-2-
phosphate, 10 nM β–glycerophosphate and 100 nM dexamethasone and was 
administered to cells every 3/4 days until the experiment endpoint at day 14. 
Additionally, untreated cells were kept either in standard or osteogenic complete 
growth medium for the duration of the assay as a control for inherent hMSC 
osteogenesis. 
3.3.3.Assessment of effective genetic manipulation following nanomiR 
treatment using qRT-PCR 
qRT-PCR analysis was carried out to determine (i) miRNA intracellular levels as 
well as mRNA relative expression level of (ii) direct miRNA targets and (iii) the 
osteogenesis marker osteocalcin (OCN, also represented as BGLAP) after 
transient transfection using the nanomiR method. The hsa-miR-133a, hsa-miR-
16 and hsa-miR-210 Taqman® MicroRNA assays as well as the following 
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validated pre-designed human Quantitect Primer Assays (Qiagen, UK) were 
applied: Hs_Runx2_1_SG, Hs_BGLAP_1_SG, Hs_SMAD5_va.1_SG, 
Hs_AcvR2a_1_SG and Hs_AcvR1b_va.1_SG. The scr nanoantagomiR group 
was set as the reference for the calculation of relative expression levels for the 
experiments with antagomiR treatments, while the scr nanomiR-mimic was set 
as the reference for the calculation of relative expression levels for the 
experiments with miR-210 mimic. Technique and calculations were carried out 
as described previously in Section 2.3.7. 
3.3.4.Assessment of alkaline phosphatase (ALP) activity as a biofunctional 
marker of osteogenesis 
ALP activity is a specific marker of biofunctional osteogenesis. In order to 
assess ALP activity in hMSCs 10 days post-treatment the SensoLyte® pNPP 
Alkaline Phosphatase Assay Kit (Cambridge Bioscience) was used under 
manufacturer’s instructions. Absorbance of the colour product generated was 
read at 405 nm using a Varioskan Flash plate reader (ThermoScientific) and 
SkanIt ® for Varioskan software. The Quant-iT PicoGreen dsDNA kit 
(Invitrogen) assay was performed as previously described in Section 2.3.4 to 
normalise levels of ALP activity quantifed.  
3.3.5.Mineral deposition assessment as end-stage marker of osteogenesis 
Histological analysis: 
Presence of calcium deposits in the extracellular matrix is regarded as an 
endpoint biofunctional parameter of osteogenesis. In order to visualise calcium 
deposits at 10 days after treatment samples were stained directly on culture-
plates with 2 % Alizarin red, which stains calcium red. Briefly, samples were 
fixed using 10 % formalin and subjected to alizarin red staining for 5 min, 
following which excess staining was removed rinsing with distilled water. 
Microscopic imaging was carried out using an inverted microscope coupled to 
the LASV4.5 digital imaging system (Leica, Germany). 
Mineral deposition quantification: 
To provide quantitative data the Calcium Liquicolor kit (Stanbio Laboratories) 
was used under manufacturer’s instructions at days 10 and 14 post-treatment. 
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Briefly, 1 ml of 0.5 M HCl was added to samples and maintained in agitation at 
4°C overnight, then 100 μl of the substrate plus reagent mix (1:1) solution was 
added to 10 μl of the samples and absorbance of the colour product generated 
was read at 595 nm using a Varioskan Flash plate reader (ThermoScientific) 
and SkanIt® for Varioskan software. The Quant-iT PicoGreen dsDNA kit 
(Invitrogen) assay was performed at the corresponding timepoints as previously 
described in Section 2.3.4 to normalise levels of calcium quantifed.  
 
3.3.6.Statistical analysis 
Experiments were performed in triplicate, unless otherwise specified within 
figure captions, and are representative of a minimum of three independent 
repetitions using two cell donors. Results were analysed as described 
previously in Section 2.3.8 using two-way ANOVA plus Tukey post-hoc test for 
analysis of several time points and one-way ANOVA plus Tukey post-hoc test 
for data assessed at a singular time point. p<0.05 was considered significant 
and p<0.001 highly significant. 
 
3.4.Results 
 
The effect of the three individual nanomiR treatments on hMSC osteogenesis is 
presented herein in three separate sections focussing on nanoantagomiR-133a, 
nanoantagomiR-16 and lastly nanomiR-210 mimic treatments. 
3.4.1.The effect of nanoantagomiR-133a treatment on hMSC osteogenesis  
 
3.4.1.1.Bioinformatic analysis supports a negative role of miR-133a in 
osteogenesis 
Bioinformatic tools provided the identification of 648 predicted hit interactions 
between potential mRNA targets and miR-133a in human species, seven of 
which were of interest for osteogenesis (Figure 3.3a). These target hits were 
then compared to the database of validated targets, miRTarBase. Fewer than 
10 % of the total predicted targets have been experimentally validated, but 
interestingly the screening identified Runx2, collagen type 1α1 (COL1A1), 
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IGFR1, and Bcl2L as validated targets. Although Runx2 is key for orchestrating 
osteogenesis, COL1A1 and IGFR1 also play a positive role in the process, 
which further supports the inhibitory role of miR-133a in this process and hence 
reinforces the hypothesised potential of antagomiR-133a to promote 
osteogenesis in hMSCs. Key targets for this study have only been validated in 
mouse cells. Since we aimed to target these pathways in human cells, 
homology of the miRNA::target interaction across human, rat and mouse 
species was also studied (Figure 3.3b). The interaction type and score (context 
percentile) was maintained across the three species. However, additional 
parameters assessed in this analysis indicated the possibility of more robust 
interactions in the case of mouse and rat species compared to in human: firstly, 
additional seed regions were found in both mouse and rat; second and more 
importantly, the amount of miRNAs predicted to interact in the areas 
neighbouring the seed region was higher in human, denoting a possible 
reduced functionality for the miR-133a::Runx2 interaction in human.    
 
Figure 3.3 Bioinformatic exploration of miR-133a. a) Putative or predicted (left circle) vs. 
validated (right circle) targets related to osteogenesis across human, mouse and rat for miR-
133a. Overlapping sections of internal circles indicate that validation has been reported in both 
species. b) miRNA::target interaction for miR-133a and Runx2 across human (hsa), mouse 
(mmu) and rat (rno)species.  
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3.4.1.2.Effective manipulation of intracellular miR-133a levels in hMSC was 
achieved using nHA-based delivery 
The temporal pattern of endogenous miR-133a expression during osteogenesis 
has not been previously assessed in hMSCs. Here, we found that hMSC miR-
133a expression continuously increased in the standard (no osteogenic 
supplementation) medium group over the course of 14 days, whereas hMSCs in 
the osteogenic medium group showed a peak at day 3 but reduced levels at the 
later timepoints of days 7 and 14, pointing to a link between suppression of 
endogenous miR133a and the progression of in vitro osteogenesis (Figure 3.4).  
 
Figure 3.4 miR-133a levels during standard vs osteogenic monolayer culture. Comparison 
with cells cultured in standard (std) growth medium over the course of 14 days demonstrated a 
natural decrease in miR-133a at later time points in osteogenic culture. Cell std medium was set 
as the reference control group and relative expression was normalised to that of 18S and 
calculated using the 2(-ΔΔCt) method. Mean + standard deviation, n = 4, * = p<0.05, ** = p<0.001. 
 
Interestingly, following nHA-based delivery of antagomiR-133a, a sustained 
miR-133a downregulation was obtained with a functionality level over 80 %, 
while miR-133a was slightly increased from 3 to 7 days in the blank nHA 
particles group (Figure 3.5). Moreover, the effect of independent treatments with 
nanoantagomiR-16 or nanomiR-210 mimic on intracellular levels of miR-133a 
was explored to assess specific miRNA manipulation 7 days after treatment of 
hMSCs (Figure 3.6). This data showed that treatment with nanoantagomiR-16 
or nanomiR-210 mimic did not alter miR-133a levels. In summary, this 
assessment indicated firstly that intracellular miR-133a levels endogenously 
decrease during hMSCs osteogenesis in vitro and secondly this can be 
99 
 
significantly potentiated at earlier timepoints using nanoantagomiR-133a 
treatment.  
 
Figure 3.5 qRT-PCR analysis of miR-133a manipulation in hMSCs using nHA-based 
delivery. NanoantagomiR-133a demonstrated a maintained suppression of miR-133a 
intracellular levels from day 3. Scr nanoantagomiR was set as the reference control group and 
relative expression was normalised to that of 18S and calculated using the 2(-ΔΔCt) method. Mean 
+ standard deviation, n = 4, ** = p<0.001. 
 
 
Figure 3.6 qRT-PCR analysis of specificity in miR-133a manipulation demonstrating non-
manipulation of miR-133a following nanoantagomiR-16 or nanomiR-210 mimic treatment. 
NanoantagomiR-16 or nanomiR-210 mimic treatment did not significantly modify intracellular 
miR-133a level. Scr nanoantagomiR was set as the reference control group for nanoantagomiR-
16 and scr nanomiR-mimic was set as the reference control group for nanomiR-210 mimic. 
Relative expression was normalised to that of 18S and calculated using the 2(-ΔΔCt) method. 
Dashed green line indicates level determined for nanoantagomiR-133a treatment as a reference 
for comparison. Mean + standard deviation, n = 4, NS = not significant variation. 
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3.4.1.3.NanoantagomiR-133a treatment enhanced hMSC osteogenic gene 
expression 
Runx2 and OCN gene levels are often analysed as the main indicators of the 
initiation and progression of osteogenesis in hMSCs (386). Here, these two 
osteogenic gene markers were analysed at day 7 to evaluate the effect of 
nanoantagomiR-133a treatment on its downstream direct target as well as the 
osteogenic response achieved as a consequence of the treatment. Runx2 
expression was increased 8.9 (± 2.97) fold with a single dose of the treatment 
(Figure 3.7a) while a 14.23 (± 3.2) fold increase was found when OCN levels 
were analysed (Figure 3.7b). In summary, this assessment indicated that 
nanoantagomiR-133a treatment was capable of enhancing levels of Runx2 and 
OCN, both crucial indicators for osteogenic differentiation in hMSCs. 
 
Figure 3.7 qRT-PCR analysis of the effect of nanoantagomiR-133a treatment on hMSC 
osteogenic gene expression. a) Runx2 and b) OCN were increased at 7 days after 
nanoantagomiR-133a treatment. Scr nanoantagomiR was set as the reference control group 
and relative expression was normalised to that of 18S and calculated using the 2(-ΔΔCt) method. 
Mean + standard deviation, n = 4, * = p<0.05, ** = p<0.001.  
 
 
 
 
 
101 
 
 
3.4.1.4.ALP activity was increased in nanoantagomiR-133a treated hMSCs 
ALP is an important marker of functional bioactivity during osteogenesis which 
also has previously been shown to be upregulated in hMSCs as a result of 
antagomiR-133a treatment (235). Bioactivity quantification normalised to 
dsDNA content, as a surrogate measure of cell number, showed 
nanoantagomiR-133a resulted in 17.37 and 13.23 fold higher levels of ALP than 
untreated cells and nHA groups respectively (Figure 3.8). These were also 1.87 
fold higher than scr nanoantagomiR group, which unexpectedly increased ALP 
activity over untreated cells. In summary, this result indicated that 
nanoantagomiR-133a treatment was able to trigger enhanced functional 
osteogenesis in hMSCs. 
 
Figure 3.8 Analysis of ALP activity in nanoantagomiR-133a treated hMSCs. Quantification 
of ALP normalised to dsDNA content demonstrated significantly increased ALP activity levels in 
nanoantagomiR-133a over scr nanoantagomiR as well as of these two groups compared to 
cells alone and blank nHA 10 days after treatment. Mean + standard deviation, n = 3, ** = 
p<0.001. 
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3.4.1.5.Mineral deposition was enhanced in nanoantagomiR-133a treated 
hMSCs  
To further assess functional osteogenesis, calcium deposition in the ECM was 
studied. Histological analysis showed enhanced calcium deposits at day 10 with 
nanoantagomiR-133a (Figure 3.9a). Subsequently, significantly enhanced 
calcium deposition, normalised to cell number, was observed for cells treated 
with nanoantagomiR-133a (Figure 3.9b). As early as day 10, calcium deposition 
was increased 4.67 fold over untreated cells (cells osteo medium). Moreover 
this effect was continued at 14 days, when nanoantagomiR-133a treatment 
enhanced calcium deposition 2.55 fold over untreated cells. In summary, this 
data indicated a potent ability of nanoantagomiR-133a to rapidly exert a 
significant mineralisation response.  
 
Figure 3.9 Analysis of calcium deposition in nanoantagomiR-133a treated hMSCs. a) 
Alizarin red staining showed calcium deposits at 10 days after treatment, scale bar= 200 µm. b) 
Calcium normalised to dsDNA content confirmed an increase in calcium deposition by day 10 
after treatment with nanoantagomiR-133a in osteogenic culture and maintained increased 
calcium levels compared to the control groups after 14 days. Mean + standard deviation, n = 3, 
* = p<0.05, ** = p<0.001, # = p<0.001 against all other groups.  
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3.4.2.The effect of nanoantagomiR-16 treatment on hMSC osteogenesis  
 
3.4.2.1.Bioinformatic analysis supports a negative role of miR-16 in 
osteogenesis 
Bioinformatic tools provided the identification of 1273 predicted hit interactions 
between potential mRNA targets and miR-16 in human species, nine of which 
were of interest for osteogenesis (Figure 3.10a). These target hits were then 
compared to the database of validated targets, miRTarBase. More than 90 % of 
the total predicted targets have been experimentally validated. Interestingly in 
addition to Smad5, the screening identified seven targets of interest for 
osteogenesis as validated in human, including and COL4A2 and IGF2R, which 
also play a positive role in the osteogenesis, as well as AcvR2a, which was 
analysed in further detail as it is familiarly related to AcvR1b, the miR-210 target 
of focus to this study. Overall these additional targets further support the 
inhibitory role of miR-16 in this process and hence reinforce the hypothesised 
potential of antagomiR-16 to promote osteogenesis in hMSCs.  
Bioinformatic tools were then searched to document further details of the miR-
16::AcvR2a and miR-16::Smad5 interactions in terms of homology across 
human, rat and mouse (Figure 3.10b). Firstly for AcvR2a the 7mer-m8 binding 
type, together with context percentile score and remaining parameters tested 
were maintained across species. In relation to Smad5, a double number of 
binding sites was predicted for the interaction in mouse, and rat context 
percentile scores were lower than those of both human and mice. Taken 
together, this data confirmed the promising potential of miR-16 to exert multiple 
functions related with osteogenesis which is predicted to hold a robust 
homology across the three species of interest of this study. 
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 Figure 3.10 Bioinformatic exploration of miR-16. a) Predicted (left circle) vs. validated (right 
circle) targets related to osteogenesis across human, mouse and rat for miR-16. Overlapping 
sections of internal circles indicate that validation has been reported in both species. b) 
miRNA::target interaction for (i) miR-16 and AcvR2a and (ii) miR-16 and Smad5 across hsa, 
mmu and rno species.  
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3.4.2.2.Effective manipulation of intracellular miR-16 level in hMSC was 
achieved using nHA-based delivery  
When miR-16 intracellular levels were monitored during hMSC osteogenic 
culture, these remained generally unaffected in the untreated cells, only 
subjected to culture in osteogenic medium (cells osteo medium). In comparison 
to this, manipulation of miR-16 levels with nanoantagomiR-16 treatment proved 
highly efficient, yielding higher than 90 % reduction at both timepoints, in 
accordance with the data presented in Chapter 2 (Figure 3.11). 
 
Figure 3.11 qRT-PCR analysis of miR-16 manipulation in hMSCs using nHA-based 
delivery. miR-16 intracellular levels demonstrated a maintained suppression with 
nanoantagomiR-16 up to 7 days after treatment. Scr nanoantagomiR was set as the reference 
control group and relative expression was normalised to that of 18S and calculated using the 2(-
ΔΔCt) method. Mean + standard deviation, n = 4, ** = p<0.001. 
 
Next, the assessment of specific miRNA manipulation was carried out analysing 
the effect of independent treatments with nanoantagomiR-133a or nanomiR-210 
mimic (Figure 3.12). This data showed that treatment with nanoantagomiR-133a 
did not vary miR-16 levels, although a significant increase was found in the 
nanomiR-210 mimic group, which again may be indicative of a yet unknown 
interaction between these two miRNAs. In summary, this data confirmed 
remarkable miR-16 inhibition using nHA-based delivery of antagomiR-16 in 
hMSCs osteogenic culture.  
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Figure 3.12 qRT-PCR analysis of specific miR-16 manipulation demonstrating non-
manipulation of miR-16 following nanoantagomiR-133a treatment. NanoantagomiR-133a 
treatment did not modify intracellular miR-16 levels in opposition with nanomiR-210 mimic. Scr 
nanoantagomiR was set as the reference control group for nanoantagomiR-133a and scr 
nanmiR-mimic was set as the reference control group for nanomiR-210 mimic. Relative 
expression was normalised to that of 18S and calculated using the 2(-ΔΔCt) method. Dashed red 
line indicates level determined for nanoantagomiR-16 treatment as a reference for comparison. 
Mean + standard deviation, n = 4, * = p<0.05. 
 
3.4.2.3.NanoantagomiR-16 treatment enhanced hMSC osteogenic gene 
expression 
To evaluate the effect of nanoantagomiR-16 treatment in hMSC osteogenic 
gene expression, the direct targets AcvR2a and Smad5, alongside the 
osteogenesis markers Runx2 and OCN were analysed at day 7 (Figure 3.13). 
As a consequence of the efficient inhibition of miR-16 with nanoantagomiR-16 
treatment, messenger RNA levels of AcvR2a and Smad5 were increased to 
10.92 (± 1.12) fold and 2.54 (± 0.55) fold respectively. Subsequently, Runx2 
and OCN expression were increased to 6.29 (± 2.3) fold and 8.19 (± 1.96) fold 
respectively with the nanoantagomiR-16 treatment. In line with the hypothesised 
negative role of miR-16 in osteogenesis, this data supported that inhibition of 
miR-16 can have a positive outcome in hMSC osteogenesis at the gene level. 
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Figure 3.13 qRT-PCR analysis of the effect of nanoantagomiR-16 treatment on hMSC 
osteogenic gene expression. a) AcvR2a, b) Smad5, c) Runx2 and d) OCN were increased 
after 7 days. Scr nanoantagomiR was set as the reference control group and relative expression 
was normalised to that of 18S and calculated using the 2(-ΔΔCt) method. Mean + standard 
deviation, n = 4, * = p<0.05, ** = p<0.001. 
3.4.2.4.ALP activity was increased in nanoantagomiR-16 treated compared to 
untreated hMSCs 
As part of the assessment of biofunctional osteogenic response, quantification 
of ALP activity showed that nanoantagomiR-16 treatment resulted in 11.32 and 
8.62 fold higher levels than untreated cells and nHA groups respectively (Figure 
3.14). These were also 1.22 fold higher than the scr nanoantagomiR group, 
which surprisingly enhanced ALP activity over untreated cells. In summary, this 
result reported a limited ability of nanoantagomiR-16 treatment to enhance 
functional osteogenesis in hMSCs at the timepoint assessed. 
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Figure 3.14 Analysis of ALP activity in nanoantagomiR-16 treated hMSCs. Quantification of 
ALP normalised to dsDNA content demonstrated increased ALP activity levels in both scr and -
16 nanoantagomiR groups compared to untreated cells and blank nHA 10 days after treatment. 
Mean + standard deviation, n = 3, ** = p<0.001. 
 
3.4.2.5.Mineral deposition was enhanced in nanoantagomiR-16 treated hMSCs  
As an indication of osteo-induction, enhanced extracellular calcium deposits 
were observed at day 10 in the cells treated with nanoantagomiR-16 using 
alizarin red staining (Figure 3.15a). Correspondingly, quantification of calcium 
deposition levels at day 10 post-seeding revealed a significant enhancement in 
the nanoantagomiR-16 treatment group to 3.59 fold over untreated cells and 
this effect was maintained until day 14, achieving a 3.53 fold increase over 
untreated cells (Figure 3.15b). Taken together, this assessment indicated that 
nanoantagomiR-16 treatment holds potential to maintain an enhanced calcium 
mineralisation response from the early time point of day 10 onwards.  
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Figure 3.15 Analysis of calcium deposition in nanoantagomiR-16 treated hMSCs. a) 
Alizarin red staining showed calcium deposits at 10 and 14 day, scale bar= 200 µm. b) Calcium 
normalised to dsDNA content confirmed an increase in calcium deposition by day 10 after 
treatment with nanoantagomiR-16 in osteogenic culture and maintained increased calcium 
levels compared to the control groups after 14 days. Mean + standard deviation, n = 3, ** = 
p<0.001, # = p<0.001 against all other groups.  
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3.4.3.The effect of nanomiR-210 mimic treatment on hMSC osteogenesis  
 
3.4.3.1.Bioinformatic analysis supports a bi-modal role of miR-210 in 
osteogenesis 
Bioinformatic tools provided the identification of 586 putative targets predicted 
for miR-210 in human species, out of which approximately 10 % have been 
experimentally validated (Figure 3.16a). Although osteogenesis-related 
molecules such as BMP-6, Smad4 and IGF-2 were shortlisted from the 
predictions hit-list, none of these were found in the validated targets reported. 
Interestingly, entries of two angiogenesis related factors, namely hypoxia 
inducible factor 3α (HIF3A) and EphrinA3 (EFNA3), are validated targets for this 
miRNA, and this process is the focus of further work presented in Chapter 5. In 
summary, the direct interaction between miR-210 and the negative factor for 
osteogenesis AcvR1b has been validated experimentally in both human and 
mouse, which further supports the hypothesis that increased miR-210 levels will 
enhance hMSC osteogenesis. 
With regards the homology of the miR-210::AcvR1b interaction across human, 
rat and mouse species (Figure 3.16b), the interaction type was maintained 
across the three species although additional binding sites were found in both 
human and rat as compared to mouse sequences, and these additional regions 
reported higher context percentile score, pointing to a more potent scope of 
their interaction. On the other hand, both human and rat sequences of the 
mRNA target site are susceptible of interaction with more neighbouring miRNAs 
than in mouse species, but these are not currently described as osteogenesis 
regulators, reinforcing a notable potency of the miR-210::AcvR1b interaction 
across the three species studied. 
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Figure 3.16 Bioinformatic exploration of miR-210. a) Predicted (left circle) vs. validated (right 
circle) targets related to osteogenesis across human, mouse and rat for miR-210. Overlapping 
sections of internal circles indicate that validation has been reported in both species. b) 
miRNA::target interaction for (i) miR-210 and AcvR1b across hsa, mmu and rno species.  
  
3.4.3.2.Effective manipulation of intracellular miR-210 level in hMSC was 
achieved using nHA-based delivery  
When miR-210 intracellular levels were monitored during hMSC osteogenic 
culture, these remained generally unaffected in the untreated cells, only 
subjected to culture in osteogenic medium (cell osteo medium). In comparison 
to this, nanomiR-210 mimic treatment prominently increased miR-210 levels 
(Figure 3.17), while treatment with the remaining nanoantagomiR-133a and 16 
did not affect miR-210 levels in hMSCs (Figure 3.18). In summary, the efficient 
delivery of miR-210 mimic using nHA particles was confirmed by this data.  
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Figure 3.17 qRT-PCR analysis of miR-210 manipulation in hMSCs using nHA-based 
delivery. miR-210 mimic treatment demonstrated a maintained increase of miR-210 intracellular 
levels from day 3. Scr nanomiR-mimic was set as the reference control group and relative 
expression was normalised to that of 18S and calculated using the 2(-ΔΔCt) method. Mean + 
standard deviation, n = 4, ** = p<0.001. 
   
Figure 3.18 qRT-PCR analysis of specificity in miR-210 manipulation demonstrating non-
manipulation of miR-210 following nanoantgomiR-133a or -16 treatment. NanoantagomiR-
133a and -16 did not significantly affect miR-210 intracellular levels day 7. As a reference for 
comparison with nanomiR-210 mimic treatment, all groups presented in this figure fall within the 
range of the bottom section of Figure 3.18. Scr nanoantagomiR was set as the reference control 
group for both nanoantagomiR-133a and nanoantagomiR-16. Relative expression was 
normalised to that of 18S and calculated using the 2(-ΔΔCt) method Mean + standard deviation, n 
= 4, NS = not significant variation.  
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3.4.3.3.NanomiR-210 mimic treatment did not enhance hMSC osteogenic gene 
expression 
To evaluate the effect of nanomiR-210 mimic treatment on hMSC osteogenic 
gene expression, the direct target AcvR1b, as well as the osteogenesis markers 
Runx2 and OCN were analysed at day 7. NanomiR-210 mimic treatment 
resulted in an effective silencing effect of AcvR1b to 0.24 (± 0.14) fold (Figure 
3.19a). Following this however, Runx2 levels remained unaffected (1.00 ± 0.20 
fold expression, Figure 3.19b), and nanomiR-210 mimic had a negative effect 
on OCN, which was reduced to 0.27 (± 0.016) fold (Figure 3.19c). In summary 
this data indicated that successful manipulation of miR-210 levels did not 
correlate with enhanced hMSCs osteogenesis at the gene level. 
 
Figure 3.19 qRT-PCR analysis of the effect of nanomiR-210 treatment on hMSC 
osteogenic gene expression. a) A decrease in AcvR1b expression was found for the 
nanomiR-210 mimic group while b) Runx2 expression was unaffected and c) OCN relative level 
was also decreased. Scr nanomiR-mimic was set as the reference control group and relative 
expression was normalised to that of 18S and calculated using the 2(-ΔΔCt) method. Mean + 
standard deviation, n = 4, NS = not significant variation, * = p<0.05. 
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3.4.3.4.ALP activity was enhanced in nanomiR-210 mimic treated compared to 
untreated hMSCs  
As part of the assessment of biofunctional osteogenic response, quantification 
of ALP activity showed that nanomiR-210 mimic treatment increased ALP 
activity to 12.4 and 9.44 fold higher levels than untreated cells and nHA groups 
respectively, although this corresponded to 0.88 fold of the levels determined 
for scr nanomiR-mimic (Figure 3.20), which had promoted a surprising increase 
in ALP activity. Hence this result indicated a restricted ability of nanomiR-210 
mimic treatment to trigger enhanced functional osteogenesis in hMSCs. 
 
Figure 3.20 Analysis of ALP activity in nanomiR-210 mimic treated hMSCs. Quantification 
of ALP normalised to dsDNA content demonstrated increase ALP activity levels in both scr and 
-210 nanomiR-mimic groups compared to untreated cells and blank nHA at 10 days after 
treatment. Mean + standard deviation, n = 3, ** = p<0.001. 
3.4.3.5.Mineral deposition was enhanced in nanomiR-210 treated compared to 
untreated hMSCs at the early timepoint of 10 days 
Enhanced calcium deposition at day 10 was observed in the cells treated with 
nanomiR-210 mimic (Figure 3.21), indicating a positive effect of the treatment 
on osteogenesis. Alizarin red staining confirmed the presence of extracellular 
calcium deposits at this time point across all groups, with a higher amount of 
small deposits found in the nanomiR-210 mimic group (Figure 3.21a). 
Quantification of calcium deposition corroborated this observation, showing a 
3.37 fold increase over untreated cells, although the scr nanomiR-mimic 
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treatment also produced a marked increase in quantified calcium deposits. 
Subsequently, at day 14 calcium deposition levels remained enhanced in the 
nanomiR-210 mimic treatment group by 1.64 fold in comparison to untreated 
cells, however this effect was approximately at the same level than the nHA 
alone group (516.39 ± 16.59 and 494.84 ± 31.91 respectively), and was highest 
for the scr nanomiR-mimic group at this timepoint (Figure 3.21b). This 
assessment indicated that increasing miR-210 levels promoted an early 
enhancement of calcium deposition, although this response was not robust 
enough to maintain enhanced functional osteogenesis at later timepoints. 
 
Figure 3.21 Analysis of calcium deposition in nanomiR-210 mimic treated hMSCs. a) 
Alizarin red staining showed calcium deposits visibly increased with nanomiR-210 mimic at 
day10, scale bar= 200 µm. b) Calcium was increased by day 10 after nanomiR-210 mimic and 
scr nanomiR-mimic treatment, which was maintained in comparison to untreated cells and blank 
particles at day 14, but the effect of nanomiR-210 mimic treatment did not surpass that of scr 
nanomiR-mimic by this later timepoint. Mean + standard deviation, n = 3, * = p<0.05, ** = 
p<0.001, # = compared to all other groups in that graph.    
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3.5.Discussion  
 
The emerging interest in the use of miRNAs as osteo-therapeutics has led to 
the application of viral or lipid based delivery of miRNA to osteoprogenitors and 
stem cells. However, non-viral and non-lipid based delivery of potential 
candidates to hMSCs is an approach understudied in the bone TE field. To our 
knowledge, this is the first study to test the therapeutic ability of antagomiR-
133a, antagomiR-16 and miR-210 mimic to enhance hMSC osteogenesis, with 
the additional novelty of using the nHA-based delivery system, as opposed to 
viral-based or commercially available lipid-based vectors. The results showed 
significant increases in Runx2 and OCN expression with nanoantagomiR-133a 
and, to a lesser extent, with nanoantagomiR-16. NanoantagomiR-133a 
treatment also resulted in the most promising enhancement of ALP activity in 
comparison with the two other nanomiR treatments assessed. Finally, calcium 
deposition was increased at both 10 and 14 days with the nanoantagomiR-133a 
and -16 groups, while nanomiR-210 mimic only had a positive effect at the early 
time point of 10 days. Taken together, the results from this study demonstrated 
that nHA-based delivery of these three miRNAs enhances hMSC osteogenesis 
albeit to different levels. Ultimately, the greatest osteogenic response of hMSCs 
was seen with nanoantagomiR-133a treatment.  
The bioinformatic exploration reported the direct interaction of both miR-133a 
and miR-16 with additional positive mediators of osteogenesis, amongst which 
COL1A1 and COL4A2 were found respectively. This data further supported the 
negative role of these two miRNAs in osteogenesis. The bioinformatic 
exploration also predicted a direct interaction between miR-210 and positive 
mediators of osteogenesis, such as BMP-6 and Smad4. Although these 
interactions have not been experimentally validated yet, this data potentially 
implied miR-210 as a negative regulator of osteogenesis, in opposition with the 
positive role described in the literature (236).  
Intracellular miRNA level manipulation was deemed successful for each of the 
nanomiR treatments studied. Initially, this study showed for the first time an 
endogenous downregulation in miR-133a levels during hMSC osteogenesis, 
which was in accordance with previous observations in C2C12 mouse 
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myoblasts and primary mouse vascular smooth muscle cells (242, 387). More 
importantly, nanoantagomiR-133a treatment reduced intracellular miR-133a 
levels to less than 0.2 fold of the scrambled (scr) nanoantagomiR control group 
which indicated a further enhanced effect over the endogenous miR-133a 
downregulation in untreated cells observed in this study. NanoantagomiR-16 
also maintained silencing effects reducing miR-16 levels to less than 0.1 fold 
over 7 days, confirming the ability of the nanomiR system to achieve over 90 % 
silencing functionality. Moreover, nanoantagomiR-16 treatment did not affect 
intracellular miR-133a levels and vice versa, which was interpreted as an 
indication of specific manipulation of miRNA levels. This further supported the 
lack of RISC deregulation suggested by the results presented earlier in Chapter 
2 using nanoantagomiR at the 20 nM dose. On the other hand, assessment of 
intracellular miR-210 following nanomiR-210 mimic treatment demonstrated a 
very prominent increase to levels that can be considered supra-physiological 
(388). Taken together, these results confirmed the capability of nHA-based 
delivery to successfully manipulate miRNA levels in hMSC monolayer 
osteogenic culture. 
Subsequently, robust manipulation of all the direct gene targets selected for 
each nanomiR treatment was demonstrated at the mRNA level. Namely 
nanoantagomiR-133a enhanced Runx2 levels, nanoantagomiR-16 increased 
AcvR2a and Smad5 levels and nanomiR-210 mimic decreased AcvR1b 
expression. Although the effect of miR-133a mimic on Runx2 mRNA levels has 
been assessed previously by Li et al. (242), who showed results consistent with 
our study, this is the first time that the interaction between miR-16 and AcvR2a 
or Smad5, as well as the interaction between miR-210 and Acvr1b, has been 
assessed at the mRNA level. Up to 84 % of the changes in protein levels 
induced by miRNA regulation in mammalian species have been reported as 
attributable to changes in mRNA expression (389, 390). Hence, when miRNA 
manipulation induces detectable alterations at the mRNA level this can be 
interpreted as of high biological relevance. In this study, the beneficial role of 
each nanomiR treatment was supported by the efficient regulation of mRNA 
levels of the direct targets assessed. 
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Additionally in this study, nanoantagomiR-133a and nanoantagomiR-16 
markedly increased Runx2 and OCN mRNA after 7 days in culture, however, 
nanomiR-210 mimic did not increase Runx2 or OCN. Several reports have 
tested the mRNA levels of Runx2 and OCN to evaluate the osteogenic 
response of bone progenitor cells, including MSCs, as part of assessing the role 
of several miRNAs in relation to osteogenesis (234, 237, 238, 386). Although 
the cell type, miRNA delivery method and miRNA dose utilised across these 
studies is heterogenous (Table 3.1), the range of changes reported for these 
genes by PCR is generally less than three-fold. The biological response to 
effective miRNA manipulation ranges from a fine-tuning to a phenotype 
switching response (391). Specifically, the fine-tuning response is associated 
with mild amplitude gene expression changes, i.e. less than three-fold, while 
higher amplitude changes, such as those observed in this chapter, better 
correlate with a phenotype-switching role (391). This fact highlights the 
promising implications of the marked increase determined for both Runx2 and 
OCN in this chapter, which was of a higher order for nanoantagomiR-133a 
treatment, but also promising for nanoantagomiR-16. With regards to the 
observations following nanomiR-210 mimic treatment, these differ from the work 
published by Mizuno et al. using different experimental conditions to those of 
this study: 100 nM miR-210 mimic (Ambion) was administered to the mouse 
NRG cell line using Lipofectamine® which resulted in a 1.3 fold increase in 
OCN mRNA expression compared to the control miRNA treatment (236). In 
summary, both nanoantagomiR-133a and -16 treatments appeared valuable as 
a pro-osteogenic therapeutic for hMSCs but a less encouraging response was 
seen with the nanomiR-210 mimic. 
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Table 3.1 Different experimental conditions across reports elucidating the implication of 
several miRNAs in osteogenesis. 
miRNA miRNA dose Delivery method Cell type Reference 
miR-29b 50-100 nM Oligofectamine® 
MC3T3, rat fetal 
calvaria OB 
Li, Z. (234) 
miR-2861 n/d Lipofectamine® 
ST2,  
mouse OB 
Li, H. (238) 
miR-196a Pre-miRNAs n/a 
Lentivirus 
 
hASC Kim, YJ. (237) 
miR-218 
Pre-miRNAs n/a 
50nM  
Lentivirus 
Oligofectamine® 
MC3T3,mMSC 
Hassan, MQ. 
(386) 
 
Subsequently, ALP activity was increased in all nanomiR treatment groups 
compared to untreated cells in osteogenic medium, being highest in 
nanoantagomiR-133a but also significant versus the nanoantagomiR scr group 
for nanoantagomiR-16. Changes in ALP activity induced by manipulation of 
miRNA levels have been assessed in a comprehensive study by 
Schoolmeesters et al. (235). In that study inhibition of miR-133a was tested 
alongside a range of selected miRNAs, and resulted in a two-fold increase in 
ALP activity over untreated cells. From the perspective of this project, the 
detection of 17-fold increase in ALP activity in the nanoantagomiR-133a group 
suggested an encouraging beneficial effect for bone TE applications. In parallel, 
the 11-fold increase in ALP activity obtained with nanoantagomiR-16, also 
posed this treatment group as worthy of consideration. Meanwhile, consistent 
with the Runx2 and OCN gene expression results, the nanomiR-210 mimic did 
not display a positive effect, which was in opposition with the previous report by 
Mizuno et al. (236). In summary, this data indicate a standout capacity of miR-
133a and miR-16 inhibition, in comparison to miR-210 enhancement, to 
functionally enhance osteogenesis in hMSCs. 
Lastly, a significant increase in calcium deposition with both nanoantagomiR-
133a and -16 was detected at each of the timepoints assessed, whereas 
nanomiR-210 mimic only increased calcium deposition at the earlier timepoint of 
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day 10.  Calcium deposition in the ECM during osteogenic culture is regarded 
as definite functional marker of osteogenesis at the standard endpoint of 14 
days in two-dimensional (2D) assays (226, 237, 238, 240, 348, 368, 369, 375, 
382, 387). Of relevance, this is the first time that calcium deposition has been 
quantified following treatment with inhibitors of miR-133a or miR-16 as well as 
with miR-210 mimics. Other RNAi strategies to enhance osteogenesis have 
also been reported to increase calcium deposition when combining different 
delivery vectors, dosage regimes and cell types. As an example of other non-
viral delivery approaches, a 2-fold increase in calcium quantification was 
reported after 14 days of osteogenic culture in both hMSC transfected with 
Chordin siRNA using lipoplexes (226) and human adipose-derived stem cells 
(hASCs) treated with 40 nM miR-148b mimic (348). Another study reported 
treatment of hASCs with baculoviruses separately encoding a range of miRNAs, 
namely miR-26a, miR-29b, miR-148b and miR-196a, demonstrating relevantly 
enhanced calcium within an approximate range of 3 to 6.8 fold over the miR-
negative control group (299) after 14 days in osteogenic culture. Comparatively, 
the data presented in this chapter enhanced calcium deposition in a 
pronounced manner after just 10 days, to levels ranging from 3.37 to 4.67 fold 
increase over untreated cells, which effectively surpassed those reported for the 
non-viral vectors, even with a single application of the low dose of 20 nM, and 
sat within the range determined for the baculovirus system. Moreover, the range 
quantified for both antagomiR treatments at the endpoint of 14 days, from 2.55 
to 3.53 fold increase over untreated cells, was still superior than that reported 
for the other non-viral vectors at this timepoint, highlighting the beneficial 
application of the nHA-based delivery. In summary, this data demonstrated the 
relevant ability of the three nanomiR treatments to rapidly increase mineral 
deposition at an early timepoint while the two nanoantagomiRs maintained this 
effect until the endpoint of analysis. 
The presented data demonstrated that nanoantagomiR-133a treatment 
displayed a superior effect on hMSC osteogenesis than nanoantagomiR-16 and 
nanomiR-210 mimic, consistent with our knowledge that the key transcription 
factor of osteogenesis, Runx2, is a direct target for interaction with miR-133a. 
The application of antagomiR-16 as an osteo-therapeutic showed promising 
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results and served as foundation experimental evidence to implicate this miRNA 
in hMSC osteogenesis. Finally, the ability of nanomiR-210 mimic treatment to 
enhance hMSC osteogenesis was limited in comparison with the two other 
treatments, however its application warrants further investigation in relation to 
additional targets implicated in survival and angiogenesis and this will be 
explored in Chapter 5 of this thesis.  
One surprising result from this study was that negative control miRIDIAN 
miRNAs, here scrambled (scr), in both the miR-mimic and antagomiR 
formulations, produced unspecific variations in ALP activity and calcium 
deposition. These commercially available controls encompass a cel-miR-67 
based sequence and are anticipated to not possess targets in mammalian 
species, meaning that they function as a random nucleotide sequence that does 
not generate biological responses. However, surprisingly, a similar effect to that 
observed in this study was obtained when the scr molecules were delivered to 
the hMSC osteogenic culture using Lipofectamine® (data not shown). 
Consistent with this, previous studies have shown that ALP activity was affected 
by the treatment with a scr pre-miR (238) and a scr miR-mimic (237). Moreover, 
scr miRIDIAN controls utilised here were titrated by Schoolmeesters et al. to 
eliminate their effect on ALP activity (235). Further explanation for this effect is 
that BLAST analysis reported 20 - 30 % homology in approximately 100 hits of 
protein-coding sequences within human genome (392). As miRNA and non-
coding research is a rapidly evolving field, it is expected that the challenging 
design of scr sequences to be used as controls may be improved in the coming 
years, providing improved negative control molecules for experimentation. 
Nevertheless, the effect of the scr sequences was surpassed by all the 
nanomiR treatments in varying degrees of significance, and the specificity of 
this effect can be related back to the adequate modification of mRNA levels of 
the direct targets assessed. 
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3.6.Conclusion 
Taken together, the results of this study demonstrated that efficient nHA-based 
delivery of three individual miRNAs - antagomiR-133a, antagomiR-16 and miR-
210 mimic - led to enhanced hMSC mediated osteogenesis. Firstly, the role of 
the three miRNAs in osteogenesis was supported by the bioinformatic analysis 
and successful miRNA intracellular level manipulation was confirmed for all 
three treatments. Next, promising enhancement of Runx2 and OCN gene levels 
was found following nanoantagomiR-133a and nanoantagomiR-16 treatment, 
but not with miR-210 mimic. ALP activity was also most enhanced with 
nanoantagomiR-133a indicating biofunctionally increased osteogenesis. Finally, 
calcium deposition was increased at both 10 and 14 days with the 
nanoantagomiR-133a and -16 groups, while nanomiR-210 mimic only had a 
positive effect at the early timepoint of 10 days. In summary, nanoantagomiR-
133a emerged as the optimal osteo-therapeutic from this study. Hence, the 
incorporation of this therapeutic in a 3D carrier to form a next generation 
miRNA-activated scaffold capable of enhancing hMSC osteogenesis was the 
focus of the research presented in Chapter 4.  
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Chapter 4. Incorporation of nanomiRs into a collagen-
nanohydroxyapatite scaffold  
 
Research presented in this chapter has been included in the following peer-
reviewed publications:  
Castaño, IM et al., A Novel Collagen-Nanohydroxyapatite microRNA-activated 
Scaffold for Tissue Engineering Applications Capable of Efficient Delivery of 
both miR-mimics and antagomiRs to Human Mesenchymal Stem Cells. J 
Control Release 2015; 200: 42-51. 
Castaño, IM et al., Next generation bone grafting: Non-Viral Inhibition of MiR-
133a Using Collagen-Nanohydroxyapatite microRNA-activated Scaffolds 
Rapidly Enhances Osteogenesis by Human Mesenchymal Stem Cells. 
Manuscript submitted. 
 
4.1.Introduction 
A critical consideration when applying miRNAs to tissue repair, and particularly 
in bone repair, relates to the need for efficient delivery systems to trigger the 
desired therapeutic effect for a specified time period within a local environment, 
which involves the combined application of a delivery vector and a 3D scaffold 
(339). Vectors, typically nanoparticles, mediate uptake processes as well as 
provide protection from nucleases and may improve the lifetime of the cargo, 
but rapid in vivo clearance of nanoparticles from target locations, owing to their 
small size, limits their local effects to occur over short time periods (340). Since 
incorporation of nanoparticles in clinically-translatable 3D scaffolds provides the 
extended time frames of localised delivery needed in many TE applications, the 
application of 3D scaffolds as delivery systems holds great promise to fully 
realise the therapeutic potential of miRNAs for TE applications (61, 195, 341). 
Composite scaffolds produced from combinations of natural polymers and CaP 
ceramics have received significant attention in the field of bone TE (124), and 
the use of coll-nHA scaffolds as GAMs for pDNA delivery, with optimised 
architecture, pore structure and mechanical strength due to the introduction of 
the nHA phase, has produced encouraging results for bone TE in recent studies 
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within our laboratory (126, 127). Thus, using nHA particles to deliver osteogenic 
miRNAs within this 3D coll-nHA platform is the focus of the current study.   
 
Recently, 3D PLGA and polyglycerol sebacate scaffolds incorporating viruses 
belonging to the baculovirus and lentivirus families have showed promising 
functional delivery of pre-miRs and miR-inhibitors to ASCs of human and rat 
origin respectively: in both cases achieving a noteworthy effect in the repair of 
bone defects in vivo (297, 299). However, clinical applicability of viral-based 
miRNA delivery methods is still limited by the threat of adverse immune 
responses in patients and the risk of insertional mutagenesis (57). Alternatively, 
non-viral, commercial lipid-based delivery vectors have recently been 
incorporated in 3D platforms such as titanium-based platforms, gelatin 
nanofibers, PEG-gelatin hydrogels and PCL porous scaffolds to enhance 
miRNA-mediated osteogenesis in rat, mouse and human BM-MSCs respectively 
(297, 299, 347-349, 393). Although lipid vectors are renowned as highly efficient 
for nucleic acid delivery, cell membrane damage associated with their detergent 
effect has been referred to as a limiting factor for their clinical application (313). 
As mentioned previously in Section 2.1 and Section 3.1 of this thesis, the nHA 
particles developed in our laboratory were shown previously to be highly 
biocompatible vectors for pDNA delivery to MSCs (319) and encompass both 
advantageous osteoinductive and osteoconductive properties for bone repair 
specifically. While the reported work collectively represents remarkable steps 
towards the realisation of miR-based bone TE, it is speculated that the coll-nHA 
porous scaffold developed previously in our laboratory holds essential 
advantages from the biomaterial standpoint, which combined with the beneficial 
aspects of nHA particles as non-viral, non-lipid vectors may significantly 
advance the field of miRNA-based bone TE.  
Having characterised the efficient delivery of reporter miRNAs as nanomiR 
complexes with the nHA particles in Chapter 2, and observed the encouraging 
ability of nanoantagomiR-133a to enhance osteogenesis through directly 
targeting the key transcription factor of osteogenesis Runx2 in Chapter 3, the 
incorporation of reporter nanomiRs and subsequently nanoantagomiR-133a as 
a therapeutic in the coll-nHA scaffolds is explored here. Hence, the coll-nHA 
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scaffolds were assessed for their ability to act as efficient reservoirs for nHA-
miRNA delivery and ultimately to serve as therapeutic platforms with enhanced 
potential for bone repair.  
 
4.2.Hypothesis & aims of the study 
 
The hypothesis for this study was that nanomiR incorporation into coll-nHA 
scaffolds may serve a two-fold purpose: (i) to provide a localised miRNA 
delivery system for a range of TE applications and (ii) by incorporating 
nanoantagomiR-133a into the scaffold, to act as a therapeutic to increase the 
regenerative potential of the coll-nHA scaffolds providing a next generation 
bone graft substitute. The study presented in this chapter thus aimed to assess 
the potential of coll-nHA scaffolds to serve as miRNA delivery platforms to 
manipulate hMSC gene expression and apply this system to therapeutically 
enhance osteogenesis.  
The specific aims of Chapter 4 were to: 
• Assess morphology of miRNA-activated scaffolds using SEM 
• Analyse hMSC viability after 3D culture within miRNA-activated scaffolds 
• Study hMSC uptake of fluorescently tagged miRNAs within the miRNA-
activated scaffolds 
• Assess silencing functionality of the delivery system following 3D culture 
of hMSCs within scaffolds activated with reporter miR-mimics and 
antagomiRs 
• Assess the potential of nanoantagomiR-133a delivery from miRNA-
activated scaffolds to decrease miR-133a levels and subsequently 
increase expression of the direct target and key transcription factor of 
osteogenesis, Runx2 
• Analyse the effect of nanoantagomiR-133a delivery from miRNA-
activated scaffolds to manipulate the expression of osteogenic markers 
in hMSCs as well as to stimulate mineral matrix deposition  
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4.3.Materials & methods 
 
4.3.1.miRNA-activated scaffold fabrication 
Coll-nHA scaffolds were manufactured according to the lyophilisation technique 
developed in the laboratory for a 1:1 ratio of collagen versus nHA weight 
content (91, 94, 97, 138). Coll-nHA scaffolds prepared following this procedure 
posses a compressive modulus of 1.5 kPa and a porosity of approx. 99.5 % (97, 
125). This technique involved the following sequential steps: 
Slurry preparation and lyophilisation: 
Coll-nHA slurries were prepared by adding 1.8 g of collagen (Integra Life 
Sciences, USA) to 330 ml of 0.05 M glacial acetic acid (AcOH, Sigma Aldrich, 
Ireland) and blending at 15,000 rpm for 90 min using an overhead blender 
maintained at 4°C (Ultra Turrax T18 Overhead Blended, IKA Works Inc., USA). 
Subsequently, nHA particles with an equivalent weight of 1.8 g were fabricated 
following the Darvan®-aided precipitation technique described in Section 2.3.1. 
Darvan® was used at 0.2 % concentration (v/v) and a centrifugation step (1 h, 
10000 rpm) was carried out, following which nHA particles were re-suspended 
in distilled water (30 ml). The nHA particle suspension was sonicated at a 
frequency of 40 KHz and 70 % amplitude in continuous mode during 2 min 
using a SLPt Sonifier® ultrasonic cell disruptor (Branson Process Equipment & 
Supply Inc. Ohio, US), then incorporated into the collagen slurry by directly 
adding the suspension onto the coll-AcOH mix over a 30 min period while 
continuing blending to a final time of 2.5 h (125). Coll-nHA slurries were de-
gassed using a Leybold D16B double stage oil-sealed rotary vane vacuum 
pump (Biopharma, UK) and freeze-dried at a final freezing temperature of -40°C 
during a 35 h cycle program using a VirTis Genesis 25 EL freeze-dryer 
(Biopharma, UK).  
Scaffold sterilisation and cross-linking: 
Coll-nHA scaffolds obtained from the lyophilisation process where subjected to 
dehydrothermal treatment at 105°C during 24 h using a Vacucell vacuum oven 
(MMM Medcenter Einrichtungen GmbH, Germany). Scaffolds were then cut into 
cylindrical discs (8 mm x 4 mm) using circular biopsy punches, and chemically 
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cross-linked for 2 h with a solution of 14 mM 1-(3-Dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDAC, Sigma Aldrich) and 5.5 mM N-
hydroxysuccinimide (NHS, Sigma Aldrich) to both sterilize and structurally 
reinforce the scaffold structure (65).  
Scaffold activation with nanomiRs: 
The following nanomiR complexes were prepared as described earlier in 
Section 2.3.1. at a final concentration of 20 nM of the following miRIDIAN 
miRNA molecules (Dharmacon): (i) scr nanomiR-mimic and scr 
nanoantagomiR, as target-lacking groups, utilised in morphological analysis and 
hMSC viability studies, as well as reference negative controls for functionality 
experiments and the scr nanoantagomiR as a negative control for osteogenesis 
experiments; (ii) scr Dy547-nanomiR-mimic and scr Dy547-nanoantagomiR to 
monitor miRNA uptake from the scaffolds, (iii) anti-GAPDH nanomiR-mimic and 
nanoantagomiR-16 as functionality reporters and (iv) nanoantagomiR-133a as 
an osteo-therapeutic. Freshly prepared nanomiR mix (75 μL) was soak-loaded 
onto coll-nHA scaffolds on each side, with an intermediate incubation time of 15 
min. 
 
4.3.2.miRNA-activated scaffold physical characterisation 
The microstructure of the miRNA-activated coll-nHA scaffolds was examined 
using SEM as this technique allows for the examination of specimens with a 
thickness in the mm range. EDAC-NHS cross-linked coll-nHA scaffold discs 
without any soak-loaded nHA particles or scrambled (scr) nanomiRs were used 
as a reference to compare structural features after loading the nanoparticles. A 
second group of coll-nHA scaffolds were soak-loaded with blank nHA particles, 
not containing miRNAs, to control for nanomiR complex formation. 
Subsequently, coll-nHA scaffolds were soak-loaded with the scr nanomiR-
mimics or nanoantagomiRs. All scaffold groups were then prepared by alcohol 
dehydration and critical point drying, fixed to an adhesive carbon stub, and then 
sputter coated with palladium/gold using a Polaron Sputter Coater (Quorum 
Tech., UK). Imaging was carried out using a Tescan MIRA XMU SEM (Tescan, 
UK) operated at 5 kV in secondary electron mode. 
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4.3.3.Cell culture 
hMSCs were cultured in complete DMEM medium as described in Section 2.3.3 
until a sufficient cell number was obtained at passage number 5-6 for 
experimentation. A total of 3 x 105 cells were seeded per scaffold, by drop-wise 
addition onto each side of the surface, with a 15-min incubation step after 
addition of nanomiRs, as adapted from the procedure of hMSC culture on coll-
nHA GAMs used in the laboratory (126). 
4.3.4.Cell viability after culture within miRNA-activated scaffolds 
Cell viability was studied to monitor potential cytotoxic effects derived from the 
3D culture of hMSCs in miRNA-activated scaffolds, for which nHA particles 
were loaded with scr miR mimic/antagomiR, which act as controls and 
encompass sequences with non-existent targets in mammalian cells. In order to 
determine the number of viable cells present across the different groups, 
dsDNA content per scaffold was analysed after 3 and 7 days in 3D culture using 
the Quant-iT PicoGreen dsDNA kit (Invitrogen) as described in Section 2.3.4. 
4.3.5.Cellular uptake of fluorescently labelled nanomiRs on miRNA-activated 
scaffolds 
To monitor nanomiR uptake on miRNA-activated scaffolds, hMSCs were 
cultured on coll-nHA scaffolds previously loaded with fluorescent Dy547 
nanomiR mimic/antagomiR complexes (emission at 547 nm, red). Live cells 
were fluorescently labelled with calcein-AM (emission at 517 nm, green; 
BioSciences) following manufacturer’s instructions prior to microscopy. Imaging 
was carried out using a Leica microscope coupled to the LAS V3.6 software 
imaging system (Leica, Ireland) and Image J software was utilised to generate 
the merged images. Effective uptake of miR-mimics or antagomiRs was shown 
by colocalisation (orange) in areas corresponding to intracellular spaces. 
4.3.6.miRNA-activated scaffold functionality assessment by qRT-PCR 
qRT-PCR was carried out to test the functionality of miRNA-activated scaffolds 
using the methodology and materials described in Section 2.3.7. The levels of 
129 
 
GAPDH messenger RNA and miR-16 were determined to assess the silencing 
ability of the reporter nanomiR-mimic and nanoantagomiR groups respectively. 
4.3.7.Analysis of the osteo-therapeutic potential of nanoantagomiR-133a-
activated scaffolds  
Osteogenic cell culture:  
hMSCs were obtained, expanded in culture and seeded drop-wise onto 
scaffolds as described in Section 4.3.3, following which they were cultured in 
complete osteogenic medium consisting of standard growth medium 
supplemented with 50 µg/ml ascorbic acid-2-phosphate, 10 nM β-
glycerophosphate and 100 nM dexamethasone. A control osteodifferentiation 
group consisting of hMSCs seeded on coll-nHA scaffolds was maintained in 
standard complete medium, meaning that no osteo-supplements were added. 
Media was replaced every 3/4 days for the duration of the assay. 
Assessment of effective miRNA and genetic manipulation using qRT-PCR:  
qRT-PCR analysis was used to determine (i) miRNA intracellular levels of miR-
133a as well as mRNA relative expression level of (ii) the direct miR-133a 
target, Runx2, and (iii) the osteogenesis markers OCN, ALP and EphrinB4 
(EPHB4) using the methodology described in Section 2.3.7. The hsa-miR-133a 
Taqman® MicroRNA assays as well as the following validated pre-designed 
human Quantitect Primer Assays (Qiagen, UK) were applied: Hs_Runx2_1_SG, 
Hs_BGLAP_1_SG and Hs_ALPL_1_SG, Hs_EPHB4_1_SG. The scr 
nanoantagomiR group was set as the reference for the calculation of relative 
expression levels.   
Osteocalcin immunofluorescence staining:  
Scaffolds were removed from culture and fixed using 10 % formalin for 30 min, 
then dehydrated using an automatic tissue processor (ASP300, Leica 
Microsystems Nussloch GmbH, Germany) prior to paraffin wax embedding. 
Sections (8 μm) were cut using a rotary microtome (Microsystems GmbH, 
Germany) and sections were mounted on L-polysine coated glass slides 
(Thermo Scientific). Samples were then deparaffinised with xylene and 
rehydrated in descending grades of alcohol (100 % to 70 %). Subsequently, 
sections were permeabilised in 1 % Triton X100 solution. Blocking in 5 % horse 
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serum (HS) was followed by incubation in a 1:50 dilution of rabbit polyclonal IgG 
anti-osteocalcin primary antibody with subsequent 1:200 dilution of FITC-
labelled goat anti-rabbit IgG secondary antibody (both from Santa Cruz Inc.) 
and mounting with Fluoroshield medium containing DAPI (Invitrogen). Digital 
imaging was carried out using a microscope system (Eclipse 90i plus DS Ri1, 
Nikon, Japan) coupled to NIS Elements software.  
Mineral deposition quantification as end-stage marker of osteogenesis:  
As a quantitative measure of osteogenesis a Stanbio Calcium Liquicolor kit 
(Stanbio Laboratories) was used following manufacturer’s instructions for 
calcium quantification. Briefly, scaffolds were removed from culture and placed 
in 1ml of 0.5 M HCl and left to shake overnight at 4°C. Calcium content 
quantified for blank coll-nHA scaffolds (non cell-seeded) was subtracted from 
the content determined for all cell-seeded groups. Absorbance of the colour 
product was read using a Varioskan Flash plate reader (ThermoScientific). 
Complementarily, the dsDNA Quant-iT PicoGreen kit (BioSciences) was used 
following manufacturer’s instructions using the Varioskan system as before.  
Histological assessment of calcium deposition:  
Serial sections prepared as described in the above section were prepared for 
histological analysis and rehydrated prior to staining with 2 % Alizarin red 
(Sigma-Aldrich, Ireland) as it stains calcium deposits red. Sections were then 
dehydrated and DPX mountant was used to attach cover slips to the slides. 
Digital imaging was carried out using a microscope system (Eclipse 90i plus DS 
Ri1, Nikon) coupled to NIS Elements software.  
4.3.8.Statistical analysis 
Experiments were performed in triplicate, unless otherwise specified within 
figure captions, and are representative of a minimum of three independent 
repetitions using two cell donors. Results were analysed as described in 
Section 2.3.7 using two-way analysis of variance (ANOVA) plus a Tukey post-
hoc test to assess several timepoints and one-way ANOVA plus Tukey post-hoc 
test for the data tested at one timepoint only. p<0.05 and p<0.001 were 
considered significant. 
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4.4.Results 
 
4.4.1.miRNA-activated scaffolds maintained an interconnected porous structure 
while retaining nanomiR complexes  
The topographic images obtained by SEM demonstrated the capability of the 
coll-nHA scaffolds to be functionalised for miRNA delivery (Figure 4.1) Pore 
size, in the 100 µm range, and interconnectivity of the pores within the 3D 
structure was maintained in all scaffolds assessed (Figure 4.1a-d). This is 
important to enable cell infiltration inside the 3D structure, therefore matching a 
key requirement for bone TE. Higher magnification images showed the retention 
of the soak-loaded blank nHA particles and nanomiRs along the collagen fibres 
(Figure 4.1e-h). At the highest magnification, single particles present in the 
composites showed differences among the groups (Figure 4. i-l). Rod-shaped 
blank nHA particles were uniformly distributed along the surface of the scaffold 
structure (Figure 4.1j). Correspondingly, nanomiR-mimics (Figure 4.1k) and 
nanoantagomiRs (Figure 4.1l) showed a similar organisation to that observed in 
Chapter 2 by TEM (Figure 2.2b-c) forming branched multiparticulate structures, 
and populations of small rod particles were also detected in the nanomiR-
loaded scaffolds. Overall, SEM observation demonstrated that nanomiR 
complexes can be effectively retained within the highly porous structure of the 
coll-nHA scaffolds. 
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 Figure 4.1 SEM analysis of nanomiR loaded coll-nHA scaffolds. a-d) Microstructural 
examination of nanomiR-loaded coll-nHA scaffolds showed the arrangement of the collagen 
fibres in an interconnected highly porous distribution, with pore size mantained in the range of 
100 µm. Scale bar = 100 µm. e-h) blank nHA particles and nanomiR complexes were deposited 
and retained on the collagen fibres. Scale bar = 10 µm. i-l) Rod-shaped blank nHA particles and 
multiparticulate nanomiR complexes were detected at higher magnification. Scale bar = 2 µm. 
Arrows indicate deposits of nHA particles (yellow) and nanomiR complexes (red). 
 
4.4.2.miRNA-activated scaffolds support nanomiR uptake without impairing cell 
viability of hMSCs 
The in vitro assessment of uptake and cell viability demonstrated that red 
fluorescence was absent in cell-seeded but non-miRNA activated scaffolds, 
indicating that auto-fluorescence in this range of wavelength generated from the 
coll-nHA scaffold itself or the hMSCs was negligible (Figure 4. 2a). On the other 
hand, deposition of Dy547-labelled nanomiRs (red) could be detected 
throughout the structure of miRNA-activated scaffolds (Figure 4. 2b). Labelling 
live cells with fluorescent calcein-AM allowed the detection of Dy547 nanomiRs 
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intracellularly, with the detection of yellow and orange areas resulting from the 
green plus red co-localisation (Figure 4. 2c). This data indicated effective 
nanomiR uptake and maintenance of hMSC viability on the scaffolds, 
corroborating the ability of nHA particles to deliver miRNAs to hMSCs within the 
3D platforms.  
 
Figure 4.2 Assessment of hMSC nanomiR internalisation & cell viability on nanomiR 
loaded coll-nHA scaffolds. a) Red fluorescence background was controlled for in the 
nanomiR-free groups and b) Dy547-labelled scrambled (scr) nanomiR-mimic or nanoantagomiR 
(red) were detected within the cell-seeded scaffolds. c) Merged images of live cells fluorescently 
labelled with calcein-AM (green) and corresponding images of Dy547-labelled scr nanomiR-
mimic or nanoantagomiR. Red fluorescence was observed colocalising within cells (yellow). 
Arrows in b) and c) indicate points of nanomiR internalisation. Scale bar = 200 µm, n = 3.  
 
Similar to the analysis carried out in Chapter 2, dsDNA quantification was 
carried out to estimate cell viability after culture within the miRNA-activated 
scaffolds. dsDNA content was not significantly different among the groups, 
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indicating no impairment of hMSC viability after culture on the miRNA-activated 
scaffolds (Figure 4.3).  
 
Figure 4.3 Assessement of hMSC cytotoxicity within nanomiR loaded coll-nHA scaffolds. 
dsDNA quantification indicated that viable cell number was maintained across all groups, 
therefore showing no treatment associated cytotoxic effects. Mean + standard deviation, n = 3, 
no statistical difference.  
4.4.3.NanomiRs maintained significant functional interference after 
incorporation into coll-nHA scaffolds 
The approach used to test the interfering functionality of nanomiRs in Chapter 2 
was adapted to the culture of hMSCs within the 3D miRNA-activated scaffolds. 
A significant 20 % interference in GAPDH expression for the nanomiR-mimic 
was obtained, with relative levels decreasing to 0.80 ± 0.20 fold, an effect which 
was maintained over the 7 day period after cell seeding (Figure 4.4). 
Subsequently, to assess whether the 3D environment of the miRNA-activated 
scaffolds results in progressive and extended functionality, GAPDH interference 
levels were analysed at a later timepoint of 14 days after hMSC seeding on the 
anti-GAPDH nanomiR-mimic activated scaffolds. Extended culture on these 
bioactive platforms to 14 days showed a reduction in GAPDH relative levels to 
0.45 ± 0.28 fold, which indicated that interfering functionality was improved to 
55 % at this time and confirmed that localised delivery of miRNAs using the coll-
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nHA scaffolds serves to achieve progressive and extended functional time 
frames.   
           
Figure 4.4 Silencing functionality of reporter anti-GAPDH nanomiR-mimic on coll-nHA 
scaffolds.  qRT-PCR analysis revealed a significant decrease in GAPDH expression against 
the reference control, scr nanomiR-mimic, which improved to 55 % silencing with the extended 
culture at 14 days. Expression levels were normalised to those of 18S and calculated using the 
2(-ΔΔCt) method. Mean + standard deviation, n = 5, * = p<0.05. 
 
Equally, the nanoantagomiR-16 activated scaffold decreased miR-16 
expression significantly to relative levels of 0.12 ± 0.08 fold over the 7 day 
period, representing an interfering functionality of 88 % for the nHA-delivered 
antagomiRs incorporated in the coll-nHA scaffolds (Figure 4.5). Consequently, 
this data showed that the nanomiR complexes within the 3D structure of the 
coll-nHA scaffolds conserved significant bioactivity and can therefore these 
scaffolds serve as an effective platform for miRNA delivery. 
 
 
 
136 
 
 
Figure 4.5 Silencing functionality of reporter nanoantagomiR-16 on coll-nHA scaffolds.  
Stem-loop qRT-PCR analysis showed that nanoantagomiR-16 treatment significantly decreased 
miR-16 expression with respect to scr nanoantagomiR, which was introduced as the negative 
control. Relative expression levels were normalised to those of 18S and calculated using the 2
(-
ΔΔCt) 
method. Mean + standard deviation, n = 5, ** = p<0.001. 
 
4.4.4.NanoantagomiR-133a activated scaffolds effectively decreased miR-133a 
intracellular levels and enhanced osteogenic gene expression  
Following demonstration of efficient delivery of scrambled (scr) and reporter 
nanomiRs to hMSCs cultured on the coll-nHA scaffolds, the possibility of 
applying this system for therapeutic miRNA-mediated osteogenesis was 
explored. For this purpose, the candidate treatment selected from the results 
presented in Chapter 3, that is nanoantagomiR-133a, was introduced into the 
scaffolds. The nanoantagomiR-133a activated scaffolds significantly decreased 
the amount of miR-133a available in hMSCs to 0.49 ± 0.14 fold that of the 
reference group (scr) after 3 days (Figure 4.6). Furthermore, at the later time 
point of 7 days, miR-133a levels were further decreased within the 
nanoantagomiR-133a activated scaffolds ( 0.22 ± 0.05 fold vs reference group) 
while nHA markedly increased miR-133a at this timepoint (5.12 ± 2.66), 
resembling the effect observed at this same timepoint in the monolayer studies 
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presented in Chapter 3. This decrease in miR-133a was able to trigger a 2.74 ± 
1.97 fold increase in the mRNA levels of the direct target of miR-133a, Runx2, 
at the initial timepoint assessed (Figure 4.7a), which serves as a hallmark for 
the initiation of the osteodifferentiation process. In addition, the mid stage 
markers of osteogenesis ALP, OCN and EPHB4 were upregulated 1.3, 1.5 and 
2 fold respectively after 7 days (Figure 4.7b-d), which, very encouragingly, was 
significant relative to the levels detected for the cell osteo medium only group. 
This data confirmed the ability of coll-nHA scaffolds to mediate a substantially 
competent manipulation of post-transcriptional gene regulation in hMSC 3D 
culture.  
 
Figure 4.6 qRT-PCR analysis of miR-133a intracellular levels in hMSC osteogenic culture 
on miRNA-activated coll-nHA scaffolds. miR-133a was significantly decreased for the 
hMSCs cultured on the nanoantagomiR-133a activated scaffolds in comparison with the scr 
nanoantagomiR scaffolds over a time course of 7 days, demonstrating a high silencing 
functionality of the non-viral based 3D delivery system. Scr nanoantagomiR was set as the 
reference control group and relative expression was normalised to that of 18S and calculated 
using the 2(-ΔΔCt) method. Mean + standard deviation, n = 5, * = p<0.05.  
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Figure 4.7 qRT-PCR analysis of the effect of nanoantagomiR-133a activated scaffolds on 
hMSC osteogenic gene expression. a) Runx2 mRNA expression was upregulated in the 
nanoantagomiR-133a activated scaffolds group after 3 days, while b) ALP, c) OCN and d) 
EPHB4 mRNA expression was upregulated in the nanoantagomiR-133a loaded scaffolds group 
after 7 days. Scr nanoantagomiR was set as the reference control group and relative expression 
was normalised to that of 18S and calculated using the 2(-ΔΔCt) method. Mean + standard 
deviation, n = 4, * = p<0.05, ** = p<0.001. 
4.4.5.NanoantagomiR-133a activated scaffolds enhanced osteocalcin protein 
levels 
To further verify the osteogenic differentiation process, the presence of 
osteocalcin (OCN) at the protein level was assessed by immunofluorescence 
staining accompanied with DAPI labelling. At 14 days after hMSC seeding on 
the nanoantagomiR-133a activated scaffolds, OCN protein expression was 
qualitatively increased in comparison to the remaining groups, although cells 
cultured in coll-nHA scaffolds also presented higher OCN levels than the nHA-
soak loaded coll-nHA scaffold and the scr nanoantagomiR activated scaffold 
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groups (Figure 4.8). At 28 days OCN expression had increased in the latter 
groups in comparison to their early timepoint levels, however the presence of 
OCN was visibly highest in the nanoantagomiR-133a activated scaffold group, 
confirming that nanoantagomiR-133a activated scaffolds resulted in increased 
osteogenic differentiation of hMSCs. In summary, this data correlated with the 
enhanced levels of OCN mRNA determined for nanoantagomiR-133a activated 
scaffolds in the gene analysis (Figure 4.7c) and collectively pointed to a robust 
enhancement of hMSC osteogenesis in 3D scaffold culture. 
 
 
 
Figure 4.8 Effect of nanoantagomiR-133a activated scaffolds on OCN protein levels. OCN 
immunofluorescence staining (green) after 14 and 28 days in 3D osteogenic culture showed 
increased protein expression in the nanoantagomiR-133a activated scaffolds in comparison with 
the control treatment groups. Nuclei (blue) were stained with DAPI, Scale bar = 50 µm. 
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4.4.6.NanoantagomiR-133a activated scaffolds enhanced mineral matrix 
deposition  
Mineral matrix deposition is regarded as an end-stage marker of functional 
osteogenesis. Similar to the assessment of mineral deposition carried out in Chapter 3, 
an early and a late timepoint of analysis, 14 and 28 days respectively, were evaluated 
to test for both an accelerated and a maintained increase in mineral matrix deposition. 
Consistent with the gene expression analysis, calcium deposition levels in 
nanoantagomiR-133a activated scaffolds were 78.4 % and 56.38 % higher than the 
untreated cells at day 14 and 28 respectively, while they were significantly increased in 
comparison to the nHA and scr nanoantagomiR groups at both time points tested 
(Figure 4.9), highlighting the ability of the antagomiR-133a activated scaffolds to rapidly 
trigger an enhanced functional osteogenesis and subsequently maintain it. Histological 
analysis using alizarin red staining depicted calcium deposition across all groups, 
which qualitatively increased from the earlier to the later timepoint; and importantly, 
more prominent, denser staining was found in the nanoantagomiR-133a treated group 
at both timepoints (Figure 4.10). In summary, this data pointed to the successful 
application of nanoantagomiR-133a for miRNA-mediated osteogenesis of hMSCs using 
the coll-nHA scaffolds as localised delivery platforms.                    
 
Figure 4.9 Effect of nanoantagomiR-133a activated scaffolds on hMSC mineral matrix 
deposition. Calcium normalised to dsDNA content confirmed an increase in calcium deposition 
by day 14 in nanoantagomiR-133a activated coll-nHA scaffolds and maintained increased 
calcium levels compared to the control groups after 28 days. Mean + standard deviation, n = 3,* 
* = p<0.001, ɸ = p<0.001 compared to all other groups, # = p<0.001 compared to nHA, scr 
nanoantagomiR and nanoantagomiR-133a activated scaffolds.  
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Figure 4.10 Alizarin red staining following 14 and 28 days of hMSC culture on 
nanoantagomiR-133a activated scaffolds. A prominently increased presence of calcium 
deposits was found within the nanoantagomiR-133a activated scaffolds at both timepoints. Non 
cell-seeded scaffolds were used as a control for the determination of basal calcium presence in 
the extracellular matrix. Scale bar = 50 µm. 
 
4.5.Discussion 
 
Incorporation of therapeutic miRNAs into 3D scaffold biomaterials is 
increasingly generating interest in the field of TE. This strategy offers the 
possibility to enhance the therapeutic potential of such scaffolds. The aim of this 
study was to assess the potential of bioactivating a coll-nHA scaffold, designed 
specifically for bone repair, to serve as miRNA delivery platforms to manipulate 
hMSC gene expression and apply this system to therapeutically enhance 
osteogenesis using antagomiR-133a. Taken together, the data presented here 
showcased the unprecedented development of the first non-viral, non-lipid 
scaffold technology to-date for the delivery of both miR-mimics and antagomiRs 
to hMSCs. When hMSCs were cultured on the miRNA-activated scaffolds, 
nanomiR internalisation and significant functional silencing with minimal 
cytotoxicity was observed. Ultimately, we demonstrated the therapeutic 
potential of the nanoantagomiR-133a activated coll-nHA scaffolds to rapidly 
enhance hMSC osteogenesis through targeting of the central transcription 
cell osteo medium nHA scr nanoantagomiR nanoantagomiR-133acell std medium
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factor of osteogenesis, Runx2, which ultimately resulted in the development of a 
highly innovative alternative to existing bone graft treatments, representing a 
promising new concept in bone TE.  
SEM showed that pore size was consistently maintained following miRNA 
incorporation in the range of ~100 µm, which has been described as adequate 
for cell infiltration and migration throughout the structure (138). Particle 
deposition within the collagen fibres in the scaffolds did not result in pore 
occlusion, and indicated the binding of the mineral particles to the scaffold 
structure, possibly through electrostatic interactions. Because of the chemical 
nature of the nHA particles, hydrophobic or covalent-bond interaction types 
cannot be established with the available active groups that the collagen fibres 
present. Both the porosity and the particle retention mechanism ensured that 
the resultant scaffolds fulfil the necessary requirements to ensure cellular 
infiltration and nanoparticle exposure (340) that must be met in order for the bio-
activated scaffold to be successful in simultaneously housing cells and locally 
delivering the therapeutic cargo. In summary, the SEM imaging indicated that 
nanomiR complexes can be effectively retained within the highly porous 
structure of the coll-nHA scaffolds, meaning that structurally, the miRNA-
activated scaffolds hold potential to serve as depots for localised miRNA 
delivery.  
The effective uptake of the nanomiR-mimic and nanoantagomiRs in hMSCs 
was demonstrated at both 3 and 7 days, as observed using fluorescence 
microscopy. As well as the nanomiR internalisation, the microscopic analysis of 
calcein-AM green labelled live cells indicated that cell viability was maintained 
across all groups. Additionally, the presence of nanomiR complexes in the 3D 
structure did not affect cell density. Noticeably, dsDNA content within each 
group did not differ between the two time points tested, reflecting a slower 
proliferation rate in 3D scaffold culture as compared to that seen in the 
monolayer experiments. This effect may relate to how cells adapt to the 
different extracellular microenvironment between 2D and 3D culture conditions. 
More specifically, cells attach to 3D scaffolds at a slower pace given that a 
larger surface area is available for cell contact (65, 280, 350), and this can 
result in delayed cell proliferation rates. Taken together, this data confirmed that 
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the deposition of nanomiR conjugates onto the scaffold did not hinder cell 
infiltration in the construct or intracellular uptake of the nanomiRs. Moreover, no 
cytotoxic effects arose from the 3D culture of hMSCs on the miRNA-activated 
scaffolds, indicating the safety and biocompatibility of this platform system.  
Both functional reporter nanomiR-mimic and nanoantagomiR complexes 
incorporated in the coll-nHA scaffolds significantly and persistently maintained 
silencing of their respective targets GAPDH and miR-16 throughout the time 
period assessed. It has previously been proposed that transfection in a 3D 
scaffold environment relies on the migration of cells throughout the matrix and 
that the larger surface area reduces the relative exposure of cells to the 
transfection complexes at early timepoints, while extended culture periods allow 
for cells to further infiltrate within the 3D structure and be exposed to the cargo 
(394). The data presented in this chapter for the anti-GAPDH nanomiR-mimic 
activated scaffolds correlated with this observation and served to confirm the 
utility of 3D scaffold biomaterials as depots for functional delivery of miRNA-
mimics for progressive and extended timeframes. The differences between 
groups found in this analysis can be explained by the more hydrophilic nature of 
the miR-mimics, which might establish stronger electrostatic interactions with 
the bioactive sites present on the collagen fibres of the scaffolds. Importantly, 
the silencing functionality detected for the nanomiR-mimic is within the range of 
the single report to-date where cells were added onto a functionalised scaffold 
(350), a result which is widely surpassed here with the nanoantagomiR-
avtivated scaffold. In the previous study, a silencing range between 0.6 to 0.8 
fold was achieved with miR-29b-mimic activated collagen-based scaffolds, 
which led to improvements in wound healing when tested in vivo. In contrast 
with our approach, the previous report involved the naked incorporation of the 
miR-mimic within the scaffold and targeted primary rat cardiac fibroblasts. Since 
hMSCs are regarded as more difficult to transfect that other cell types, including 
fibroblasts, it is proposed that the complexes of both miR-mimics and 
antagomiRs with the nHA particles are a key element for the relevant silencing 
efficiency demonstrated by the miRNA-activated scaffolds developed in this 
chapter. 
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Next, the therapeutic potential of manipulating miR-133a levels using the 
miRNA activated scaffold platform to enhance hMSC ostegenic differentiation 
was demonstrated for the first time. Only 8 studies have been published to date 
which have used miRNAs as osteo-therapeutics in 3D biomaterials in 
comparison with the panel of over 30 miRNAs described to be involved in 
osteogenesis (58, 297, 299, 347-349, 393, 395). It is important to note that the 
majority of miRNAs tested as osteo-therapeutics so far, with the exception of 
miR-31 (297, 395), directly target molecules which are part of secondary 
signalling pathways in many cases (393), meaning that their ability to drive the 
osteogenesis process on their own is limited. The innovative approach 
developed in this study resulted in miRNA-mediated manipulation of Runx2, the 
transcription factor regarded as the primary driver of the osteogenic pathway. 
The results presented showed a significant decrease in miR-133a intracellular 
levels and subsequently increased expression of Runx2 at the early timepoint of 
3 days. This highlighted the capability of the coll-nHA scaffolds to functionally 
deliver the therapeutic nanoantagomiR-133a complexes with beneficial 
repercussions in modulating Runx2 levels. As a consequence of the increased 
Runx2 production, upregulated expression of a panel of osteogenic markers in 
hMSCs at the genetic level as well as enhanced presence of osteocalcin at the 
protein level at successive timepoints was demonstrated. Most importantly, the 
effective genetic manipulation of hMSCs on the nanoantagomiR-133a activated 
scaffolds subsequently translated into a rapidly and significantly enhanced 
calcium deposition on the scaffolds, which was maintained until the end 
timepoint of analysis. Calcium production is interpreted as hallmark of 
effectively enhanced osteogenic differentiation of hMSCs (226, 237, 238, 240, 
348, 368, 369, 375, 382, 387), hence this result perhaps signifies the more 
significant outcome of the study presented in this chapter, where collectively 
this data pointed to a robust and coordinated enhancement in hMSC 
osteogenesis within the miR-activated scaffolds in comparison to the non-
activated coll-nHA scaffolds.  
A major advantage of the systems developed in this chapter relates to 
incorporating the nanomiR complexes in the 3D scaffolds in a cell-free manner 
and hence utilising the coll-nHA scaffolds as reservoirs for the localised delivery 
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of the miRNA complexes i.e. with a view to transfecting host cells when applied 
in vivo. This differs from the typical application of cell-mediated miRNA therapy 
in scaffolds shown in the literature (58, 297, 299, 347, 348, 395), where the 
scaffolds do not mediate the localised miRNA delivery to the cells, but the cells 
are instead seeded on the scaffolds after having internalised the miRNAs in 
advance of seeding. Our approach is a major breakthrough as it means that the 
miRNA activated scaffolds have the potential to exist as an ‘off-the-shelf’ 
platform which could be used for a variety of therapeutic applications depending 
on the specific miRNA chosen for delivery. While this system was developed 
with bone regeneration in mind, the functionalisation process described in this 
study may be applied to other scaffolds and to the incorporation of any miRNA 
with a role in tissue regeneration, therefore representing a promising approach 
for a wide variety of TE applications.   
 
4.6.Conclusion 
 
In summary, the research presented in this chapter demonstrated the significant 
potential of coll-nHA scaffolds to serve as the first non-viral, non-lipid localised 
miRNA delivery scaffold platforms developed in the field to-date. This platform 
was capable of efficient delivery of mature miRNA molecules and gene 
expression manipulation in human MSCs, a particularly difficult cell type to 
transfect effectively. The microstructure of the miRNA-activated scaffolds 
promoted effective cell infiltration, while efficient uptake and significant silencing 
functionality was demonstrated for both nanomiR-mimics and nanoantagomiRs.  
When antagomiR-133a was applied, this advanced system led to a successful 
reduction of miR-133a intracellular levels, achieved a subsequent increase in 
Runx2 in the MSCs and most importantly accelerated calcium deposition on the 
scaffolds - thus showing the therapeutic potential of the platform. 
Angiogenesis in addition to osteogenesis plays a major role during the process 
of bone fracture repair. In Chapter 5 we investigated the application of this 
miRNA delivery system to deliver different miRNA combinations in order to 
achieve a simultaneous effect on both MSC-mediated angiogenesis and 
osteogenesis.  
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Chapter 5. Investigation of nanomiR-210 mimic as (i) a pro-
angiogenic therapeutic and (ii) as a simultaneous pro-
angiogenic and pro-osteogenic therapeutic as a part of a dual 
nanomiR formulation 
 
5.1.Introduction 
The beneficial application of nHA-based miRNA delivery for use in bone repair 
has been demonstrated in Chapters 3 & 4 of this thesis with the focus of 
enhancing hMSC osteogenesis. Importantly, angiogenesis also plays a pivotal 
role in bone repair (396, 397) and based on their biodegradability and 
biocompatibility, nHA particles are hypothesised to serve as potentially useful 
miRNA delivery vectors for applications beyond osteogenesis. Hence in this 
chapter the focus was placed on the nHA-based delivery of therapeutic miRNAs 
to enhance angiogenesis simultaneously to enhancing osteogenesis.  
MSCs have potential to mediate angiogenesis via secretion of pro-angiogenic 
factors (378, 398), as well as acting as pericytes to provide support for the 
newly formed vascular networks (399). Additionally, it is known that VEGF plays 
a pivotal role during angiogenesis and stimulates vessel formation in bone 
defects, which has served as the rationale for its use in bone TE (144, 400, 
401). While VEGF promotes endothelial cell migration, proliferation, survival 
and differentiation (146), it has also been implicated in the stimulation of bone 
repair through a number of mechanisms. These include (i) promoting bone 
turnover (152), (ii) stimulating the differentiation of osteoblasts (402, 403) and 
(iii) recruiting osteoprogenitor cells and MSCs to the defect site (404, 405), as 
well as (iv) promoting the survival and activity of bone-forming cells at the defect 
site (71, 406). Recent efforts have unravelled the role of several miRNAs in 
regulating angiogenesis either positively or negatively (Figure 5.1;  (383, 407-
412)), as well as their ability to further enhance MSC angiogenic capacity (347). 
Hence, strategies for manipulating miRNA levels have begun to be proposed to 
treat angiogenesis-related pathologies such as cardiovascular diseases (413), 
diabetes and diabetes induced retinopathy (414-416), as well as exacerbated 
vascularisation associated with several cancer types (417).  
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Figure 5.1 Panel of miRNAs influencing angiogenesis and neovascularisation and their 
reported targets (experimentally validated).  Inner circle: red ovals accompanied by red 
brake symbols (  ) indicate proteins with inhibitory role in angiogenesis, green ovals 
accompanied by green arrows (        ) indicate proteins which display an activator role in 
angiogenesis. Outer circle: miRNAs represented in blue are positive regulators of angiogenesis 
and miRNAs depicted in red are negative regulators of the process (383, 407-412). 
An exciting property towards the therapeutic application of miRNAs is the multi-
faceted transcriptional control that they exert over entire gene cohorts (381). 
From a bone repair perspective, miRNAs simultaneously targeting osteogenic 
and angiogenic processes are of particular interest (347). This rationale was 
explored by Li et al. who harnessed the bi-functional potential of miR-26a to 
simultaneously enhance hMSC-mediated angiogenesis and osteogenesis in 
vivo (347). As described in Chapter 3, a bi-functional positive role for miR-210 in 
angiogenesis and osteogenesis is also established in different cell types. 
Specifically, it has been shown that up-regulation of miR-210 expression was 
induced by VEGF (418), which upregulated endothelial cell tubulogenesis,(an in 
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vitro marker for angiogenesis) by targeting EphrinA3 ligand (383). EphrinA3 
belongs to the ephrin superfamily (419) and has been described to ultimately 
inhibit the initiation of the transcription program of pro-angiogenic genes (383). 
Additionally, miR-210 mimic accelerated angiogenesis in vivo in a pre-clinical 
model of anterior cruciate ligament injury (420). Collectively, this indicates the 
potential of miR-210 level manipulation as a promising strategy to control 
angiogenesis. While we demonstrated in Chapter 3 that miR-210 mimic delivery 
did not drive a robustly enhanced osteogenic response, in this study we aimed 
to assess the pro-angiogenic therapeutic potential of this miRNA in hMSCs and 
to determine whether it might have the potential to simultaneously direct 
angiogenesis and osteogenesis. 
With this in mind, the exploration of a combinatorial miRNA therapy was further 
proposed in the second part of this chapter. This approach was inspired by a 
number of in vitro and in vivo studies targeting angiogenesis and osteogenesis 
simultaneously by combinatorial growth factor or gene delivery, all of which 
have reported synergistic effects on bone repair (127, 353, 354, 421, 422). 
Previous work carried out in our laboratory using combinatorial pDNA delivery 
of BMP-2 and VEGF comparatively assessed the in-house synthesised nHA 
particles and PEI as delivery vectors, where nHA-based GAMs outperformed 
the in vivo bone repair capacities of the PEI counterpart GAMs (127). Building 
on this concept, having successfully utilised nHA particles to deliver individual 
miRNAs to hMSCs directly from coll-nHA scaffolds, it was proposed in this 
chapter that this system might be a promising platform for combined delivery of 
multiple miRNA therapeutics.  
Combinatorial miRNA delivery is a very new concept. Indeed the combination of 
a miRNA with another therapeutic, including pDNA or small chemical drugs has 
been recently reported (299, 423) and only two studies in the literature have 
approached dual miRNA delivery to promote osteogenesis in vitro (58, 235). 
These studies involved the assesment of osteo-therapeutic efficiency of 
antagomiR-27a, antagomiR-489 and miR-148b mimic in a monolayer and a 3D 
hydrogel scaffold respectively (58, 235). The study presented in this chapter 
thus focused on investigating the pro-angiogenic and pro-osteogenic 
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therapeutic potential of two nHA-miRNA combinations: miR-210 mimic plus 
antagomiR-133a and miR-210 mimic plus antagomiR-16.  
5.2.Hypothesis & aims of the study 
 
The underlying hypothesis of this study was that nanomiR-210 mimic treatment 
may enhance the pro-angiogenic capabilities of hMSCs and thus 
simultaneously enhance hMSC osteogenesis when administered in a dual 
nanomiR formulation. Hence this chapter aimed (i) to assess the effect of the 
nanomiR-210 mimic alone to influence the pro-angiogenic capabilities of 
hMSCs through the direct targeting of EphrinA3 and (ii) to explore the potential 
of a nanomiR-210/133a dual formulation or (iii) a nanomiR-210/16 dual 
formulation to simultaneously enhance the pro-angiogenic and osteogenic 
capabilities of hMSCs. 
The specific aims of Chapter 5 were to: 
• Assess the effective manipulation of miR-210 and its direct target 
EphrinA3 following nanomiR-210 mimic treatment  
• Investigate VEGF secretion by hMSCs following nanomiR-210 mimic 
treatment  
• Study the effect of pro-angiogenic factors secreted by hMSCs, following 
nanomiR-210 mimic treatment, to influence angiogenic and proliferation 
capabilities of endothelial cells  
• Examine hMSC pro-angiogenic and osteogenic ability following treatment 
with a nanomiR-210/133a dual formulation 
• Examine hMSC pro-angiogenic and osteogenic ability following treatment 
with a nanomiR-210/16 dual formulation 
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5.3.Materials & methods 
 
5.3.1.Assessment of the pro-angiogenic effect of nanomiR-210 mimic treatment  
 
5.3.1.1.hMSC cell culture and nanomiR-210 mimic treatment 
hMSCs were cultured in complete DMEM medium as described in Section 2.3.3 
until sufficient cell numbers were obtained at passage number 5-6 for 
experimentation. 24 hours in advance of the nanomiR treatment cells were 
plated at a density of 5 x 104 cells per well in 6 well plates. At the time of 
administering the control (blank nHA particles), scr or -210 nanomiR-mimic 
treatments, complexes were prepared at the 20 nM dose following the 
procedure detailed in Section 2.3.1. 
5.3.1.2.Assessment of effective manipulation of miR-210 and its direct target 
EphrinA3 following nanomiR-210 mimic treatment 
qRT-PCR analysis of miR-210 and EphrinA3 manipulation: 
qRT-PCR analysis was carried out to determine the effective manipulation of 
miR-210 intracellular levels as well as mRNA relative expression level of the 
direct target EphrinA3 (EFNA3) after transient transfection with nanomiR-210 
mimic. The hsa-miR-210 Taqman® MicroRNA assay as well as the validated 
pre-designed human Quantitect Primer Assay Hs_EFNA3_1_SG, (Qiagen, UK) 
were applied. The scr nanomiR-mimic group was set as the reference for the 
calculation of relative expression levels. Technique and calculations were 
carried out as described previously in Section 2.3.7. 
EphrinA3 immunofluorescence staining and confocal imaging:  
To further investigate the effect of miR-210 manipulation on its direct target 
EphrinA3 at the protein level, immunofluorescence staining followed by confocal 
microscopy imaging was carried out. To allow detailed observation of the 
presence of EphrinA3, hMSCs were seeded on tissue-culture ready plastic 
coverslips of 25 mm diameter (Sarstedt Inc., Ireland) within 6-well plates and 
subjected to treatment as described at the beginning of this section. At the 
timepoints of analysis, namely 7 and 10 days, medium was removed and 
samples rinsed with PBS, fixed in 10 % formalin and permeabilised in 1 % 
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Triton-X100 solution. Following blocking in 5 % horse serum (HS) samples were 
incubated in a 1:50 dilution of rabbit polyclonal IgG anti-EFNA3 primary 
antibody (Santa Cruz Inc.) and subsequently in a 1:200 dilution of Alexa488-
labelled (green) goat anti-rabbit IgG secondary antibody (Invitrogen). Samples 
were then mounted on microscopy glass slides (Fisherbrand, UK) using 
Fluoroshield mounting medium (Invitrogen), which contains DAPI to stain cell 
nuclei (blue). To do so, coverslips were placed onto microscopy glass slides 
leaving the cell monolayer in the inside of the interacting surface between the 
two parts. As a final preparatory step, glass coverslips of 35 mm diameter 
(VWR International LLC.) were placed over the plastic coverslips and the final 
three-layered preparation was sealed using transparent nail polish.  
Digital imaging was performed using an upright Carl Zeiss 710 confocal laser 
scanning microscope in sequential scanning mode and controlled by the Zen 
2008 software. All images were captured using identical imaging parameters 
optimised according to the software. The increase in the signal to noise ratio 
produced by 4x averaging was used to ensure the punctate distribution of 
EFNA3 was not misinterpreted. Z stacks encompassing the whole cell were 
captured using a Plan-Apochromat 40x/1.4 Oil DIC M27 objective. FIJI (424) 
was used to generate the final images which are maximum image projections of 
the Z stacks. 
 
5.3.1.3.Assessment of the effect of hMSC treatment with nanomiR-210 mimic 
on VEGF secretion 
VEGF Quantikine plus Duo Set Development enzyme-linked immunosorbent 
assay (ELISA) Kit (R&D Systems) was used according to manufacturer’s 
instructions to quantify levels of VEGF secreted into the medium by hMSCs in 
culture or subjected to nanomiR-210 mimic treatment. Absorbance of the 
coupled enzymatic reaction of biotin-streptavidin-HRP (horseradish peroxidase) 
was read at 450 nm and background corrected at 570 nm using a Varioskan 
Flash plate reader (ThermoScientific) and SkanIt ® for Varioskan software. 
5.3.1.4.Assessment of the effect of nanomiR-210 mimic treatment on 
endothelial cell behaviour 
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Since nanomiR-210 mimic treatment of hMSC was anticipated to enhance the 
secretion of angiogenesis-related growth factors, the ability of these soluble 
factors to influence endothelial cell behaviour was tested. In order to do so, 
conditioned media (CM) was collected from hMSCs treated with the control or 
nanomiR-210 mimic groups after 7 days in culture and stored at -20°C until 
analysis, when it was sterile filtered and diluted in a 1:1 ratio with standard 
endothelial growth medium with the VEGF supplement removed.  
Human umbilical vein endothelial cell (HUVEC) culture: 
To assess the pro-angiogenic effect of nanomiR-210 mimic treatment HUVECs 
were employed as a model endothelial cell. HUVECs (Lonza, Wokingham, Ltd.) 
were cultured in EndoGROTM-2 (EGM-2) medium (Merck Millipore Ltd.) 
containing 2 % FBS, 5 % L-Glutamine, ascorbic acid 0.05 µg/ml, hydrocortisone 
hemisuccinate 1 ng/ml, heparin sulfate 0.375 u, IGF-1 0.015 ng/ml, epidermal 
growth factor (EGF), basic FGF and VEGF 0.005 ng/ml (EndoGRO™-VEGF 
Supplement Kit, Merck Millipore Ltd.). HUVECs were maintained in an incubator 
at standard culture conditions. Media was replaced every 3 days and cells were 
passaged upon reaching 80-90 % confluency. 
 
HUVEC MatrigelTM assay:  
In order to assess the ability of VEGF released by hMSCs in response to 
nanomiR-210 treatment to enhance angiogenesis, a Matrigel™ assay was 
carried out. Matrigel™ is a basement membrane matrix commonly used to 
observe angiogenesis in vitro as it allows the formation of an interconnected 
tubular network (tubulogenesis) by endothelial-like cells (363, 425, 426). Prior to 
commencement of the assay, all pipette tips and 48-well plates were placed at 
4°C overnight, and Matrigel™ was allowed to thaw on ice at 4°C. Matrigel™ 
(120 µl per well) was allowed to set for 30 min in standard culture conditions. 
Subsequently, HUVECs were plated in triplicate onto the Matrigel™ matrix at a 
seeding density of 3 x 105 per well. HUVECs were cultured in 1ml of the 
different CM, with a control group cultured in 100 % EGM-2 medium with no 
VEGF. The wells were imaged under a 10x objective at 5 random locations in 
each well at 24h post seeding using a Leica DMIL inverted microscope coupled 
to the LASV4.5 digital imaging system (Leica, Germany). The length of tubule 
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network formation (µm) and number of tubules formed by endothelial cells was 
measured in response to the various culture conditions and used as a surrogate 
marker of angiogenesis.   
HUVEC proliferation assay:  
In order to further investigate the pro-angiogenic functionality of nanomiR-210 
treatment, its potential to act as a mitogen for endothelial cell proliferation was 
investigated. Endothelial cells display a proliferative response when subjected 
to the effect of pro-angiogenic factors, including VEGF and angiopoietin1 (427). 
As such, HUVECs were plated at a seeding density of 2 x 104 cells/well in 12-
well plates, cultured in the appropriate CM groups (as above) and harvested for 
dsDNA quantification after 3 days of culture. dsDNA quantification was 
performed using the dsDNA Quant-iT PicoGreen dsDNA kit (BioSciences, 
Ireland) as described in Section 2.3.4. 
5.3.2.Analysis of the simultaneous pro-angiogenic and pro-osteogenic effect of 
miR-210 mimic delivery as part of a dual nanomiR treatment 
 
5.3.2.1.hMSC cell culture  
 
hMSCs were cultured in complete DMEM medium as described in Section 2.3.3 
until sufficient cell numbers were obtained at passage number 4-5 for 
experimentation. 24 hours in advance of the nanomiR treatment cells were 
plated at a density of 5 x 104 cells per well in 6 well plates. Immediately after the 
addition of the treatments, hMSCs were cultured in complete osteogenic 
medium as described in Section 3.3.2. 
 
5.3.2.2.NanomiR-dual system 
The preparation of nanomiR complexes was modified to explore the dual 
delivery of miR-mimics and antagomiRs (Figure 5.2). nHA particles (150 µl) 
were synthesised following the method described in Section 2.3.1 and added to 
a miRNA solution containing 0.25 M CaCl2. The miRNA solution was prepared 
at the final concentration of 20 nM, in which the effective dose of both miR-
mimic and antagomiR components was respectively 10 nM, that is, effectively 
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half than that of the single nanomiR-mimics or nanoantagomiRs assessed in 
Chapters 3 and 4 of this thesis.  
 
Figure 5.2 Schematic of the miRNA dosage regime differences between single and dual 
nanomiR formulation. While a final miRNA concentration is set at 20 nM in all groups, the 
effective dose of each therapeutic in the dual formulation is half that of the same molecule in the 
single nanomiR group. Colour coding: Addition of miR-mimic, blue, plus antagomiR, red, make 
result in purple to represent the nanomiR-dual groups from here onwards.  
This procedure was applied to generate the control and treatment groups 
detailed in Table 5.1. In this study single scr nanomiR-mimic and nanomiR-210 
mimic (used at 20 nM respectively) were administered to hMSCs additionally to 
serve as a comparative reference. 
Single treatment Dual treatment
nanoantagomiR
20 nM
nanohydroxyapatite
(nHA) 150 µl
antagomiR
20 nM
miR-mimic 
20 nM
nanohydroxyapatite
(nHA) 150 µl
nanomiR-mimic
20 nM
antagomiR
10 nM
miR-mimic 
10 nM +
nanohydroxyapatite
(nHA) 150 µl
nanomiR-dual 
20 nM
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Table 5.1 Composition of the nanomiR-dual formulations tested in this chapter. 
Group Tested as 
miR-mimic 10 nM 
(miRIDIAN) 
antagomiR 10 nM 
(miRIDIAN) 
scr nanomiR-dual 
target lacking, negative 
control  
nc#1 available from 
supplier, sequence based 
on cel-miR-67 
nc#1 available from 
supplier, sequence based 
on cel-miR-67 
nanomiR-210/133a dual treatment (i) 
sequence based on hsa-
miR-210 
sequence based on hsa-
miR-133a 
nanomiR-210/16 dual treatment 
sequence based on hsa-
miR-210 
(ii) 
sequence based on hsa-
miR-16 
5.3.2.3.Assessment of effective manipulation of miR-210 and its direct targets 
EFNA3 and AcvR1b using qRT-PCR analysis 
qRT-PCR analysis was carried out to determine the compare manipulation of 
miR-210 intracellular levels as well as mRNA relative expression level of the 
direct targets EFNA3, involved in angiogenesis, and AcvR1b, involved in 
osteogenesis, after transient transfection with nanomiR-210 mimic single 
treatment or nanomiR-dual formulations. The hsa-miR-210 Taqman® MicroRNA 
assay as well as the validated pre-designed human Quantitect Primer Assays 
Hs_EFNA3_1_SG and Hs_ACVR1B_va.1_SG (Qiagen, UK) were applied. The 
scr nanomiR-dual group was set as the reference for the calculation of relative 
expression levels. Technique and calculations were carried out as described 
previously in Section 2.3.7. 
5.3.2.4.Investigation of the effect of hMSC treatment with nanomiR-dual on 
VEGF secretion using ELISA  
VEGF Quantikine plus Duo Set Development ELISA Kit (R&D Systems) was 
used as described earlier in section 5.3.1. to quantify levels of VEGF secreted 
into the medium by hMSC osteogenic culture when subjected to transient 
transfection with nanomiR-210 mimic single treatment or nanomiR-dual 
formulations. Briefly, absorbance of the coupled enzymatic reaction was read at 
450 nm and background corrected at 570 nm. 
5.3.2.5.Analysis of the effect of nanomiR-dual treatment on endothelial cell 
behaviour 
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Transient transfection of hMSCs with nanomiR-210 mimic single treatment or 
nanomiR-dual formulations was anticipated to enhance the secretion of a panel 
of angiogenesis-related growth factors by hMSCs during their osteogenic 
differentiation. In parallel with the methodology applied to asses this objective in 
the first part of this study (Section 5.3.1.4), the ability of these soluble factors to 
influence HUVEC behaviour was tested in terms of tubulogenesis (Matrigel TM) 
and proliferation assays. In order to do so, CM collected from hMSCs 
osteogenic culture at 3 and 7 days was pooled together and banked at -20°C 
until commencement of the assays described below, when it was thawed, sterile 
filtered and used undiluted.  
HUVECs culture, MatrigelTM and proliferation assays were carried out as 
described in Section 5.3.1.4. Briefly, complete EGM-2 medium (Merck Millipore 
Ltd., Ireland) was replaced every 3 days in culture and cells were passaged 
upon reaching 80 - 90 % confluency. For the MatrigelTM assay all materials were 
pre-chilled O/N and 120 µl Matrigel™ per well (~1 cm2) were seeded with 3 x 
105 HUVECs and cultured in 1ml of the different CM, with a control group 
cultured in 100 % EGM-2 medium void of VEGF. Following imaging at 4h post 
seeding, quantification of total tubule number and total tubule length (µm) per 
micrograph section (10x) was carried out using Image J software. For the 
proliferation assay, 3 x 104 cells/well were seeded in 12-well plates, cultured in 
the appropriate CM groups and harvested for dsDNA quantification after 3 days 
of culture. 
5.3.2.6.Analysis of the effect of nanomiR-dual treatment on hMSC osteogenic 
gene expression using qRT-PCR  
qRT-PCR analysis was carried out as indicated above to determine relative 
mRNA expression level of the osteogenic markers Runx2 and OCN after 
transient transfection with nanomiR-dual formulations. The validated pre-
designed human Quantitect Primer Assays Hs_RUNX2_1_SG and 
Hs_BGLAP_1_SG (Qiagen, UK) were applied.  
5.3.2.7.Mineral deposition assessment as end-stage marker of osteogenesis 
In order to visualise calcium deposits at 14 days after transient transfection with 
nanomiR-dual formulations, samples were stained directly on culture-plates with 
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2 % Alizarin red as previously described in Section 3.3.5. Macroscopic imaging 
was carried out using a personal digital camera. To provide quantitative data 
the Calcium Liquicolor kit (Stanbio Laboratories) was used under 
manufacturer’s instructions at 10 and 14 days post-treatment as previously 
described in Section 3.3.5.  
5.3.3.Statistical analysis 
Experiments were performed in triplicate, unless otherwise specified within 
figure captions, and are representative of a minimum of three independent 
repetitions using two cell donors. Data analysis was performed using the 
SigmaPlot 11.0 software package. Results were presented as the mean + 
standard deviation and subjected to a two-way analysis of variance (ANOVA) 
plus a Tukey post-hoc for analysis of several time points and one-way ANOVA 
plus Tukey post-hoc test for data assessed at a singular time point.. p<0.05 and 
p<0.001 were considered significant differences. 
 
5.4.Results 
 
5.4.1.Pro-angiogenic effect of nanomiR-210 mimic treatment  
 
5.4.1.1.Effective manipulation of miR-210 but not its direct target EphrinA3 was 
achieved following nanomiR-210 mimic treatment 
The effective manipulation of miR-210 levels following nanomiR-210 mimic 
treatment of hMSCs was assessed as the first step to analyse the effect of this 
treatment in angiogenesis. Similarly to the observation from Chapter 3, 
intracellular level of miR-210 was prominently increased in the nanomiR-210 
mimic group after 3 days compared to all other groups, and this was further 
enhanced at 7 days in culture, which was quantified as greater than 6000 fold 
change (6155.59 ± 452.75) (Figure 5.3a). Interestingly, both cell and nHA 
groups contained higher miR-210 levels than the scr nanomiR-mimic group at 
day 3, while by 7 days miR-210 levels were maintained at the relative level 
baseline for the three control groups. Overall this data pointed at an efficient 
delivery of miR-210 mimic using the nHA-based delivery. 
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The levels of the miR-210 direct target involved in angiogenesis, EphrinA3 
(EFNA3), were decreased in both untreated cells and nanomiR-210 mimic 
groups to approximately 0.3 fold as compared with scr nanomiR-mimic control 
at 3 days, while nHA particles alone induced an increase to 1.6 fold (Figure 
5.3b). At the later timepoint of 7 days, the untreated cell group displayed the 
lowest levels of EphrinA3 at 0.2 fold versus the scr nanomiR-mimic control, but 
nHA and nanomR-210 mimic also presented decreased levels of this gene. In 
contrast to the effect hypothesised, nanomiR-210 mimic treatment did not 
silence EFNA3 levels below those of untreated cells. Altogether this data 
indicated a negligible silencing effect over EFNA3 following the efficient miR-
210 mimic delivery using nHA particles. 
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Figure 5.3 Analysis of hMSC genetic manipulation of miR-210 & EFNA3 levels following 
nanomiR-210 mimic treatment. a) NanomiR-210 mimic treatment successfully increased miR-
210 levels intracellularly at 3 and 7 days after treatment. b) EFNA3 expression was significantly 
reduced for the cell and miR-210 mimic groups in comparison with the scr group at the 7 day 
timepoint. Scr nanomiR-mimic was set as the reference control group and relative expression 
was normalised to that of 18S and calculated using the 2(-ΔΔCt) method. Mean + standard 
deviation, n = 3, * = p<0.05, ** = p<0.001.  
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To further characterise the biological effect of nanomiR-210 mimic on the 
protein levels of the direct target EphrinA3, immunofluorescence staining was 
carried out. A higher presence of EphrinA3 was quantified in the untreated cells 
and nHA groups after both 7 and 10 days in culture; however nanomiR-210 
mimic did not reduce the EphrinA3 protein levels in comparison with the scr 
nanomiR-mimic group, which was more pronounced at the 10 day timepoint 
(Figure 5.4). This data again pointed to negligible biological effect following the 
efficient miR-210 mimic delivery using nHA particles. 
 
Figure 5.4 Assessment of EphrinA3 protein expression following nanomiR-210 mimic 
treatment. Composite depicting representative confocal microscopy images of a) DAPI labelling 
(blue, nuclei) of the negative control of EphrinA3 staining (no primary antibody) and b) EphrinA3 
immunofluorescence staining (green) merged with DAPI labelling (blue, nuclei) at 7 and 10 days 
after nanomiR treatment. Scale bar = 20 µm, n = 3. c) Quantification of green fluorescence (%) 
indicated that nanomiR-210 mimic treatment did not reduce EphrinA3 protein levels when 
compared with the scr nanomiR-mimic group. Mean + standard deviation, n = 3, ** = p<0.001, 
NS = not significant.  
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5.4.1.2.VEGF secretion was enhanced in nanomiR-210 mimic treated 
compared to untreated  hMSCs  
VEGF is the main secreted growth factor that promotes angiogenesis, and miR-
210 levels have been shown to increase following VEGF supplementation, 
supporting a pro-angiogenic activity of miR-210 (383). Based on this, VEGF 
secretion in nanomiR-210 mimic treated hMSCs was evaluated. The ELISA 
data indicated non-significant changes in the levels of VEGF secretion at day 3, 
within the range of 1000 to 2000 pg/ml (Figure 5.5). After 7 days VEGF 
secretion was significantly enhanced in both scr nanomiR-mimic and nanomiR-
210 mimic groups, the latter to a higher magnitude of ~ 4200 pg/ml, 
corresponding to a 77 % increase over that of untreated cells. Taken together 
this result indicated that nanomiR-210 mimic was able to enhance the secretion 
of VEGF by hMSC after 7 days in comparison to untreated cells.    
 
Figure 5.5 Analysis of the effect of nanomiR-210 mimic treatment on VEGF secretion by 
hMSCs. ELISA assays indicated that both scr nanomiR-mimic and nanomiR-210 mimic 
treatment enhanced VEGF protein secretion at 7 days in standard culture conditions. Mean + 
standard deviation, n = 3, * = p<0.05, NS = not significant variation.  
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5.4.1.3.NanomiR-210 mimic treated MSCs had limited influence on endothelial 
cell behaviour  
The increased VEGF secretion determined for the nanomiR-210 mimic 
treatment in the previous section was anticipated to be accompanied by the 
secretion of additional soluble pro-angiogenic factors. To further examine the 
biological response of endothelial cells (HUVEC) to these soluble factors, 
conditioned media from the different treatment groups was applied firstly in a 
MatrigelTM tubulogenesis assay. Quantification of tubule formation at 24h 
showed that longer tubules were formed in the untreated cell group in 
comparison with the nanomiR-210 mimic group (Figure 5.6a). This indicated 
that the pro-angiogenic factors secreted upon hMSC treatment with nanomiR-
210 mimic were unable to enhance tubule formation by HUVECs, compared to 
untreated cells. Secondly, the HUVEC proliferation assay showed a trend 
towards higher proliferation in the nanomiR-210 mimic CM group after 3 days in 
culture (Figure 5.6b). This pointed to an enhanced presence of soluble pro-
proliferation factors in nanomiR-210 mimic conditioned medium. Taken 
together, this data demonstrated some capability, albeit modest, of nanomiR-
210 mimic treatment to induce a pro-angiogenic effect on hMSCs when 
compared to untreated cells. 
Figure 5.6 Analysis of the capability of nanomiR-210 mimic treated hMSC conditioned 
medium (CM) to influence endothelial cell behaviour. a) Quantification of HUVEC tubule 
formation in MatrigelTM. When average tubule length was assessed, longer tubules were 
detected in the positive control, cell and nanomiR-210 mimic groups in comparison to nHA and 
scr groups after 24 h. Mean + std deviation, n = 15, * = p<0.05, ** = p<0.001. b) A trend towards 
higher HUVEC proliferation was determined in the nanomiR-210 mimic group after 3 days. 
Mean + standard deviation, n = 3, non-significant differences. 
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5.4.2.Simultaneous pro-angiogenic and pro-osteogenic effect of miR-210 mimic 
delivery as part of a dual combination with antagomiR-133a 
The results above and in Chapter 3 showed the limited capability of miR-210 
mimic to separately induce a therapeutic pro-osteogenic and pro-angiogenic 
effects. We next hypothesised that a nanomiR-210/133a dual formulation may 
induce a simultaneous pro-angiogenic and pro-osteogenic effect beneficial for 
bone repair.  
5.4.2.1.Effective manipulation of miR-210 following nanomiR-210/133a dual 
treatment did not lead to silencing of EFNA3 and AcvR1b  
Intracellular miR-210 level was prominently increased following both nanomiR-
210 mimic and nanomiR-210/133a dual treatment after 3 days in osteogenic 
culture (Figure 5.7a). Interestingly, the nanomiR-210/133a dual formulation, 
containing only 10 nM of miR-210 mimic, increased intracellular levels 8 x 103 
fold over the control scr group, an effect which was 3.18 times higher than that 
achieved with the single miR-210 mimic administered at the 20 nM dose. Taken 
together, this data confirmed the efficient delivery of miR-210 mimic using nHA 
particles in both the single and the dual nanomiR formulations.  
Subsequently, the simultaneous effect of miR-210 manipulation on 
angiogenesis and osteogenesis, through the direct targeting of EFNA3 and 
AcvR1b respectively, was demonstrated after 3 days in osteogenic culture 
(Figure 5.7b-c). NanomiR-210 mimic successfully silenced EFNA3 to 0.5 ± 0.32 
fold (Figure 5.7b), below that of untreated hMSCs (0.93 ± 0.5 fold). Additionally, 
this treatment silenced AcvR1b levels to 0.21 ± 0.05 fold (Figure 5.7c), 
consistent with previous observations in Chapter 3. Surprisingly, the nanomiR-
210/133a dual formulation did not correlate with improved silencing of either 
EFNA3 or AcvR1b compared with the single miR-210 mimic administration, 
demonstrating unmodified levels of EFNA3 expression (1.1 ± 0.07 fold), and 
increased expression of AcvR1b (1.37 ± 0.24 fold). Taken together, this data 
indicated a complex relationship between the effective delivery of miR-210 
mimic achieved with the nanomiR-210/133a dual and negligible silencing of the 
direct miR-210 targets.  
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Figure 5.7 Comparative analysis of effectivity in miR-210, EFNA3 & AcvR1b manipulation 
following treatment with nanomiR-210 mimic & nanomiR-210/133a dual. a) Both groups 
containing miR-210 mimic successfully increased miR-210 intracellularly. b) EFNA3 expression 
was silenced with nanomiR-210 mimic after 3 days. c) A marked decrease in AcvR1b 
expression was found at the same time point in osteogenic culture for the nanomiR-210 mimic 
group, while nanomiR-210/133a dual increased AcvR1b when compared to untreated cells. Scr 
nanomiR-dual was set as the reference control group and relative expression was normalised to 
that of 18S and calculated using the 2(-ΔΔCt) method. Mean + standard deviation, n = 4, NS = not 
significant variation, * = p<0.05, ** = p<0.001, ɸ= p<0.05 compared to nHA treatment.  
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5.4.2.2.VEGF secretion was enhanced in both nanomiR-210 mimic & nanomiR-
210/133a dual treated hMSCs  
VEGF secretion was increased in both nanomiR-210 mimic and nanomiR-
210/133a dual treated hMSCs (1334.85 ± 148.22 pg/ml and 1391.4 ± 172.35 
pg/ml respectively) compared to all other groups after 3 days in osteogenic 
culture (Figure 5.8). At the later timepoint of 7 days, a single administration of 
20 nM miR-210 mimic produced lower VEGF than its counterpart scr group, to a 
level that was not significantly increased over that of untreated cells. 
Conversely, VEGF secretion was highest in the nanomiR-210/133a dual group, 
which corresponded to a 47.4 % increase over VEGF secreted by untreated 
cells and 42.77 % higher than the counterpart scr nanomiR dual group at the 
same timepoint. Taken together, this result indicated that nanomiR-210/133a 
dual was able to further potentiate the effect of miR-210 mimic on VEGF 
secretion at the later timepoint assessed in hMSC osteogenic culture. 
 
Figure 5.8 Comparative analysis of the effect of nanomiR-210 mimic & nanomiR-210/133a 
dual treatment on VEGF secretion by hMSCs. NanomiR-210 mimic & 210/133a dual groups 
enhanced VEGF protein secretion over untreated cells 3 days after treatment. At the later time 
point of 7 days the nanomiR-210/133a dual group achieved higher levels in comparison to all 
other groups. Mean + standard deviation, n = 3, * = p<0.05, ɸ = p<0.05 compared to cell osteo 
medium, Ɵ = p<0.001 compared to nanomiR-210 mimic and nanomiR-210/133a dual, # = 
p<0.001 vs all other groups.  
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5.4.2.3.NanomiR-210/133a dual treatment did not enhance osteogenic gene 
expression 
Runx2 and OCN were analysed after 7 days in osteogenic culture as the main 
indicators of the initiation and progression of osteogenesis in hMSCs. Runx2 
levels remained unaffected (0.89 ± 0.20 fold) with nanomiR-210/133a dual 
treatment, in a similar level to that determined for nanomiR-210 mimic 
previously in Chapter 3 (Figure 5.9a). OCN expression was also unaffected in 
the nanomiR-210/133a dual group, although this level was greater than that 
previously determined for nanomiR-210 mimic (Figure 5.9b). In summary this 
data indicated that nanomiR-210/133a dual treatment did not correlate with 
enhanced hMSC osteogenesis at the gene level. 
Figure 5.9 qRT-PCR analysis of the effect of nanomiR-210/133a dual treatment on hMSC 
osteogenic gene expression markers. a) Runx2 expression was unmodified in the nanomiR-
210/133a dual treatment by 7 days. b) No significant changes were detected in OCN relative 
expression level 7 days after treatment but all groups were above the level previously 
determined OCN relative level for nanomiR-210 mimic. Dashed blue line represents 
corresponding expression level determined for nanomiR-210 mimic previously in Chapter 3. Scr 
nanomiR-dual was set as the reference control group and relative expression was normalised to 
that of 18S and calculated using the 2(-ΔΔCt) method. Mean + standard deviation, n = 4, NS = not 
significant variation.  
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5.4.2.4.Mineral deposition was not enhanced in nanomiR-210/133a dual treated 
hMSCs  
Calcium deposition quantification indicated that the scr nanomiR-dual group 
enhanced calcium deposition to the same level than the nanomiR-210/133a 
dual treatment (Figure 5.10a), at both day 10 and day 14, which was also 
maintained to the levels previously determined for nanomiR-210 mimic. 
Additionally, alizarin red staining indicated higher presence of extracellular 
calcium deposits at 14 days in both the scr and nanomiR-210/133a dual groups 
in comparison with the untreated cells (Figure 5.10b). In summary, while some 
increases over untreated cells were seen, this assessment indicated that 
nanomiR-210/133a dual was not able to further enhance the effect of the miR-
210 mimic on calcium deposition. 
       
Figure 5.10 Effect of nanomiR-210/133a dual treatment on hMSC calcium matrix 
deposition. a) Calcium quantification normalised to dsDNA content showed that nanomiR-
210/133a dual treatment did not enhance calcium deposition after 10 or 14 days in osteogenic 
culture. Dashed blue and black lines (day 10 and 14 respectively) represent corresponding fold 
increase of nanomiR-210 mimic over untreated cells determined previously in Chapter 3. Mean 
+ standard deviation, n = 3, ** = p<0.001, ɸ = p<0.01 compared to all other groups. b) 
Macroscopic images of alizarin red staining indicated increased calcium deposition in both the 
scr and nanomiR-210/133a dual groups after 14 days in osteogenic culture.  
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5.4.3.Simultaneous pro-angiogenic and pro-osteogenic effect of miR-210 mimic 
delivery as part of a dual nanomiR treatment in combination with antagomiR-16 
For the last part of this study, it was hypothesised that a dual formulation 
combining miR-210 mimic with antagomiR-16, that also robustly enhanced 
osteogenesis in Chapter 3 and additionally directly interacts with targets of the 
same family as miR-210, could potentiate the therapeutic effect of miR-210 
mimic as well as inducing a simultaneous pro-angiogenic and pro-osteogenic 
effect, which would be highly beneficial for bone tissue repair. 
5.4.3.1.Effective manipulation of miR-210 and its direct targets EFNA3 and 
AcvR1b was achieved with nanomiR-210/16 dual treatment 
Intracellular miR-210 levels were prominently increased following both 
nanomiR-210 mimic and nanomiR-210/16 dual treatment after 3 days in 
osteogenic culture (Figure 5.11a). Interestingly, the opposite pattern to that 
observed in Section 5.4.2.1 was found between the two miR-210 mimic 
containing groups: the nanomiR-210/16 dual formulation, containing only 10 nM 
of miR-210 mimic, lead to intracellular levels increased to 3 x 102 fold over the 
control scr group, an effect which was 8.5 times lower than that achieved with 
the single miR-210 mimic administered at the 20 nM dose. This data confirmed 
the efficient delivery of miR-210 mimic in both the single treatment and the 
nanomiR-210/16 dual formulation.  
Subsequently, the simultaneous effect of miR-210 manipulation over 
angiogenesis and osteogenesis, through the direct targeting of EFNA3 and 
AcvR1b respectively, was demonstrated after 3 days in osteogenic culture 
(Figure 5.11b-c). Here, the successful 50 % silencing of nanomiR-210 mimic 
over EFNA3 was further improved to 0.15 ± 0.14 fold with the nanomiR-210/16 
dual formulation (Figure 5.11b), in contrast to the observations for the nanomiR-
210/133a dual system (Figure 5.7b). Additionally, AcvR1b silencing was also 
seen with the nanomiR-210/16 dual formulation (0.32 ± 0.11 fold; figure 5.12c). 
These data showed an improved manipulation of the direct target involved in 
angiogenesis with less pronounced increase in miR-210 intracellular levels, 
indicating that a more relevant genetic manipulation may be achieved through 
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moderately altering miRNA levels with the nanomiR-210/16 dual formulation. 
Taken together, this data indicated the effective delivery of nanomiR-210/16 
dual and the functional silencing of the direct miR-210 targets.  
 
Figure 5.11 Comparative analysis of effectivity in miR-210, EFNA3 & AcvR1b 
manipulation following treatment with nanomiR-210 mimic & nanomiR-210/16 dual. a) 
miR-210 analysis confirmed that all groups containing miR-210 mimic successfully increased 
miR-210 intracellularly. b) The effect of nanomiR-210 mimic silencing EFNA3 expression was 
further promoted with the nanomiR-210/16 dual group at the same time point. c) A marked 
decrease in AcvR1b expression was found after 3 days in ostoegenic culture for the nanomiR-
210 mimic and nanomiR-210/16 dual groups. Scr nanomiR-dual was set as the reference 
control group and relative expression was normalised to that of 18S and calculated using the 2(-
ΔΔCt) method. Mean + standard deviation, n = 4, * = p<0.05, ** = p<0.001, ɸ = p<0.05 compared 
to nHA treatment.  
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5.4.3.2.VEGF secretion was enhanced in nanomiR-210/16 dual treated hMSCs 
NanomiR-210 mimic increased VEGF secretion by hMSCs compared to all 
other control groups after 3 days in osteogenic culture, but this effect was 
significantly augmented in nanomiR-210/16 dual treated hMSCs (Figure 5.12). 
While the nanomiR-210 mimic did not increase VEGF over untreated cells at 
the later timepoint of 7 days, nanomiR-210/16 dual treatment markedly 
increased VEGF secretion over all other groups, corresponding to an 84.3 % 
increase over VEGF secreted by untreated cells and 78.5 % higher than the 
counterpart scr group. Taken together, this result indicated that nanomiR-
210/16 dual was able to significantly enhance the effect of the miR-210 mimic 
on VEGF secretion at both timepoints assessed in hMSC osteogenic culture. 
 
Figure 5.12 Comparative analysis of the effect of nanomiR-210 mimic & nanomiR-210/16 
dual treatment on VEGF secretion by hMSCs. NanomiR treatment enhanced VEGF protein 
secretion over untreated cells with highest levels for the nanomiR-210/16 dual group at both 3 
and 7 days after treatment. Mean + standard deviation, n = 3, * = p<0.05, ** = p<0.001, ɸ = 
p<0.05 compared to cell osteo medium, θ = p<0.001 compared to nanomiR-210 mimic, # = 
p<0.001 vs all other groups.  
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5.4.3.3.The capacity of hMSCs to influence HUVEC behaviour was enhanced  
following treatment with nanomiR-210/16 dual 
To further examine the biological response of HUVECs to the increased VEGF 
secretion determined above, conditioned media (CM) from the different 
treatment groups was applied in a MatrigelTM tubulogenesis assay and a 
proliferation assay. Firstly, the MatrigelTM assay indicated an enhanced 
tubulogenic capability of HUVECs maintained in the nanomiR-210/16 dual CM 
group, in comparison to all other types of CM (Figure 5.13 a-c). The 
quantification of this assay at 4 h showed that tubule length was significantly 
increased in the nanomiR-210/16 dual CM group, being the highest group 
immediately after the positive control (complete endothelial medium - 
ENDOGRO - lacking VEGF) (Figure 5.14a). Secondly, the HUVEC proliferation 
assay showed a trend towards higher proliferation in the nHA and nanomiR-
210/16 dual CM groups compared to the remaining CM groups after 3 days in 
culture (Figure 5.14b). Taken together, this data demonstrated an improved 
capability of nanomiR-210/16 dual formulation over nanomiR-210 mimic alone 
to induce a pro-angiogenic effect on hMSCs when compared to untreated cells.  
 
Figure 5.13 Analysis of the capability of nanomiR-210/16 dual treated hMSC conditioned 
medium (CM) to influence HUVEC tubulogenesis. a-c) Representative bright field images of 
HUVECs after 4 h in MatrigelTM assay. n = 15, scale bar = 100 µm. a) A complex and 
interconnected network of tubules was observed in the positive control group (complete 
ENDOGRO - VEGF). b) scr nanomiR-dual CM representing the relegated tubule-forming 
capacity of negative control groups and c) nanomiR-210/16 dual group demonstrating an 
increased length in the tubules formed in comparison to the negative control group. 
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Figure 5.14 Analysis of the capability of nanomiR-210/16 dual treated hMSC conditioned 
medium (CM) to influence HUVEC behaviour. a) Quantification of HUVEC tubule formation 
after 4 h in MatrigelTM. Longer tubules were detected in the positive control and nanomiR-210/16 
dual groups, followed by nHA. Mean + std deviation, n= 15, *=p<0.05,**=p<0.001. b) HUVEC 
proliferation in nanomiR-hMSC CM: A trend towards higher proliferation was determined in the 
nanomiR-210 mimic group vs scr nanomiR-mimic and in the nanomiR-210/16 dual vs scr 
nanomiR-dual after 3 days. Mean + standard deviation, n = 3, ** = p<0.001, NS=not significant 
variation. 
5.4.3.4.NanomiR-210/16 dual treatment did not enhance osteogenic gene 
expression 
Runx2 and OCN were analysed after 7 days in osteogenic culture. The levels 
determined for both Runx2 and OCN following nanomiR-210/16 dual treatment 
(Figure 5.15) exceeded those previously determined for nanomiR-210 mimic on 
its own (Chapter 3). However, in comparison to the control groups of this study, 
the effect of nanomiR-210/16 dual on Runx2 level was deemed non-significant 
and OCN expression remained unaffected. In summary this data indicated that 
nanomiR-210/16 dual treatment did not correlate with enhanced hMSCs 
osteogenesis at the gene level. 
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Figure 5.15 Comparative qRT-PCR analysis of the effect of nanomiR-210 mimic & 
nanomiR-210/16 dual treatment on hMSC osteogenic gene expression. Non-significant 
changes in a) Runx2 expression and b) OCN relative expression were found 7 days after 
nanomiR-210/16 dual treatment. Dashed blue line represents corresponding expression level 
determined for nanomiR-210 mimic previously in Chapter 3. Scr nanomiR-dual was set as the 
reference control group and relative expression was normalised to that of 18S and calculated 
using the 2(-ΔΔCt) method. Mean + standard deviation, n = 4, NS = not significant variation, * = 
p<0.05.  
5.4.3.5.Mineral deposition was enhanced in nanomiR-210/16 dual treated 
hMSCs 
The nanomiR-210/16 dual group demonstrated the greatest calcium deposition 
levels in comparison to all other groups at both 10 and 14 days (Figure 5.16a). 
This result largely surpassed the calcium deposition levels previously 
determined for nanomiR-210 mimic, corresponding to a 1.96 fold increase at the 
earlier timepoint and a 2.65 fold increase at the later timepoint. Additionally, 
alizarin red staining confirmed the presence of calcium deposits in the 
nanomiR-210/16 dual group after 14 days (Figure 5.16b). In summary, this 
assessment indicated that nanomiR-210/16 dual was able to further potentiate 
the effect of miR-210 mimic on calcium deposition. 
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Figure 5.16 Effect of nanomiR-210/16 dual treatment on hMSC calcium matrix deposition. 
a) Calcium quantification normalised to dsDNA content showed highest levels of calcium 
deposition in the nanomiR-210/16 dual group at both 10 and 14 days in osteogenic culture. 
Dashed blue and black lines (day 10 and 14 respectively) represent corresponding fold increase 
of nanomiR-210 mimic over untreated cells determined previously in Chapter 3. Mean + 
standard deviation, n = 3, ** = p<0.001, ɸ = p<0.001 in comparison to all other groups.  b) 
Macroscopic images of alizarin red staining indicated increased calcium deposition in the 
nanomiR-210/16 dual group.  
 
5.5.Discussion 
The application of miRNA therapeutics simultaneously targeting angiogenesis 
and osteogenesis might be an attractive avenue for future bone repair 
strategies. This chapter aimed firstly to investigate the pro-angiogenic 
therapeutic potential of nanomiR-210 mimic and subsequently the capacity of a 
combinatorial miRNA therapy approach, namely nanomiR-210/133a dual and 
nanomiR-210/16 dual formulations, to simultaneously enhance the pro-
angiogenic and osteogenic capabilities of hMSCs. The data presented here 
showed that nanomiR-210 mimic treatment resulted in effective manipulation of 
miR-210, albeit with no silencing effects on EphrinA3 compared to untreated 
cells and limited pro-angiogenic effect in terms of VEGF secretion or endothelial 
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cell response. Subsequently, while nanomiR-210/133a dual treatment of 
hMSCs did not result in a robust simultaneous pro-angiogenic and osteogenic 
effect, the nanomiR-210/16 dual treatment proved beneficial in this regard; this 
was demonstrated by the effective genetic manipulation of miR-210 and its 
direct targets, significantly increased VEGF secretion and calcium deposition, 
as well as enhanced endothelial cell tubulogenic potential compared to 
untreated cells. Taken together, the results showcased the promise of using 
nHA-based delivery of multiple miRNAs as a prospective therapy use in TE.  
Initially, the effective manipulation of miR-210 levels following nanomiR-210 
mimic treatment of hMSCs was demonstrated, although this effect did not result 
in functional EphrinA3 silencing in comparison to untreated cells. miR-210 
induction of EphrinA3 silencing has been demonstrated in two different cell 
types, namely HUVECs and U2OS cells, using a 40 nM miRNA dose delivered 
by a commercial lipid-based vector (383). While it was hypothesised that this 
effect of miR-210 could be extended to the MSCs, the data presented in this 
chapter did not support this hypothesis. This might be explained by the findings 
of relatively low endogenous expression of EphrinA3 in the untreated hMSCs 
along the culture period, which evidenced a putative limitation of the strategy 
based on reducing expression of this target.  
The nanomiR-210 mimic treatment did however enhance secretion of VEGF by 
hMSCs. VEGF-induced angiogenesis has been reported to stimulate increases 
in miR-210 levels (383, 418), however, the increase of VEGF as a consequence 
of enhanced miR-210 levels in vitro has not been reported previously. This 
study thus provided evidence for the first time that miR-210 level manipulation 
can beneficially impact VEGF secretion by hMSCs, therefore showing potential 
in angiogenesis-mediated bone TE strategies (151). Interestingly however, the 
endothelial cells showed a limited tubulogenesis capacity in response to 
conditioned medium from the treated hMSCs in comparison to untreated cells 
although a trend towards higher proliferation was observed. Importantly, the 
influence of miR-210 on angiogenesis has been strongly associated as a 
response to hypoxic (low oxygen) conditions in vitro (428, 429) and during 
osteonecrosis in vivo (430). This may suggest that in order to fully realise the 
pro-angiogenic effect of miR-210 mimic treatment on hMSCs, exploration of 
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experimental hypoxic conditions is worthy of future consideration. Taken 
together, this data indicated that nanomiR-210 mimic showed potential to 
enhance the secretion of VEGF by hMSCs after 7 days in culture, but overall 
this was not sufficient to influence endothelial cell behaviour. 
The secondary focus of this chapter was the evaluation of a simultaneous pro-
angiogenic and osteogenic response in hMSCs following combinatorial miRNA 
delivery. Although previous studies have not used a combinatorial miRNA 
delivery approach to simultaneously target angiogenesis and osteogenesis, 
superior bone repair  has been reported with co-delivery of angiogenic and 
osteogenic growth factors (GFs) or plasmid DNA (145, 286, 292). We proposed 
that by combining miR-210 mimic with antagomiR-133a a simultaneous pro-
angiogenic and pro-osteogenic effect could be obtained, which would be more 
potent than the single miR-210 mimic treatment. The ability of both nanomiR-
210 mimic and nanomiR-210/133a dual groups to increase miR-210 intracellular 
level was demonstrated. However, while the nanomiR-210 mimic treatment 
achieved functional silencing of the direct angiogenesis and osteogenesis 
targets, EphrinA3 and AcvR1b respectively, no silencing was detected for the 
nanomiR-210/133a dual group. This may be due to a negative interaction 
between miR-210 and miR-133a, unrelated to base-pair complementarity 
between the two molecules (392), which may take place at a signalling level. 
Interestingly, the silencing of EphrinA3 following single nanomiR-210 mimic 
treatment in hMSC osteogenic culture was more effective than that observed in 
standard culture. It is proposed that the effective detection of this silencing 
effect can be related to an endogenous pattern of increased EphrinA3 
expression in osteogenic culture in comparison with standard culture.  
Further analysis indicated that nanoantagomiR-210/133a dual treatment did not 
result in a simultaneous pro-angiogenic and osteogenic effect. While VEGF was 
increased at both 3 and 7 days, osteogenic gene expression and calcium 
deposition were not enhanced. Altogether, this data indicated a complex and 
perhaps detrimental interaction when miR-210 mimic and antagomiR-133a were 
combined. This effect has also been noted for certain combinations of GFs and 
genes that separately are positive for angiogenesis, osteogenesis, or both 
processes. As an example, FGF-2 combinations with BMP-2 or VEGF have 
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reported detrimentral effects in MSC mediated osteogenesis and bone repair 
(174, 431). This is an indication of the complexity of possible cross-signalling 
responses between the components of the mix. Overall the data presented in 
this part of the study demonstrated an unfavourable effect of the miR-210 mimic 
plus antagomiR-133a combination as a therapy to enhance simultaneous 
angiogenesis and osteogenesis.  
For the last part of this study, an alternative combinatorial miRNA delivery 
approach utilising antagomiR-16 in combination with miR-210 mimic was 
undertaken. Here, consideration was placed on the fact that some direct targets 
of the two miRNAs are familiarly-related molecules and part of associated 
pathways. Specifically, the pair of tyrosine-kinase receptors AcvR1b and 
AcvR2a are described to counter-balance TGFβ signalling (379). The data from 
this study demonstrated that the highly effective genetic manipulation of miR-
210 levels and its direct targets EphrinA3 and AcvR1b could be improved with 
the nanomiR-210/16 dual treatment. The nanomiR-210/16 dual treated hMSCs 
displayed significantly increased VEGF secretion over all other groups. This 
result was supported by the detection of longer tubules formed by endothelial 
cells when subjected to nanomiR-210/16 dual conditioned medium. This is 
consistent with combinatorial GF or gene delivery approaches where increased 
angiogenesis and osteogenesis were observed when BMP-2 plus VEGF were 
dually delivered (127, 165, 355). Taken together, this data indicated that 
nanomiR-210/16 dual significantly enhanced the angiogenic capabilities of 
hMSCs in comparison to a single nanomiR-210 mimic treatment.  
Furthermore, assessment of osteogenesis in this nanomiR-210/16 dual group 
revealed improved Runx2 and OCN gene expression in comparison with the 
levels previously determined for the nanomiR-210 mimic. Moreover, a greater 
enhancement in calcium deposition was demonstrated at both 10 and 14 days 
for this nanomiR-210/16 dual group, indicating that the dual treatment was able 
to further enhance functional osteogenesis in comparison with single miR-210 
mimic delivery. Only two studies to-date have assessed combinatorial miRNA 
delivery (58, 235). From these studies a synergistic effect in ALP activity was 
demonstrated for the miR-148b mimic plus antagomiR-489 combination, 
although notably this dual treatment did not increase the calcium deposition 
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levels induced by the single miR-148b treatment. This outcome underlined that 
simultaneous delivery of various miRNAs is a complex task, although it holds 
promising potential as a therapeutic approach. 
In summary, the successful results with the nanomiR-210/16 dual group 
highlighted the ability of the nHA particles to deliver pro-angiogenic miRNA 
therapeutics. This was an important addition to the previous success in 
delivering reporter and pro-osteogenic miRNA therapeutics presented in 
previous chapters of this thesis. Moreover, this observation is consistent with 
the benefits of nHA as the vector of choice in the GAMs developed in our 
laboratory to address combined angiogenesis and osteogenesis (127). Taken 
together, the data presented in this chapter showcased a highly beneficial 
interaction when miR-210 mimic and antagomiR-16 were combined, resulting in 
an exciting capability of this combinatorial nanomiR delivery approach to 
simultaneously enhance hMSC angiogenesis and osteogenesis.  
 
5.6.Conclusion 
While the results from this chapter demonstrated a limited therapeutic effect of 
hMSC treatment with either single nanomiR-210 mimic or a nanomiR-210/133a 
dual treatment, a promising simultaneous pro-angiogenic and pro-osteogenic 
response with a nanomiR-210/16 dual treatment was demonstrated. The 
nanomiR-210/16 dual formulation remarkably improved direct target silencing, 
enhanced endothelial cell tubulogenesis and increased calcium deposition at 
both 10 and 14 days. Overall, this study successfully presents nanomiR-210/16 
dual treatment as the first combinatorial miRNA delivery approach to 
simultaneously target angiogenesis and osteogenesis. This represents a highly 
beneficial paradigm for bone repair applications. Moreover, this work underlines 
the possibility of extending nHA-based miRNA delivery to pathways beyond 
osteogenesis by tailoring the miRNA therapeutic incorporated in the complexes. 
As such, the work presented in this chapter presents enormous potential for 
alternative TE applications. 
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Chapter 6. Discussion 
 
6.1.Overview 
The field of tissue engineering (TE) focuses on creating new tissue for the 
therapeutic regeneration of defects within the human body (9). A substantial 
and unmet need for the development of tissue-engineered approaches to repair 
bone exists. Implantation of bone grafts harvested from a patient or donor 
remains the gold standard for bone repair, in spite of having documented failure 
rates as high as 30 % (26). With this in mind, bone TE research concentrates 
on developing 3D scaffolds capable of directing cells to lay down new bone (23) 
and is increasingly shifting towards the use of these scaffolds to act as carriers 
for therapeutic biomolecules. microRNAs (miRNAs) have recently emerged as 
highly promising therapeutics to direct bone repair; however, the development 
of a safe and efficient localised delivery system is required for successful 
clinical translation. Thus, the introduction of miRNA therapeutics within 3D 
scaffolds was the concept guiding the research presented in this thesis. 
A series of collagen-based scaffolds have previously been developed in our 
laboratory, including a collagen-nanohydroxyapatite (coll-nHA) scaffold with 
optimised properties for bone repair (97). This scaffold has demonstrated 
potential as a depot for localised delivery of genes - in the form of plasmid DNA 
-, which are also known as gene-activated matrices (GAMs; (126, 127, 346, 
394)). Moreover, in house-synthesised nHA particles and polyethylenimine 
(PEI) complexes were incorporated within these GAMs as non-viral plasmid 
DNA delivery vectors (126, 127). PEI is a popular non-viral vector due to its high 
transfection efficiency but has also been shown to be cytotoxic, while nHA 
particles are generally regarded as safe but less efficient for transfection. Hence 
it was of major relevance that the nHA-based GAMs demonstrated improved 
capacity to induce bone repair in comparison to PEI-based GAMs in vivo (127). 
In the context of producing superior bone graft substitutes, the overall goal of 
the research presented in this thesis was to establish the potential of using nHA 
to act as a non-viral vector for the delivery of a series of miRNAs to human 
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MSCs and to determine, from a panel of select candidates, the optimal miRNA 
therapeutic leading to enhanced osteogenesis and angiogenesis before 
ultimately producing miRNA-activated scaffolds capable of mediating enhanced 
osteogenesis by human MSCs.   
Chapter 2 of this thesis focused on assessing the potential of these in house-
synthesised nHA particles as non-viral vectors for miRNA delivery to human 
MSCs, a particularly difficult cell type to transfect effectively. The data 
presented here showed that nHA particles combined with both miR-mimics and 
antagomiRs, formed complexes (we term nanomiRs), which resulted in efficient 
delivery with limited cytotoxicity at a 20 nM dose. A single administration of our 
reporter nanomiR achieved high uptake efficiency and further translated into 
high silencing levels, comparable to viral and lipid-based vectors (219).  
 
The aim of Chapter 3 was to determine the pro-osteogenic therapeutic efficacy 
of nHA-based delivery of antagomiR-133a, antagomiR-16 and a miR-210 
mimic, targets with known osteogenic influence, and establish the optimal 
candidate for incorporation in a miRNA-activated scaffold. The results 
demonstrated that nHA-based delivery of these three miRNAs enhanced human 
MSC mediated osteogenesis, albeit to different levels. Ultimately, the 
nanoantagomiR-133a treatment showed the highest increases in Runx2 and 
OCN expression and ALP activity as well as rapidly enhancing calcium 
deposition as early as 10 days, sustaining this effect up to day 14.  
Subsequently, Chapter 4 assessed the potential of the coll-nHA scaffolds as 
miRNA delivery platforms to manipulate human MSC gene expression and the 
application of this system to therapeutically enhance osteogenesis using 
antagomiR-133a. This work led to the development of the first non-viral, non-
lipid scaffold technology to-date for the delivery of both miR-mimics and 
antagomiRs to human MSCs. When human MSCs were cultured on these 
scaffolds, nanomiR uptake and significant functional silencing with minimal 
cytotoxicity was observed. Ultimately, we demonstrated the therapeutic 
potential of the nanoantagomiR-133a activated coll-nHA scaffolds to effectively 
inhibit miR-133a resulting in upregulation of Runx2 expression and rapidly 
enhanced deposition of mineralised bone matrix. Taken together, Chapter 4 
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presents a highly promising concept in bone TE to effectively utilise miRNA 
therapeutics for enhanced osteogenesis.  
An alternative approach was adopted in Chapter 5 which investigated the 
therapeutic efficacy of nHA-based delivery of the miR-210 mimic to enhance the 
pro-angiogenic capabilities of human MSCs. In addition, we assessed the 
potential of combinatorial delivery of the miR-210 mimic with antagomiR-133a 
or antagomiR-16 to simultaneously enhance the angiogenesis and 
osteogenesis capabilities of human MSCs. Overall, this study presents 
nanomiR-210/16 dual treatment as the first combinatorial miRNA delivery 
approach to simultaneously enhance angiogenesis and osteogenesis. This 
represents a highly beneficial paradigm for bone repair applications and also 
underlines the possibility of extending nHA-based miRNA delivery to pathways 
beyond osteogenesis by tailoring the miRNA therapeutic combinations 
incorporated in the system.  
The following sections will summarise the key findings and implications from 
each individual chapter and review the possible future directions which have 
arisen from this research. 
6.2.Chapter 2: Investigation of nanohydroxyapatite particles as non-viral 
vectors for microRNA delivery to human mesenchymal stem cells  
Recently in the field of TE, incorporating RNA interference (RNAi) therapeutics, 
such as siRNAs and miRNAs, in non-viral delivery systems has gained 
significant interest (281). Notably, commercial vectors with recognised safety 
limitations have been applied for these few studies and miRNA delivery systems 
using nano-sized hydroxyapatite particles (nHA) have not been reported 
previously. The data presented in this study supported the hypothesis that in 
house-synthesised nHA particles can act as non-viral vectors for miRNA 
delivery to human MSCs, a particularly difficult cell type to transfect effectively 
(219). Taken together, the results presented in this chapter demonstrated the 
relevant potential of using these natural-based nanoparticles as delivery vectors 
to apply miRNA therapeutics to TE.   
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Initially in this study it was determined that nHA particles formed negatively 
charged complexes in the 300 nm range with both miR-mimics and 
antagomiRs, which was consistent with the nHA-pDNA complexes which 
previously demonstrated successful transfection of human MSCs (124, 126). 
Classically, it is estimated that cellular uptake requires positively charged 
particles of less than 200 nm (366). However, evidence of successful uptake of 
miRNA-PEI or miRNA-chitosan complexes greater than 500 nm in size (256), 
as well as of negatively charged siRNA lipoplexes (367) has been noted, which 
support the potential of our nHA particles for effective miRNA delivery. Given 
that the overall aim of this thesis was to successfully incorporate nanomiRs 
within a 3D scaffold, the physicochemical features of nanomiRs were deemed 
fit-for-purpose.  
 
No evidence of permanent nHA- or miRNA-derived cytotoxicity was found. In 
relation to vector safety and cytotoxicity, CaP-based delivery of nucleic acids is 
known to minimise cytotoxicity, and even enhance cell proliferation (370). 
Although CaPs can transiently reduce metabolic activity (322, 371), consistent 
with the effect observed in this study, vectors like Lipofectamine® 2000 and 
RNAiMax® (280, 367, 372) have been associated with irreversibly impaired cell 
viability. Taken together, the results of this study demonstrated that nanomiR 
treatment did not have a permanent detrimental effect on human MSC viability. 
Analysis of uptake and intracellular localisation of nanomiRs demonstrated that 
complexes were found inside the cells in all treatment groups and at all 
timepoints. The amount of Dy547 nanoantagomiR complexes observed was 
notably higher than that of the Dy547 nanomiR-mimic treatment. Differences in 
the uptake kinetics of the two types of molecules were revealed, which we 
proposed might be beneficial for the combinatorial delivery of miR-mimics and 
antagomiRs that was pursued later, as presented in Chapter 5. Of note, the 
uptake efficiencies determined for nanomiRs were higher than those previously 
reported for nHA-mediated delivery of pDNA (12 %), which was shown to be 
successful for enhanced bone repair (126, 127). This prospect combined with 
the ability of single miRNAs to intercept entire gene cohorts indicates that 
nanomiR delivery may have enhanced therapeutic efficacy over nHA-pDNA 
delivery in vivo. 
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Having determined the high intracellular uptake of nanomiR complexes by 
human MSCs, greater than 90 % silencing functionality was demonstrated with 
a single dose of nanomiR treatment, which was generally maintained over time. 
Interestingly, this level of silencing was comparable with the level described for 
viral and lipid-based vectors for delivery of siRNAs and shRNAs in different cell 
lines, but much higher than for miRNA delivery to stem cells (219). NanomiR 
silencing functionality was also superior in comparison to CaP-based siRNA 
delivery systems targeting different tumour-model cell lines, which have 
reported a 8 -10 % range of silencing efficiency at 20 nM doses (324, 373) and  
60 % silencing functionality for a 10 nM dose (325). In summary, the nanomiR 
delivery system developed in this chapter outperformed the silencing efficiency 
of a range of RNAi delivery vectors, pointing to a significant potential for 
therapeutic applications beyond the bone TE field. Consequently based on 
these results, the single 20 nM dose was selected as the optimal concentration 
for this system and brought forward for further application in the studies 
presented in the following chapters of this thesis. 
 
6.3.Chapter 3: Nanohydroxyapatite-based delivery of osteogenesis-related 
miRNAs to enhance hMSC osteogenic differentiation 
The emerging interest in the use of miRNAs as osteo-therapeutics has led to 
the application of viral or lipid-based miRNA delivery to osteoprogenitors and 
stem cells. However, minimal investigation into non-viral and non-lipid based 
delivery of potential miRNA candidates to human MSCs has been carried out in 
the TE field. Ours is the first study to test not only the therapeutic ability of 
antagomiR-133a, antagomiR-16 and miR-210 mimic to enhance human MSC 
osteogenesis but also to use a nHA-based delivery system. Taken together, the 
results from this study demonstrated that nHA-based delivery of each of these 
three miRNAs enhances human MSC osteogenesis albeit to different levels 
depending on which one was used. Ultimately, nanoantagomiR-133a induced 
the greatest osteogenic response of human MSCs and hence was established 
as the optimal therapeutic candidate for incorporation in a miRNA-activated 
scaffold.  
183 
 
Our exploration of bioinformatic databases revealed the direct interaction of 
both miR-133a and miR-16 with additional targets that are positive mediators of 
osteogenesis, further supporting the negative role of these two miRNAs in 
osteogenesis, while a bi-functional role of miR-210 in osteogenesis and 
angiogenesis was underlined by the bioinformatic analysis. Intracellular miRNA 
level manipulation was deemed successful for each of the nanomiR treatments 
studied. Specifically, nanoantagomiR-133a and nanoantagomiR-16 reduced 
intracellular levels of their target miRNAs to less than 0.2 and 0.1 fold 
respectively compared to the control group (scrambled nanomiR) over 7 days. 
Additionally, this study showed for the first time an endogenous downregulation 
in miR-133a levels during human MSC mediated osteogenesis, which was in 
accordance with previous observations in mice cells (242, 387). The nanomiR-
210 mimic treatment also manipulated miR-210 levels effectively, as 
demonstrated by the prominent increase of intracellular miR-210, to levels that 
can be considered supra-physiological (388). Taken together, these results 
confirmed the capability of nHA-based delivery to successfully manipulate 
miRNA levels in human MSC osteogenic culture. 
Subsequently, robust manipulation of all the direct gene targets selected for 
each nanomiR treatment was demonstrated at the mRNA level. This result 
supported the beneficial effect of each of these three nanomiR treatments. The 
highest increase in both Runx2 and OCN levels was seen with nanoantagomiR-
133a treatment, followed by nanoantagomiR-16. Other studies in miRNA-
induced osteogenesis have reported a range of changes for these genes 
generally less than three-fold. The pronounced changes observed in this 
chapter, markedly higher than previous reports, may indicate a phenotype 
switching effect (391) of relevant benefit as osteo-therapeutics. Following on 
from this finding, the nanoantagomiR-133a group demonstrated a 17-fold 
increase in ALP activity compared to untreated cells, followed by a 11-fold 
increase with nanoantagomiR-16, consistent with the Runx2 and OCN gene 
expression results. The nanomiR-210 mimic did not display a positive effect, 
which was in opposition with the previous report by Mizuno et al. using the 
mouse NRG cell line (236). miRNA-induced changes in ALP activity were also 
assessed in a study by Schoolmeesters et al. (235), where inhibition of miR-
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133a resulted in a two-fold increase in ALP activity over untreated cells. In this 
project, the significantly enhanced ALP activity following nanoantagomiR-133a 
treatment denoted a standout capacity of this treatment group to increase 
osteogenesis, which is encouraging for its potential use in bone TE applications.  
Most importantly from a therapeutic perspective, a significant increase in 
calcium deposition to levels ranging from 3.37 to 4.67 fold over untreated cells 
was detected, at the early timepoint of 10 days, across the three treatment 
groups assessed. At the endpoint of analysis, 14 days, both nanoantagomiR-
133a and -16 treatments resulted in a 2.55 to 3.53 fold increase over untreated 
cells, whereas nanomiR-210 mimic did not maintain the effect detected at 10 
days. Calcium deposition is regarded as an end-stage marker of osteogenesis 
(226, 237, 238, 240, 348, 368, 369, 375, 382, 387) and other non-viral RNAi 
delivery approaches have reported a 2-fold increase in calcium quantification 
(226, 348). Comparatively, the data presented in this chapter showed superior 
calcium deposition response using these three nanomiR treatments than 
previously assessed non-viral vectors, highlighting the beneficial application of 
the nHA-based delivery. Overall, nanoantagomiR-133a treatment displayed a 
superior effect on human MSC osteogenesis than nanoantagomiR-16 and 
nanomiR-210 mimic, and was selected for the work presented in Chapter 4. 
Additionally, the application of antagomiR-16 as an osteo-therapeutic, with 
results implicating this miRNA in human MSC osteogenesis for the first time, 
served as the basis for further investigation. Finally, although the ability of 
nanomiR-210 mimic treatment to enhance human MSC osteogenesis was 
comparatively limited, its application to additional targets implicated in 
angiogenesis warranted further study in Chapter 5.  
 
6.4.Chapter 4: Incorporation of nanomiRs into a collagen-nano 
hydroxyapatite scaffold  
The primary goal of this research thesis was to incorporate therapeutic miRNAs 
into our 3D scaffold biomaterials. The research presented in this chapter thus 
investigated the hypothesis that coll-nHA scaffolds might serve as effective 
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miRNA delivery platforms capable of manipulating human MSC gene 
expression in order to therapeutically enhance osteogenesis.  
nanomiR complexes were shown to be effectively retained within the highly 
porous structure of the coll-nHA scaffolds and internalised in human MSCs, 
leading to significant manipulation of gene expression without affecting cell 
viability. Both functional reporter nanomiR-mimic and nanoantagomiR 
complexes significantly maintained silencing of their respective targets, GAPDH 
and miR-16, confirming the capability of coll-nHA scaffolds as depots for 
sustained miRNA delivery. This correlated with the observation that, due to the 
cell migration throughout the 3D scaffold, extended culture periods result in 
improved functionality outcomes (394). The silencing functionality detected for 
the nanomiR-mimic is within the range reported from a previous study for cells 
added onto a functionalised scaffold (350), a result which was widely surpassed 
with the nanoantagomiR-activated scaffold. These results are even more 
impressive when it is considered that human MSCs are regarded as particularly 
difficult to transfect.  
Having established the significant potential of the coll-nHA scaffolds for delivery 
of reporter miRNAs, the osteo-therapeutic potential of incorporating antagomiR-
133a levels was demonstrated for the first time. Only 8 studies have been 
published to date which have used miRNAs as osteo-therapeutics in 3D 
biomaterials. This is low considering that over 30 miRNAs have now been 
identified to play a role in osteogenesis (58, 297, 299, 347-349, 393, 395). 
These previous 3D studies have relied on  commercially available transfection 
methods associated with cytotoxicity concerns (367) and none of them 
performed assessment of direct silencing functionality (58, 393). The innovative 
approach developed in this chapter showed a significant decrease in miR-133a 
intracellular levels, resulting in increases in Runx2 and consequently, a panel of 
osteogenic markers was upregulated at the gene level, which was accompanied 
by enhanced presence of osteocalcin protein within the ECM and most 
importantly, translated into rapidly enhanced calcium deposition on the 
scaffolds. Taken together, this data pointed to a robust and coordinated 
therapeutic enhancement in human MSC-mediated osteogenesis within the 
miR-activated scaffolds illustrating the therapeutic potential of the system.  
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A major advantage of this system relates to the fact that the nanomiR 
complexes are incorporated in the 3D scaffolds prior to cell seeding i.e. utilising 
the coll-nHA scaffolds as reservoirs for the localised delivery of the miRNA 
complexes with a view to transfecting host cells when applied in vivo. This 
approach differs from ex vivo ‘cell-mediated’ miRNA therapy systems that 
introduce miRNAs in the cells and then seed the transformed cells onto 
scaffolds (58, 297, 299, 347-349, 395), as it means that the miRNA activated 
scaffolds have the potential to exist as an ‘off-the-shelf’ platform. While this 
system was developed with bone regeneration in mind, the functionalisation 
process described in this study may be applied to other scaffolds and to the 
incorporation of any miRNA with a role in tissue regeneration, therefore 
representing a promising approach for a wide variety of TE applications. 
Considering the positive results reported to-date on the ongoing clinical trials of 
miR-122 inhibitor, Miravirsen – by Santaris Pharma -, for hepatitis C (277) and 
miR-34 mimic, MRX-34 - by Mirna Therapeutics -, for liver cancer treatment 
(278), the clinical translation of the technology developed in this chapter has the 
potential to impact the market of tissue engineered musculoskeletal products. 
 
6.5.Chapter 5: Investigation of nanomiR-210 mimic as (i) a pro-angiogenic 
therapeutic and (ii) as a simultaneous pro-angiogenic and pro-osteogenic 
therapeutic as a part of a dual nanomiR formulation 
The final study presented in this thesis focussed on the application of miRNA 
therapeutics capable of simultaneously targeting angiogenesis and 
osteogenesis. We firstly investigated the pro-angiogenic therapeutic potential of 
nanomiR-210 mimic, showing effective manipulation of miR-210, albeit with 
limited pro-angiogenic effect in terms of endothelial cell response. 
Subsequently, exploration of two combinatorial miRNA approaches, namely 
nanomiR-210/133a dual and nanomiR-210/16 dual formulations, demonstrated 
that only the nanomiR-210/16 dual treatment was able to simultaneously 
enhance the pro-angiogenic and pro-osteogenic capabilities of human MSCs. 
Taken together, the results showcased the promise of using nHA-based 
delivery of multiple miRNAs as a prospective therapy in bone TE.  
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Initially, the effective manipulation of miR-210 levels following nanomiR-210 
mimic treatment did not correspond with functional silencing of the direct target 
EphrinA3. While miR-210 induction of EphrinA3 silencing has been 
demonstrated in two different cell types (383), the data presented in this chapter 
did not support the hypothesis that this effect could be extended to the MSCs. 
However, this study showed for the first time that miR-210 level manipulation 
can enhance VEGF secretion by human MSCs although not to a sufficient level 
that it enhanced tubulogenesis and proliferation of endothelial cells (HUVECs). 
Notably, the influence of miR-210 on angiogenesis has been strongly 
associated with hypoxic (low oxygen) conditions (428-430), perhaps suggesting 
that to fully realise the pro-angiogenic potential of miR-210 mimic, hypoxic 
conditions might be required. Taken together, this data pointed to the 
differences in miRNA manipulation depending on cell type and indicated a 
limited therapeutic efficacy of nanomiR-210 mimic to enhance the pro-
angiogenic capabilities of human MSCs through the direct targeting of the 
EphrinA3 gene. 
The second part of this chapter evaluated the simultaneous pro-angiogenic and 
osteogenic response in human MSCs following combinatorial miRNA delivery of 
miR-210 mimic with antagomiR-133a. The efficient ability of nanomiR-210/133a 
dual to increase miR-210 intracellular level was demonstrated. However, no 
silencing of the direct angiogenesis and osteogenesis targets, EphrinA3 and 
AcvR1b respectively, or increased mineralisation was detected although 
increased VEGF levels were seen. Although combinatorial delivery of growth 
factors or genes has generally accounted for superior bone repair outcomes 
than delivery of the individual components (145, 286, 292), detrimental 
response seen for FGF-2 combinations with BMP-2 or VEGF (174, 431) 
illustrates that complex cross-talk may occur. Taken together, this data pointed 
to minimal potential of the combination of miR-210 mimic plus antagomiR-133a 
for bone repair. 
Most interestingly, the final study showed that an improved therapeutic 
response could be achieved if the correct therapeutic combination was 
identified. In this study, an alternative combinatorial approach using the 
combination of antagomiR-16 plus miR-210 mimic was undertaken. Results 
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demonstrated the highly effective manipulation of miR-210 levels and the direct 
targets EphrinA3 and AcvR1b with this nanomiR-210/16 dual treatment. This 
combination significantly enhanced VEGF secretion by human MSCs, and 
longer tubules were formed by HUVECs in response demonstrating the 
potential of this combinatorial approach as a pro-angiogenic therapeutic. In 
addition, the osteogenesis assessment revealed increased calcium deposition 
at both 10 and 14 days indicating that nanomiR-210/16 dual combination was 
also able to enhance functional osteogenesis. To summarise, the results of this 
study highlighted the ability of nHA particles to deliver pro-angiogenic miRNA 
therapeutics, consistent with the benefits of nHA as the vector of choice in the 
delivery of pro-angiogenic and pro-osteogenic plasmid DNA within GAMs 
developed previously in our laboratory (127). Taken together, this data 
showcased an exciting capability of this combinatorial nanomiR delivery 
approach to simultaneously enhance the angiogenesis and osteogenesis 
capabilities of human MSCs.   
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6.6.Future Work 
• This study demonstrated the potential of in-house synthesised nHA 
particles to deliver both miR-mimics and antagomiRs, quantifying uptake 
efficiency and silencing functionality utilising different molecules in each 
case. Further insight could be obtained on uptake and functionality of 
nanomiRs by using fluorescently-tagged silencing reporters or 
incorporating a fluorophore in the core of the nHA particles, in 
combination with in situ hybridisation techniques (219, 388).  
 
• The considerable potential of antagomiR-133a, antagomiR-16 and miR-
210 mimic as osteo-therapeutics was demonstrated in vitro by way of 
PCR analysis, ALP activity and calcium deposition, all hallmarks of 
osteogenesis which yielded conclusive data in this study. It would be 
interesting to carry out a high-throughput analysis such as the pSILAC-
proteomic analysis (381), to evaluate in more detail the possible 
widespread effects on human MSC fate and metabolism resultant from 
manipulation of each of these miRNAs.  
 
• Commercially available negative control miRNAs were shown to produce 
unspecific responses by human MSCs. Significant homology in human 
protein-coding genes can be determined for these sequences by BLAST 
analysis (392), which underlines the challenging design of these control 
sequences. It is expected that improvements in the coming years will 
generate advanced candidates which will more adequately serve as 
negative controls. 
 
• Perhaps the most obvious follow on study from this research is to assess 
the systems developed in vivo. An investigation of the capability of the 
miRNA-activated scaffolds to mediate in vivo miRNA delivery, together 
with the induction of bone healing following application of the antagomiR-
133a activated scaffolds would categorically identify the therapeutic 
potential of this system as a bone graft substitute. In order to do so, rat 
calvarial and/or femoral defect models could be assessed, which are 
widely accepted in bone research as preclinical models to monitor defect 
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healing in response to the bone graft substitute applied (432).  This 
research is planned in the coming months in our laboratory.  
 
• This work has laid the foundation for combinatorial miRNA delivery 
harnessing a simultaneous pro-angiogenic and pro-osteogenic effect. A 
more thorough investigation of downstream molecular mechanisms 
involved in the interaction of the miRNAs utilised in this combinatorial 
approach would be worth performing. In addition, and of clear relevance 
to this entire thesis, is that the optimal combinatorial group identified i.e. 
the miR-210-mimic plus antagomiR-16 dual group merits incorporation 
into the coll-nHA scaffolds and subsequent in vivo investigation in order 
to realise its full potential as an advanced bone graft substitute.  
 
• For the purpose of this research, a localised delivery system for reporter 
miR-mimics and antagomiRs as well as the osteo-therapeutic 
antagomiR-133a was developed using the coll-nHA scaffolds. It would be 
of great interest to adapt these 3D platforms for a plethora of other tissue 
repair applications. For instance, the system could be applied to cartilage 
regeneration by delivering miR-140 mimic (433), and this could be 
combined with other scaffolds optimised for cartilage repair in our 
laboratory (66, 96). Neurogenesis and lung recovery are also areas 
where miRNA therapeutic candidates are starting to emerge, such as 
miR-106b and miR-375 (434, 435). Ongoing research in our laboratory is 
focussing on the optimisation of collagen-based scaffolds for the repair of 
both tissue types (unpublished data) and hence offers the possibility to 
design miRNA-activated scaffolds targeting both neural and lung repair.  
 
• A further translation opportunity for the system developed in this thesis 
relates to RNAi-activated scaffolds attracting interest as advanced in vitro 
models for drug development (436) by offering a closer representation of 
the complex microenvironment found in vivo. Such approach is garnering 
efforts in the landscape of cancer research. The application of miRNA-
activated scaffolds to the field of miRNA-related cancer research may 
thus generate significant interests in the near future.  
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6.7.Thesis Conclusions  
• This study has demonstrated the potential of in-house synthesised nHA 
particles as non-viral vectors for delivery of both miR-mimics and 
antagomiRs to human MSCs in a highly efficient and minimally cytotoxic 
manner, with single administration of low miRNA doses rendering very 
pronounced silencing activities to a level comparable to viral and lipid-
based vectors. Ultimately, a 20 nM dose was deemed optimal for this 
system.  
 
• Efficient nHA-based delivery of antagomiR-133a, antagomiR-16 and 
miR-210 mimic led to enhanced osteogenesis by human MSCs. 
Comparative analysis revealed that nanoantagomiR-133a showed 
greatest potential as an osteo-therapeutic while both antagomiR-16 and 
the miR-210 mimic were deemed to warrant further investigation. 
 
• This study has developed the first non-viral, non-lipid, ‘off-the shelf’ 3D 
system for microRNA delivery. The coll-nHA scaffolds demonstrated 
significant potential as delivery platforms to manipulate human MSC 
gene expression when incorporating both miR-mimics and antagomiRs. 
AntagomiR-133a activated scaffolds upregulated Runx2 and 
orchestrated accelerated calcium deposition thus showcasing the osteo-
therapeutic potential of this innovative strategy. 
 
• While the miR-210 mimic showed a limited pro-angiogenic therapeutic 
efficacy, the combinatorial delivery of the miR-210 mimic with 
antagomiR-16 demonstrated significant potential to simultaneously 
enhance the angiogenesis and osteogenesis capabilities of human 
MSCs. This combinatorial miRNA approach represents a highly 
beneficial paradigm for bone repair applications. Moreover, this work 
underlines the possibility of extending nHA-based miRNA delivery to 
pathways beyond osteogenesis by tailoring the miRNA therapeutic 
incorporated in the complexes.  
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